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Abstract
The main objective of this project is to develop a polymer based near infrared
(NIR) particle that can serve as both, diagnostic and therapeutic agents, for fighting
cancer. Specifically these particles will be designed to have high-contrast, high signal
to noise ratios, long in vivo circulation lifetimes, and facilitate easy attachment of
functional and target components.
Cancer is a disease where the growth of abnormal cells is uncontrollable and is one of the
leading causes of death worldwide. Malignant cancer cells are more effectively treated when identified
early in the disease. Identification of tumors using fluorophores, small molecules that emit visible
light when excited, is gaining clinical interest. Specific interest is in near-infrared emission due to the
lack of absorption of this radiation in human tissue, which facilitates deep tissue imaging. During
imaging with small molecule fluorophores, the fluorophores clear from the body quickly reducing
imaging effectiveness. The effectiveness of imaging can be enhanced by attaching the fluorophores
to a particle. Nanometer sized particles do not clear from the body rapidly and allows the material
designer to attach other ”payloads” to the particle. This multifunctional ”nano-device” can be used
to deliver diagnostic (fluorophores) and therapeutic (drugs) agents to the afflicted tissue.
In this current project sub-100 nm poly(propargyl acrylate) (PA) particles are surface-
functionalized with fluorophores or targeting molecules through a copper(I) catalyzed azide-alkyne
Huisgen 1,3-Dipolar cycloaddition, and used for the following applications:
(1) Switching fluorescence of surface modified colloids with near-infrared emitters via pro-
tein interaction for contrast-enhanced imaging: The colloidal particles surface-functionalized with
fluorophores exhibit a protein triggered activation/deactivation of the emission. Dispersing the par-
ticles into an aqueous solution, such as phosphate buffered saline (PBS), results in an aggregation
of the hydrophobic fluorophores and a cessation of emission. The emission can be reinstated, or
ii
activated, by the conversion of the surface-attached fluorophores from an aggregate to a monomeric
species with the addition of an albumin. This activated probe can be deactivated and returned to a
quenched state by a simple tryptic digestion of the albumin. The methodology for emission switching
offers a path to maximize the signal from the typically weak quantum yield inherent in NIR fluo-
rophores. Preliminary fluorescence imaging studies indicate that the brightness of the functionalized
polymer based nanoparticles improved considerably.
(2) Surface modified colloids with targeting molecules to disrupt Survivin activity and en-
hance apoptosis in cancer cells: Survivin belongs to the family of inhibitor of apoptosis proteins (IAP)
and is present in most cancers while being below detection limits in most terminally differentiated
adult tissues, making it an attractive protein to target for diagnostic and, potentially, therapeutic
roles. Sub-100 nm poly(propargyl acrylate) (PA) particles which are surface-functionalized with
an azide terminated Survivin ligand derivative (azTM), originally proposed by Abbott Labs and
speculated to bind directly to Survivin (protein) at its dimer interface. Using affinity pull-down
studies, it was determined that the PA/azTM nanoparticles selectively bind Survivin and the parti-
cles can enhance apoptotic cell death in glioblastomas and other Survivin over-expressing cell lines
such as A549 and MCF7 relative to cells incubated with the original Abbott-derived small molecule
inhibitor.
(3) A bioresponsive and versatile particle-protein-dye system for small molecule delivery
and FRET based imaging: Colloidal particles are surface-functionalized with small molecules such
as fluorophores and ligands through an environmentally-sensitive linker. The linker used is an
azide modified bovine serum albumin (azBSA) which prevents opsonization and releases the small
molecule upon digestion. Attachment of the fluorophore to the particle through the azide modified
bovine serum albumin (BSA) quenches the emission and is specifically activated upon the denature
or digestion of the azBSA. This resulted in an enhanced tumor to background signal ratio. A
fluorescence resonance energy transfer (FRET) pair of dyes can be attached to the particle and the
azBSA, and the FRET efficiency can be increased by unfolding the protein. These dye modified
particles gave promising results in photodynamic therapy studies performed in human head and
neck squamous carcinoma cells (UMSCC22A). Further, a targeting ligand can also be attached to
the particles using the same strategy to achieve higher accumulations of the desired small molecule
inside the tumor. In addition, preliminary imaging and toxicity studies were carried out in human
lung carcinoma cells (A549) using a Survivin targeting ligand attached to PA-azBSA particles and
iii
an enhanced cell death relative to free molecule treatment was observed.
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Cancer is a disease where the growth of abnormal cells is uncontrollable and is one of the
leading causes of death worldwide, accounting for 13 % of all deaths[1]. Malignant cancer cells are
more effectively treated when identified early in the disease. Identification of tumors using nanopar-
ticle technologies is significantly impacting molecular imaging methods[2]. Molecular imaging plays
a vital role in the healthcare sector. Abnormal conditions and diseases are often diagnosed through
imaging. In addition, therapeutic methods used for the treatment of abnormalities is also guided by
imaging. At present, there are various forms of imaging techniques employed: tomography, magnetic
resonance imaging (MRI), gamma scintigraphy, ultrasound, and optical imaging (cf. Figure 1.1).
Computed tomography gives high resolution images and has the ability to differentiate between
tissues, but has several drawbacks such as high cost and exposure to radiation, and also require a
contrast agent for enhanced tissue contrast[3, 4]. Magnetic resonance imaging gives high resolution
images with better contrast and there is no exposure to radiation, but the issues of the high cost and
low sensitivity compared to radionuclide and optical techniques are still present[3, 5, 6]. In addition,
MRI cannot be used in patients with metallic devices such as pacemakers[7]. Gamma scintigraphy,
which includes positron emission tomography (PET) and single-photon emission computed tomog-
raphy (SPECT), suffers from all the three major drawbacks: exposure to radiation, low resolution
and high cost[7, 8, 9]. Ultrasound is a low cost, non-invasive and simple procedure with no radiation
but the images obtained are low in resolution[3, 5, 7]. Optical imaging is a highly sensitive and
low cost procedure[7, 10, 11]. The main advantages of optical imaging are: (1) can be used as an
imaging agent in both live and fixed cells and tissues; (2) no additional substrate is required for visu-
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alization; and (3) multiple probes with different spectral characteristics could potentially be used for
multichannel imaging[3, 12, 13]. The setbacks for optical imaging is that images obtained are low in
resolution and has a limited tissue penetration[7]. Some of the other general drawbacks, which are
not specific to any one imaging technique, are long lasting side effects on patients, time-consuming,
complex in nature and often prove to be expensive and tedious for the patient even with medical
insurance. In most situations, due to the issues mentioned, the abnormalities are not detected until
later stages of the disease when treatments are less effective. To this end, a better imaging system is
required to overcome the limitations. In this current project, the developments in the field of optical
imaging with near-infrared (NIR) fluorophores is of interest.
Figure 1.1: Typical molecular imaging instruments and images representative of each modality.(a) magnetic
resonance imaging (MRI) (b) computed tomography (CT) (c) positron emission tomography (PET) (d) single-
photon emission computed tomography (SPECT) (e) optical imaging (f) ultrasound (Reprinted with permission
from Ref. [7] Copyright 2010 Elsevier B. V.)
In recent times, the use of NIR fluorophores in imaging has gained popularity. Fluorophores
are small molecules with specific functional groups, which absorb light at a defined wavelength and re-
emit light at a longer wavelength. These fluorophores overcome drawbacks such as background noise
and facilitate for deeper imaging in human body[14]. Unfortunately, small molecule fluorophores have
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four major limitations: (1) limited aqueous solubility, (2) short in vivo circulation lifetimes, (3) low
quantum efficiencies, and (4) low signal to noise ratios. The mentioned drawbacks can be overcome
by either encapsulating the fluorophore inside a nanoparticle or attaching it to the surface of the
nanoparticle. In addition, targeting agents and drugs can be loaded onto the nanoparticles along
with the fluorophore to create a single and multifunctional ”nanodevice” for tumor theranostics.
Over the years, there has been development of fluorescent nanocarriers such as surface cross-linked
micelles,[15, 16], dendrimers,[17] biodegradable polymeric nanoparticles,[18, 19] magnetic and other
metal particles,[20, 21] and liposomes,[20] for tumor diagnosis. Among these technologies, platforms
based on polymeric materials, especially biodegradable nanoparticles, are of particular interest due to
the flexibility offered by macromolecular synthesis methods, high drug loading capacities, improved
drug solubility and their ease of multifunctionalization[22, 23, 24].
In this chapter, the commonly used NIR fluorophores will be discussed. That discussion will
be followed up with the developments in fluorescence imaging with three polymer based platforms:
cross-linked micelles, polymersomes and polymer-core nanoparticle (cf. Figure 1.2). At the end
strategies such as targeting and activation for the nanoprobes will be presented.
Figure 1.2: Schematic structures of (a) polymer cross-linked micelles, (b) polymersomes, and (c) polymer-core
nanoparticles (Adapted from Ref. [25])
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1.1 Small molecule imaging
Small molecule organic fluorophores have always been in demand at biomedical communities
for imaging and image guided surgery or therapy. Imaging with far-red and near-infrared dyes such
as cyanine, squaraine, thiazine, oxazine, porphyrins and phthalocyanines, is very common and most
of them have been approved for clinical trials. Recently, a new class of dyes borondipyrromethane
(BODIPY) derivatives have emerged and are gaining popularity. Despite the widespread utilization
of these dyes, there is still a need for better systems due to the limitations of small molecules. Imaging
with small molecules have shortcomings such as water insolubility, aggregation, low quantum yield,
insufficient photostability, low tumor to background ratio, and short in vivo circulation lifetimes.
Recently, Luo and colleagues published an overview of near-infrared (NIR) dyes and their potential
applications in cancer imaging[26]. Based on that review, the following sub-sections will highlight
the main points of some of the popular classes of dyes.
Figure 1.3: Structures of (a) cyanine, (b) squaraine, (c) phthalocyanine, and (d) boron dipyrromethane dyes
1.1.1 Cyanine dyes
The general structure of the cyanine dyes consists of two aromatic nitrogen-containing het-
erocycles, acting as both electron donors and acceptors. The two aromatic rings are joined by a
single or odd number of methine groups in which (n + 1) bi-electrons are distributed over n atoms
4
that produce a delocalized cation across the methine chain (cf. Figure 1.3a)[26, 27, 28]. Depending
on the methine chain length the cyanine dyes absorb between the visible and infrared regions of the
electromagnetic spectrum[29]. In 1856, C. H. G. Williams synthesized the first cyanine dye[29, 30].
Since then many analogs with varying lengths of methine chain were used to demonstrate the appli-
cation in various biomedical applications ranging from angiography to photodynamic therapy[26].
Cyanine dyes make up the majority of commercial fluorescent probes for in vivo imaging. Of all the
cyanine dyes, indocyanine green (ICG) is the most popular and was approved by the FDA 50 years
ago for evaluating blood flow and clearance[26, 27]. ICG and many other dyes generally exhibit
high molar extinction coefficients but low quantum yields, poor photostability, high plasma protein
binding rate and undesired aggregation[31]. To overcome some of the limitations, new analogs that
have a cyclohexenyl in the middle of the methine chain and moieties such as carboxylic and sulfonate
were introduced[32, 33]. These improved water solubility, photostability and quantum yields but
the improvement was not sufficient.
1.1.2 Squaraine dyes
Squaraine dyes are 1, 3 - zwitter ionic donor-acceptor-donor (D-A-D) structures with the
central acceptor four membered squaryl ring flanked by donor aromatic/ heterocyclic rings on
either side (cf. Figure 1.3b)[34]. In 1965, Treibs and colleagues first reported the synthesis of
squaraine dyes, which have extremely intense absorption bands, high molar absorption and good
photoconductivity[26, 35, 36]. Despite these molecules having excellent physical-chemical proper-
ties, they gained importance only in late 2000s due to their limitations such as water solubility,
aggregation, chemical stability and only few analogs of the dye emit at wavelengths higher than 800
nm[26]. Most importantly, the squarate bridge was susceptible to chemical attack by nucleophiles.
Around 2005, Gassensmith and colleagues synthesized a rotaxane molecule encapsulating a squaraine
dye. The rotaxane cage protected the squaraine ring and inhibited aggregation, which improved the
chemical and photo stability of the dye[37]. In 2007, Umezawa and colleagues developed another
alternative squaraine derivative dye of improved hydrophilicity due to the four water-solubilizing
sulfonate moieties added to the general structure[38]. All these solutions to squaraine made the dye
very promising for protein detection and in vivo imaging.
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1.1.3 Porphyrin and phthalocyanine dyes
Porphyrins are tetrapyrrolic molecules that consist of four pyrrolic sub-units linked on op-
posing sides through four methine (CH) bridges. Phthalocyanine molecules are an extension of
porphyrins where each pyrrolic ring of porphyrin is extended by a benzene ring (cf. Figure 1.3c)[39].
The central cavity of the phthalocyanine contains two hydrogen atoms and these atoms can be re-
placed by more than 70 metal atoms. In addition, a variety of substituents can be added to the
periphery of the macrocycle or to the axial positions of the central atom[26]. These blue or greenish
color dyes absorb strongly in the red and near-infrared part of the visible spectrum. In 1907, Braun
and Tcherniac synthesized the first metal-free and copper phthalocyanines[40]. In vitro fluorescence
imaging with phthalocyanines and porphyrins dates back to late 1980s and early 1990s[41]. In 1993,
photofrin was the first chromophore in this class of dyes to be approved for clinical use in 1993 for the
treatment of bladder cancer[39]. Since then there have been several analogs of the dyes synthesized
and used. The low water solubility set back the popularity of these dyes for imaging. In 2012, a new
phthalocyanine chemistry was used to create a series of PEGylated cationic molecules, which has
promising in vitro behavior against cancer cells[42]. In the field of tumor theranostics, these dyes
are more successful than the other classes of dyes due to their ability of being used as fluorophores
in imaging and photosensitizers in photodynamic therapy. Recently, Yumita and colleagues synthe-
sized a novel porphyrin derivative and demonstrated a mechanism that is related to generation of
singlet oxygen to achieve destruction of cancer cells through sound rather than light[43].
1.1.4 Borondipyrromethane dyes
Borondipyrromethanes (BODIPY) have a general structure of 4, 4’ - difluoro - 4 - bora
- 3a, 4a - diaza - s - indacene (cf. Figure 1.3d). In 1968, Treibs and Kreuzer first reported the
synthesis of BODIPY dyes[44]. These molecules typically have the following characteristics: sharp
fluorescence with high quantum yield, excellent thermal and photochemical stability, and extinction
coefficients around 80000 M−1 cm−1[45]. Despite having such attractive properties, BODIPYs were
not preferred as they emit in the yellow to deep-red region and the extinction coefficients were
considered to be relatively low[26]. To overcome this disadvantage there were two effective solutions
put forth. First, polymeric and copolymeric BODIPY dyes were synthesized to shift the emission to
the near-infrared region[46]. Second, modification of pyrrole core shifts the emission to the red end
6
of the spectrum. The most significant modification includes aryl groups to the BODIPY. Using this
modification, BODIPYS of molar extinction coefficients of 253,000 M−1 cm−1 and emitting in the
near-infrared region can be obtained[47, 48].
1.2 Imaging with polymer based nanoparticles
Nanosized objects accumulate more efficiently in tumors and increase tumor to background
ratio (TBR) due to enhanced permeability and retention (EPR) effect. EPR effect results in passive
targeting of nanoparticles to tumor sites. Blood vessels supplying tumor tissues have larger pore
sizes compared to those in healthy tissue and tumor tissues have poor lymphatic drainage, which
allows preferential tumor accumulation of nanoparticles and this phenomenon is called the EPR
effect[49, 50, 51, 52]. Small animal studies indicate that a 50 fold increase in accumulation of
nanoparticles within tumor tissues due to EPR effect and an increase in in vivo circulation lifetimes
can be obtained[52]. Apart from the increased accumulation and lifetimes, the nanoparticles have
another advantage, which is that they provide an increased surface area per volume for increased
loading of the fluorophore and other moieties[51]. To this end, conjugating the small molecule
fluorophore to nanoparticles is preferred over using the fluorophore by itself for optical imaging.
In addition to the EPR effect, the particle characteristics such as size distribution, surface charge,
biocompatibility, biodegradation behavior and availability of functional groups for conjugation play
an important role in determining circulation lifetimes and accumulation in tumor tissues[25, 51].
It is established that biodegradable microparticles made of starch, albumin or poly lactic acid, are
rapidly cleared by the reticuloendothelial system (RES) and are unable to enter capillaries, making
them less attractive for imaging applications[51]. As mentioned previously, polymeric nanocarriers
are of particular interest due to the flexibility offered by macromolecular synthesis methods, high
drug loading capacities, improved drug solubility and their ease of multifunctionalization[22, 23, 24].
The first preparation and characterization of polymeric nanoparticles was reported in 1976 and since
then the research in this area has grown significantly[51, 53]. It has been established in literature
that neutrally charged particles, with an average diameter of 10 - 100 nm, and molecular weights
up to 800 kDa were required to obtain longer circulation lifetimes[51, 54]. In addition, choosing the
right parent polymer is an important step in the design of the systems because polymer type can
determine the ultimate behavior of the system in different environments[51]. Based on the above
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mentioned requirements for the nanocarrier, some of the successful organic fluorescent carriers used
in fluorescence imaging will be discussed in detail in the following sections (cf. Figure 1.2).
1.2.1 Crosslinked micelles
A crosslinked micelle (CM) is a nanocarrier that is based on self-assembled aggregation of
amphiphilic molecules or surfactants with the fluorescent probes conjugated to it. Micelles have a
dynamic structure in equilibrium and at critical micellar concentration (CMC) they exist as free
monomers, so care should be taken to ensure that the concentration is below the CMC to avoid fast
and undesired release of the probe upon administration[25]. Typically, CMs usually range in 5 -
150 nm in size[55], which allows extravasation and permeation into tissues and avoids clearance by
the RES[56]. The CMs are simple aqueous based preparations with highly tunable emission wave-
lengths and an expanded stokes shift of the dye from 20 nm to about 160 nm[57], which make them an
attractive carrier for fluorescence imaging. In addition, most CMs are not toxic and biologically com-
patible. The exceptions are surfactant based micelles as the large amounts of surfactant used might
lyse the cell membrane and denature proteins, so they have a low preference[56]. In polymer based
micelles, the hydrophobic units of the block copolymers form the hydrophobic core of the micelle and
hydrophilic units surround the core forming a hydrophilic shell and thus making the micelle sterically
stable along with protecting it from mononuclear phagocytic system (MPS) uptake[55, 56]. Using
this strategy a number of block co-polymer micelles that encapsulate near infrared chromophores
have been synthesized over the years and applied for imaging purposes[25, 58, 59]. Recently, in
2013, Chen and colleagues synthesized PEGylated tripropargyl amine micelles conjugated to BOD-
IPY fluorophores, which had excellent water solubility and membrane permeability, and increased
stokes shift without any covalent structure modification of the fluorophore[57, 60]. In addition, they
observed that these BODIPY conjugated PEGylated tripropargyl amine micelles readily penetrate
cell membranes and preferentially accumulate in the cytoplasm instead of the nucleus of the cell (cf.
Figure 1.4)[60]. It was noticed that in most of the micelles, Poly(ethylene glycol) (PEG) remained
as the choice of the hydrophilic unit as they are widely accepted and easily available[55]. It was also
noticed that the recent advances in the crosslinked micelles were in making ”smart” micelles that
respond to various biological stimuli and pH of the environment, and target specific tissues (cf. Fig-
ure 1.5)[55, 61]. In addition to synthesizing stimuli responsive micelles, there has been development
of micelles based on recombinant proteins. Kim and colleagues developed a 50 nm recombinant
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protein micelle for targeted in vivo imaging. In these micelles, the multiple fluorescent probes were
covalently conjugated to surface amines of crosslinked amphiphilic elastic-mimetic protein micelles
using N-hydroxysuccinimide ester chemistry [62].
Figure 1.4: (a) Fluorescence, (b) transmission, and (c) overlapping fluorescence/ transmission images of Hela
cells observed by confocal laser scanning microscopy. The cells were incubated with BODIPY conjugated surface
crosslinked micelles at a concentration of 1 mM for 30 min at 37 oC under a humidified atmosphere containing 5 %
CO2. The excitation wavelength was fixed at 561 nm and the fluorescence signals were collected between 570 620
nm. (Reprinted with permission from Ref. [57] Copyright 2013 The Royal Society of Chemistry)
Figure 1.5: Temperature triggered self-assembly of an ELPBC to form multivalent spherical micelles. An N-
terminal ELP[V1A8G7−n] gene (hydrophilic, high Tt) and C-terminal ELP[V5−n] gene (hydrophobic, low Tt) are
seamlessly fused together to create a gene that encodes an ELPBC . When the size and ratio of the blocks are correctly
selected, the ELPBC self-assembles into a spherical micelle at ca. 40 oC. In the cartoon shown, upon self-assembly
the spherical micelles present multiple copies of an affinity targeting moiety (green triangle) and sequester a drug or
imaging agent (lightning bolt) within the core of the micelle. (Reprinted with permission from Ref. [61] Copyright
2008 American Chemical Society)
1.2.2 Polymersomes
Polymersomes are artificial vesicles or tiny hollow spheres that enclose a solution and have
radii ranging from 50 nm to 50 µm[63]. They have a large hydrophilic reservoir and a thick hydropho-
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bic lamellar membrane that supports the storage of a large quantity (i.e. more than 10 mol/ wt %)
of hydrophobic fluorescent dyes and can protect the dyes from quenching and degradation[64, 65].
The long polymer chains regulate the mean fluorophore - fluorophore interspatial separation as well
as the fluorophore - localized electronic environment[63]. Greater fluorescence was obtained for more
hydrophobic fluorophores when relatively apolar membranes such as poly(γ-methyl ε-caprolactone)
was used and the more amphiphilic fluorophores were better dissolved when bilayers of poly(ε-
caprolactone) was used[65]. For most polymersomes, the outer shell is a layer of dense polyethylene
oxide (PEO), which confers the stealth like character and results in increased biocompatibility,
structural integrity in plasma, and circulation lifetimes[63, 64, 66]. In addition, the surface has
terminal groups like -OH, which can be used to covalently conjugate targeting molecules, drugs and
biomolecules to create a multifunctional unit[64]. There has been extensive work and investiga-
tion into developing the polymersomes as stimuli responsive multimodality agents but it is beyond
the scope of this project and we will focus on the polymersomes that contributed significantly for
fluorescence imaging[65, 66, 67]. Initially, Hammer and colleagues synthesized poly(ethylene oxide)-
block-poly(ethylethylene) (PEO-b-PEE) diblock copolymers based polymersomes and expanded that
technique to generate a number of biocompatible PEO-based amphiphilic block copolymers such
as poly(ethylene oxide)-block-poly(butadiene) (PEO-b-PBD)[66]. They loaded these polymersomes
with hydrophobic dyes such as Nile Red and also hydrophilic dyes such as Calcein and demonstrated
its use in deep-tissue fluorescence based imaging[66, 68]. PEO-b-PBD polymersomes encapsulating
porphyrin based fluorophores generated a fluorescence signal that was penetrable through 1 cm of
solid tumor[66]. However, the problem with these systems were that they were not biodegradable
and not fully biocompatible. To this end, around 2006, Ghoroghchian and colleagues developed
the first set of self-assembled polymersome that was composed entirely of United States Food and
Drug Administration (FDA) approved biodegradable diblock copolymers. They were a fully biore-
sorbable diblock copolymers of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and
the diblock copolymer poly(ethylene oxide)-block-poly((γ-methyl ε-caprolactone) (PEO-b-PMCL)
(cf. Figure 1.6)[65]. In 2012, Massignani and colleagues developed poly(2-(methacryloyloxy)ethyl
phosphorylcholine)-poly(2-diisopropylaminoethyl methacrylate) (PMPC-PDPA) diblock copolymers
based polymersomes and loaded it with a Rhodamine fluorophore, which had enhanced emission
compared to free Rhodamine and CellTracker dye[69]. This increase was attributed to the effective
dye delivery when the polymersome was used. Recently, in 2014, Quan and colleagues synthe-
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sized a fluorescent polymersome that could encapsulate hydrophobic or hydrophilic drugs instead of
the traditional polymersome encapsulating fluorophores. It was prepared by self-assembly of block
copolymer hydrophilic poly(ethylene glycol) boron-dipyrromethenes (MPEG-BODIPY) in aqueous
solution. These ca. 57 nm particles exhibited low toxicity and high accumulation in the tumor site
through passive targeting[70].
Figure 1.6: Schematic depiction of the incorporation of various oligo(porphyrin)-based NIRFs within polymersomes.
(a) The NIRFs vary with respect to the number of porphyrin subunits (N), the linkage topology between porphyrin
monomers, and the nature and position of ancillary aryl-group substituents (R). (b) Various diblock copolymer
compositions have been utilized to form NIR-emissive polymersomes. (c) Membranous interactions between polymers
and specific ancillary aryl group substituents vary the conformational populations assumed by the NIRF and can be
used to tune its emission wavelengths. (d) Engineering the chemical composition and thickness of the polymersome
membrane and helps to drive individual NIRFs into dielectric environments of matching polarity. (e) a family of




The polymer-core nanoparticles can be divided into two categories: natural and synthetic.
As the category name’s suggest, particles made from natural polymers such as dextran, albumin,
gelatin, chitosan, heparin, bacteriophages or lipoproteins fall under the natural category and the
particles synthesized from synthetic or artificially produced polymers such as poly(amino acids),
poly(alkyl-cyano acrylates), poly(esters), poly(orthoesters), poly(urethanes), and poly(acrylamides)
are considered synthetic[25, 51]. In this current project the focus is on the synthetic polymer-core
nanoparticles. The polymer-core nanoparticles are particles that have an inner core made up of cross-
linked polymer and the fluorophore is either encapsulated within the core or covalently conjugated
to the polymer. Encapsulation protects the fluorophore from direct interactions that could decrease
its emission but at the same time cannot form beneficial host/guest assemblies or complex with
biomacromolecules. Further, encapsulating the fluorophore suffers from leakage and non-specific
release of the fluorophore. These drawbacks are overcome easily when the fluorophore is covalently
conjugated to the outside of the particle[25, 71]. For the inner core, hydrophobic polymers such as
poly(lactic-co-glycolic acid) (PLGA), poly(3-caprolactone) (PCL) and poly(methyl methacrylate)
(PMMA) are preferred, as the hydrophobic matrix provides a strong affinity for the entrapment
of poorly water-soluble fluorophores and drugs[72, 73]. Typical nanoparticle size varies from 50 -
500 nm and the optimum nanoparticle size for tumor accumulation is between about 70 and 200
nm as the nanoparticle uptake by the RES in the size range between 150 and 300 nm.[74, 75].
In addition, it has been well established in literature that a coating of PEG on the hydrophobic
particle is necessary to render the nanoparticles biocompatible, avoid rapid clearance by the RES
and also increase the circulation lifetime, which increases accumulation and allows their distribution
in different tissues[25, 71, 76, 77, 78]. The following paragraph briefly summarizes some of the
biodegradable polymer-core nanoparticle systems that have been developed.
As mentioned previously poly(lactic acid) (PLA) based systems are the most popular choices
for the nanoparticles. PLA and its copolymers are one of the most extensively investigated matrix
material for nanoparticles based diagnostic and drug delivery applications as they offer excellent bio-
compatibility, biodegradability into metabolizable moieties, and good manufacturing abilities[72, 79].
In addition, PLGA is approved by the FDA and is a component of many biodegradable market prod-
ucts for parenteral application[73, 80]. Initially, in 2004, Saxena and colleagues prepared 300410 nm
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PLGA nanoparticles entrapping ICG by a modified spontaneous emulsification solvent diffusion
method and were able to achieve over 74 % loading of the fluorophore in the particles[81, 82]. Later
in 2006, they demonstrated the use of these particles for tumor diagnosis and photodynamic ther-
apy and also determined the biodistribution of ICG loaded PLGA nanoparticles in healthy C57BL/6
mice (female,10-week old)[83]. In 2011, Schadlich and colleagues encapsulated different fluorophores,
Nile Red and DiR (a carbocyanine based fluorophore), in PEGylated PLA nanoparticles and carried
out in vivo and ex vivo imaging studies to study the impact of particle size in tumor accumulation,
distribution and elimination[73, 84]. Apart from the encapsulated systems, there were other cova-
lently conjugated fluorophore-PLA or PLGA nanoparticles. In 2010, Tong and colleagues developed
Cy5-conjugated polylactide (Cy5-PLA) nanoparticles. They found these particles to have excellent
signals with low tumor to background ratio fluorescence in various organs when administered intra-
venously to balb/c mice (cf. Figure 1.7)[85]. In 2012, Reul and colleagues, evaluated the concept of
covalently labeling poly(lactide-co-glycolide) (PLGA) with a near-infrared (NIR) dye to obtain stable
NIR fluorescent nanoparticles. For their studies, they coupled PLGA with DY-700 (a near infrared
fluorophore) and injected intravenously into mice. According to their results, these particles had
very good stability and preferentially accumulated in the liver where the free fluorophore wouldn’t
earlier, and could be developed further into a finely traceable PLGA nanosystem for fluorescence
imaging[80].
Apart from PLA based nanosystems there have been particles based on other polymers such
as poly(propargyl acrylate) (PA), poly(styrene-co-methacrylic acid), and poly(acrylic acid) (PAA).
In 2011 Rungta and colleagues prepared sub-100 nm PA nanoparticles which had azide-terminated
indocyanine green (azICG) covalently conjugated to the surface. The azICG was attached to the
particles via azide/alkyne Huisgen cycloaddition using a copper catalyst[31]. Recently, it was re-
ported that since the inception of ”click” cycloaddition reaction in the field of drug discovery in
2001 by Sharpless and coworkers[86], it has been used by numerous researchers to prepare nanosized
particles including polymeric micelles and nanoparticles, liposomes and polymersomes, capsules,
metal and silica nanoparticles, carbon nanotubes and fullerenes, or bionanoparticles for tumor di-
agnostic and drug delivery applications[87]. In addition, significant growth and interest is seen
in developing new processes for the ”click” reaction to achieve high reaction kinetics, excellent
biocompatibility, selective labeling of specific targets, easily accessible reactive tags and long shelf-
life[87], and in future it can be expected that a majority of the nanosystems for tumor theranostics
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Figure 1.7: In vivo biodistribution of intravenously administered Cy5-PLA nanoparticles. Visceral organ biodistri-
bution of Cy5-PLA nanoparticles following lateral tail vein injection using the LI-COR Odyssey scanner. Accumulation
of Cy5-PLA nanoparticles within visceral organs allows for greater than 10-fold increase in fluorescent intensity in
comparison with background autofluorescence. Splenic accumulation of Cy5-PLA nanoparticles is the greatest for all
visceral organs examined (spleen, liver, kidney, lung, and heart); Bar 5 5 mm. (Reprinted with permission from Ref.
[85] Copyright 2010 WILEY-LISS INC.)
will utilize the ”click” reaction. In 2011, Palma and colleagues, prepared BF2 chelated tetraary-
lazadipyrromethenes (near infrared dye) conjugated poly(styrene-co-methacrylic acid) particles. The
dye was attached to the nanoparticles via a standard N-hydroxysuccinimide (NHS) and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDCI) coupling reaction. Using those particles, they were
able to obtain promising results for real time in vitro imaging in MDAMB-231 (breast cancer),
HEK293T (kidney), and CAKI-1 (renal cancer) cell lines (cf. Figure 1.8)[88]. In 2013, Tao and
colleagues reported the synthesis of the first biocompatible NIR-II agent nanoparticles, for in vivo
imaging. These particles had the IR-1061, a commercially available water insoluble polymethine
dye, embedded in an amphiphilic polymer poly(acrylic acid) (PAA) matrix. These nanoparticles
also had a coating of the surfactant DSPE-mPEG (a polyethylene glycol-conjugated phospholipid,
ca. 5 kDa) for improved biocompatibility and longer circulation lifetimes. Using these IR-1061
nanoparticles, the inner organs and blood vessels of mice were imaged and the results matched with
the images previously obtained with inorganic carbon nanotubes and quantum dots[89]. Most of the
recent literature published on nanoparticle systems not only are biocompatible, fully biodegradable
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and exhibit high signals but also designed to target particular cells or tumors and avoid healthy
cells. Specific details of these systems and examples will be discussed in the next section.
Figure 1.8: Real-time fluorescence imaging of BF2 chelated tetraarylazadipyrromethenes (near infrared dye)
conjugated poly(styrene-co-methacrylic acid) particles uptake into HEK293T cells (scale bar 10 m). (Reprinted with
permission from Ref. [88] Copyright 2011 American Chemical Society)
1.3 Targeting
Up to this point we have seen examples of passive targeting of tumors in fluorescence imag-
ing. Encapsulating or conjugating small molecule fluorophores to nanoparticles allow the particles
to preferentially accumulate in tumors due to EPR effect (cf. Figure 1.9)[49, 50]. In this case,
the size is used to passively target tumors. Apart from size, modifying the surface charge of the
nanoparticles is the other way to passively target the tumors. The surface charge of tumors is highly
negative when compared to normal cells[90], so if the surface of the nanoparticles is modified to be
more cationic then the nanoparticles bind electrostatically to the negatively charged phospholipid
head groups expressed on tumors and in turn preferentially accumulate in tumors[91, 92, 93, 94].
However, passive targeting is not always successful as the EPR effect, the phenomenon utilized in
passive targeting for increased accumulation, is not commonly observed in some types of tumors such
as gastric and pancreatic, and also in some other tumors the core might not be well perfused[52]. To
this end, it is necessary to add an active targeting component to the nanoparticles so that they affect
tumors and avoid healthy cells (cf. Figure 1.9). The characteristics required for an ideal target are
that they should be universally and uniquely expressed by the tumors. In most cases the target is an
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overexpression of a particular cell surface marker in tumors. The overexpression of the target group
facilitates increased binding of the targeting agent, which in turn increases the cellular uptake of
the targeting agent[55]. Recently, Prabhu and colleagues studied the different targeting approaches
for polymeric nanoparticles[91]. According to them, the targeting agents can be divided into three
categories: ligand - based, tumor cell and tumor endothelium targeting. In ligand - based targeting,
the ligand binds specifically to a receptor this is dominantly overexpressed by tumor cells, and the
ligands used vary from small molecules, vitamins, carbohydrates, peptides, antibodies, proteins and
nucleic acids[49, 91, 95, 96]. In tumor cell targeting, the cell surface receptors that are overexpressed
by tumors are targeted, and some of the commonly targeted receptors are transferrin, folate, and
epidermal growth factor receptors (EGFRs), and glycoproteins[91, 97, 98, 99, 100, 101, 102]. In tu-
mor endothelium targeting, the endothelial cells are targeted to prevent angiogenesis, as it plays an
important role in regulating cancer growth. Targeting vascular endothelial growth factors (VEGF)
receptor, αvβ3 integrin, vascular cell adhesion molecule - 1 (VCAM - 1), and matrix metallopro-
teinases (MMP) are some examples of tumor endothelium targeting[91, 103, 104, 105, 106, 107].
In the majority of the applications, the targeting agent is not used by itself but is attached to
the fluorophore or a nanocarrier to improve the accumulation and most of these targeting agents
are attached via a simple covalent conjugation technique or electrostatic interactions. Attaching
the targeting agent directly to the small molecule fluorophore compromises the emission and other
properties of the probe so attaching the targeting agents to nanocarriers which doesn’t alter the flu-
orophore’s properties is preferred[56]. In addition, conjugating the targeting agent to the polymeric
nanocarrier overcomes the hurdles such as weak reproducibility and poor control of tuning the num-
ber of targeting agents attached to the particle[72]. Once the polymeric particle is conjugated with
the desired amount of the targeting agent, they can be utilized to accumulate in a specific tumor
for imaging applications. Some examples of fluorescence imaging with polymeric nanoparticles are
reviewed below.
Zheng and colleagues developed a novel ICG containing phospholipid-polyethylene glycol
(ICG-PL-PEG) based micelle. They attached two targeting agents, a small molecule called folic
acid (FA) and a large protein called integrin αvβ3 monoclonal antibody (mAb), to the ICG-PL-PEG
micelles and displayed their target specificity using three different cell lines. The three cell lines used
were EMT6 (murine mammary tumor cells), U87-MG (human glioblastoma cancer cells) and MCF-7
(human breast cancer cells). Laser scanning confocal microscopy, flow cytometry and other in vitro
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Figure 1.9: Schematic representation of different mechanisms by which nanocarriers can deliver drugs to tumors.
Polymeric nanoparticles are shown as representative nanocarriers (circles). Passive tissue targeting is achieved by
extravasation of nanoparticles through increased permeability of the tumor vasculature and ineffective lymphatic
drainage (EPR effect). Active cellular targeting (inset) can be achieved by functionalizing the surface of nanoparticles
with ligands that promote cell-specific recognition and binding. The nanoparticles can (i) release their contents in
close proximity to the target cells; (ii) attach to the membrane of the cell and act as an extracellular sustained-release
drug depot; or (iii) internalize into the cell. (Reprinted with permission from Ref. [49] Copyright 2007 Nature
Publishing Group)
experiments were employed to confirm that the targeting probe was mainly internalized into cells
via ligand-receptor or antigen-antibody mediated endocytosis pathway. In addition, according to
their data the amount of targeting agent conjugated to the ICG-PL-PEG micelle doesn’t affect the
integrity and properties of the nanoprobe[56].
Pang and colleagues developed a 1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindotricarbocyanine
Iodide (DiR) (fluorophore) loaded methoxy poly(ethylene glycol)-poly(σ-caprolactone) based poly-
mersome. Apart from the fluorophore the polymersome was loaded with drugs, doxorubicin (Dox)
and tetrandrine (Tet), to give a therapeutic functionality to the system. These multifunctional poly-
mersomes were conjugated with a targeting agent called Lactoferrin (Lf) and this polymersome was
referred as Lf-PO-Dox/Tet-DiR. Lf is a novel brain targeting ligand, which enables drug-loaded poly-
mersome to transport across the blood-brain barrier (BBB) with higher efficiency when compared
to another targeting agent called transferrin. In vitro studies in C6 cells (rat glial tumor cells) were
utilized to show that Lf-PO-Dox/Tet-DiR polymersomes were uptaken through receptor-mediated
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endocytosis while the free Dox accumulated mainly through a diffusion mechanism. Moreover, in
vivo studies carried out in glioma model rats further confirmed that the Lf-PO-DiR crossed the
BBB and had an increased accumulated at the tumor site, which is indicated by the strong increase
in fluorescence at the site of the tumor (cf. Figure 1.10). Overall, they constructed a promising
targeted nanoprobe for diagnosis and therapy of gliomas[67, 108].
Figure 1.10: (a) Design of lactoferrin-conjugated biodegradable polymersome for glioma targeting. Polymersomes
are simultaneously loaded with doxorubicin (Dox) as a model antitumor drug and tetrandrine (Tet) as an multi drug
resistance (MDR) inhibitor. Lactoferrin (Lf) was conjugated on the surface of polymersomes, as glioma targeting
ligand and to help overcome the obstruction of the BBB. (b) Accumulation of targeted polymersomes in glioma (EPR
effect and overcoming BBB) was evidenced by fluorescence imaging. (c) The specific interaction of Lf-conjugated
polymersomes with glioma cells enhanced drug delivery into these cells, improving the chemotherapy of glioma as
showed by the improved survival in rats. (Reprinted with permission from Ref. [67] Copyright 2012 Wiley Periodicals
Inc.)
Le Droumaguet and colleagues developed a Rhodamine B (fluorophore) functionalized poly
(alkyl cyanoacrylate) (RhB-PACA) nanoparticles for fluorescence imaging. The RhB-PACA nanopar-
ticles were surface functionalized with biologically active targeting ligands such as biotin, curcumin
derivatives, and a monoclonal anti-Aβ1−42 antibody. In vitro studies were carried out in two can-
cer cell lines, MCF7 (human breast adenocarcinoma cells) and M109 (murine lung cancer cells),
which both overexpress biotin receptors on their surfaces (cf. Figure 1.11). The results obtained
confirmed that the biotin conjugated RhB-PACA nanoparticles were uptaken by the cells through a
specific receptor mediated endocytic pathway as the fluorescence seen was mainly around the vesi-
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cles surrounding the nuclei. Moreover the fluorescence signal of covalently conjugated Rhodamine
B to PACA nanoparticles was fine and strong in comparison to the typical diffuse signal obtained
when hydrophobic dyes are encapsulated. The specificity of biotin targeting strategy was further
supported by in vitro studies carried out in L1210 cells that do not overexpress biotin. The biotin-
RhB-PACA nanoparticles did not show the same strong fluorescence in L1210 cells as shown in
MCF7 and M109 cells[22].
Figure 1.11: Internalization of rhodamine B-labeled NPs. Fluorescence microscopy images of MCF7 cells showing
the cellular uptake of nonfunctionalized (N0) and biotin-functionalized (N1) NPs (red) after 5 h of incubation. The
nuclei were stained with DAPI (blue), phalloidin-fluorescein isothiocyanate (Ph-FITC, green) was used to label F-
actin, and the last column represents the overlay of all types of staining. (Reprinted with permission from Ref. [22]
Copyright 2012 American Chemical Society)
1.4 Activation
One of the issues noticed with the polymer-core nanoparticles was that the emission of the
probe was initially quenched, when dispersed in aqueous solutions due to aggregation of the fluo-
rophore on the surface of the particles[31]. This drawback turned out to be an advantage to the
nanoparticulate system because the probes are in ”turned off” state under normal conditions and
”turned on” only under specific diseased conditions, which results in enhanced tumor to background
ratio[109]. To this end, identifying different activation techniques for the nanoprobes is necessary
to develop activatable NIR nanoprobes. To date, various general activatable small molecule probes
have been developed to image tumors and in most of these systems, the emission is ”turned on”
upon binding to a specific protein, enzyme or receptor[109]. Pham and colleagues reported a probe
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that is activated upon binding to matrix metalloproteinase 7 (MMP), a protease overexpressed
in tumors[110]. Tung and colleagues developed a NIR probe that activates when interacted with
Cathepsin D, which is another protease overexpressed in tumors[111]. Urano and colleagues devel-
oped pH-activatable probes based on BODIPY fluorophore that had a cancer-targeting monoclonal
antibody conjugated to it[112]. These activatable probes mentioned so far are small molecule probes
and not particulate based. There are only a handful of systems reported for activatable NIR poly-
meric nanoparticles. In 2011, Rungta and colleagues, used PA particles modified with an azide
terminated ICG to demonstrate the activation of fluorescence when mixed with bovine serum albu-
min (BSA) (cf. Figure 1.12)[31]. It is well established in literature that the albumins can ”turn on”
the emission of aggregated fluorophores[113]. Albumins bind to the hydrophobically aggregated flu-
orophore via a combination of hydrophobic, hydrogen bonding, and electrostatic interactions, which
deaggregates the fluorophores and turns on the emission[113]. Later in 2011, Palma and colleagues
demonstrated that the emission of BF2 chelated tetraarylazadipyrromethenes (near infrared dye)
conjugated poly(styrene-co-methacrylic acid) particles can be activated by sodium dodecylsulfate
(SDS), a surfactant. In addition, they demonstrated the activation in vitro in MDAMB-231 (breast
cancer), HEK293T (kidney), and CAKI-1 (renal cancer) cell lines. According to them, the phospho-
lipids in the cell membrane, specifically lecithin is responsible for the activation and the mechanism
is similar to that of SDS[88]. These two strategies of activation work but they are not specific enough
like the MMP7 sensitive small molecule probe. There has been advancement in the development of
nanoparticle systems which respond to various stimuli and environments to ”turn on” emission (cf.
Figure 1.5)[55, 61, 114], but not particles which activate emission upon binding to specific proteins
or receptors that are overexpressed in tumors. It is expected that future endeavors in the field of
tumor nanotheranostics will be in the direction of developing ”smart” activatable NIR nanoparticles.
1.5 Overview
Although there has been significant advancement in developing polymer based nanoparti-
cles for optical imaging, it still has several drawbacks and not one system addresses all the issues
completely. To this end, it is necessary to improve a current nanoprobe and add multifunctionality
so that a single ”nanodevice” can be used to target, image and treat tumors effectively. The main
objective of this project is to develop a polymer based near infrared (NIR) particle that
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Figure 1.12: (a) Increase in photoluminescence intensity ratio of PA-azICG-azPEG1K particles dispersed in a
phosphate buffered solution (PBS) with the addition of 0.014 mM BSA; time evolution of the intensity at 819 nm
relative to the initial intensity. Inset presents photoluminescence of particles after 2 min (◦), 37 min (•), and 1174
min (5) . Excitation energy at a wavelength of 710 nm; particle density of 1.259 x 1012 cm−3. (b) Optical image of
fluorescence intensity of PA-azICG-azPEG1K particles in deionized water (far left), PBS (center), and 2 h after the
addition of 0.014 mM BSA to the PBS solution (far right); images taken with a Caliper Xenogen IVIS Lumina II XR
Instrument with 745nm excitation filter and ICG emission filter; particle density of 1.259 x 1012 cm−3 (Reprinted
with permission from Ref. [31] Copyright 2011 WILEY-VCH Verlag GmbH & Co. KGaA)
can serve as both, diagnostic and therapeutic agents, for fighting cancer. Specifically
these particles will be designed to have high-contrast, high signal to noise ratios, long
in vivo circulation lifetimes, and facilitate easy attachment of functional and target
components.
The chapters of this dissertation can be summarized as follows:
Chapter 2 presents sub-100 nm colloidal particles which are surface-functionalized with
fluorophores that operate in the near-infrared (NIR) spectrum, through a copper(I) catalyzed azide-
alkyne Huisgen 1,3-Dipolar cycloaddition. These functionalized nanoparticles exhibit a protein trig-
gered activation/deactivation of the emission. The methodology for emission switching offers a path
to maximize the signal from the typically weak quantum yield inherent in NIR fluorophores. Pre-
liminary fluorescence imaging studies indicated that the brightness of the functionalized polymer
based nanoparticles improved considerably.
Chapter 3 presents sub-100 nm colloidal particles which are surface-functionalized with an
azide terminated Survivin ligand derivative (azTM) originally proposed by Abbott Labs and specu-
lated to bind directly to Survivin (protein) at its dimer interface. Using affinity pull-down studies,
it was determined that the PA/azTM nanoparticles selectively bind Survivin and the particles can
enhance apoptotic cell death in glioblastomas and other Survivin over-expressing cell lines such as
A549 and MCF7 relative to cells incubated with the original Abbott-derived small molecule inhibitor.
Chapter 4 presents sub-100 nm colloidal particles which are surface-functionalized with small
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molecules such as drugs or fluorophores through an environmentally-sensitive linker. The linker used
is an azide modified bovine serum albumin (azBSA) which prevents opsonization and releases the
small molecule upon digestion. This strategy offers a delivery functionality to the colloidal particles.
Additionally, the particles can be used for fluorescence resonance energy transfer (FRET) based
imaging application. A FRET pair of dyes were attached to the particle and the azBSA, and the
FRET efficiency was increased by unfolding the protein via heating and addition of denaturants.
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Chapter 2
Switching fluorescence of surface
modified colloids with




The synthesis of the azide modified chromophores was conducted or aided by Dr. Yuriy
P. Bandera at Clemson University. The confocal imaging studies were carried out with the aid of
Dr. Hsin-I Hung, Dr. Venkat Ramshesh, Megan F. Duperreault, and Dr. Anna-Liisa Nieminen at
Medical University of South Carolina. The results presented in this chapter have been published
as Jetty et al., Protein triggered fluorescence switching of near-infrared emitting nanoparticles for
contrast-enhanced imaging. Journal of Materials Chemistry B, 2013. Content has been reproduced
with permission from Royal Society of Chemistry.
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2.2 Introduction
Optical imaging in medical applications is especially attractive due to its noninvasive nature,
though it can be hindered by limitations of resolution and penetration depth which are a result of the
high absorption, auto fluorescence, and scattering found in biological tissues. To circumvent some
of these issues, there is an interest in developing near-infrared (NIR) fluorophores since there is a
region of reduced absorption for this wavelength range, providing maximum penetration of light and
facilitating deep tissue imaging[115]. Unfortunately, the quantum yield of organic NIR fluorophores
is typically low (< 0.2) in physiological conditions[116, 117] and routes to achieve a higher tumor
to background signal ratio (TBR) are desirable. Achieving a higher TBR can be accomplished by
both preferentially accumulating the probe in a targeted tissue and, once sequestered, activating the
probe’s fluorescence only in this region[118, 119, 120].
A myriad of activation schemes have been proposed[119, 121], though the approach was ini-
tially demonstrated with polymeric agents that emitted a signal after an enzymatic attack[13, 120].
The underlying mechanism for activation is a conversion of an aggregated quenched fluorophore
back to its emissive monomeric state. To that end, the significant variations in the emission spectra
of photoluminescent dyes which are routinely observed when they form supramolecular host/guest
assemblies or complex with biomacromolecules[122, 123, 124, 125] and have been exploited in de-
signing activatable contrast agents by this group[31] as well as others[88]. As indicated earlier, in
addition to activating the emission only in the tissue of interest, to achieve maximum TBR, the
contrast agent must accumulate in the targeted tissue while clearing rapidly from non-target organs
and tissues. Small molecule fluorophores are rapidly cleared because of a short in vivo circulation
life due to non-specific binding to proteins[116], thus improving the tumor to background ratio, but
this also reduces the absolute amount of accumulation at the target. This weak accumulation is in
addition to a limited aqueous solubility which frustrates parenteral administration[126].
Compared with conventional molecular scale fluorophores, dye-doped particles have demon-
strated improved in vivo detection and enhanced targeting efficiencies through longer circulation
times, designed clearance pathways, and multimeric binding capacities[77]. Since the initial report
on isolating fluorophores through their encapsulation in a particle was presented[127], a multitude
of efforts have been described, using both polymeric[128, 129] and inorganic[130, 131, 132, 133,
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Figure 2.1: Schematic of 50 nm poly(propargyl acrylate) (PA) particles surface modified with an azide-terminated
squaraine (azSQ) and polyethylene glycol (azPEG) through an aqueous-phase “click” transformation in the (a)
aggregated & nonfluorescent state and in the (b) albumin activated fluorescent state. Particles could be deactivated
and returned to the quenched state through a trypsin digestion of the albumin.
moieties have the potential to combine imaging, early detection, prevention, and the treatment of
cancer with a single type of colloidal “nanodevice”[78, 137, 138, 139, 140]. Within the nanodevice
conceptualization, the design of a sub-100 nm particle that exhibits NIR fluorescence that can be
modulated on or off by specific proteins within a cancer cell is of particular interest[31, 88].
In the current effort, poly(propargyl acrylate) (PA) colloids were surface modified with an
azide terminated squaraine-based dye, a NIR emitting fluorophore, and polyethylene glycol through
a copper-catalyzed azide/alkyne cycloaddition performed in water[86]. The placement of the flu-
orophore onto the surface of the particles allows for the dye to form a guest/host complex with
available proteins and this feature was exploited in achieving a fluorescence activation of the parti-
cles when in a quenching aqueous medium. In addition, the removal of the bound proteins from the
particle was achieved through their enzymatic digestion, resulting in a deactivation of the emission.
Reversibility may be a crucial feature if these probes are intended for real-time monitoring of in vivo
events. These particles described a “fluorescent switch” that can be modulated on or off through the
incorporation of simple proteins and/or enzymes and are a promising platform for developing protein
or multi-protein complex sensitive contrast agents for biotechnology and biomedical applications.
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Table 2.1: Fluorophore grafting density and fluorescence quantum yield (φ) of surface functionalized
PA particles; Fluorophore and particles dispersed in methanol
compound fluorophore grafting density quantum yield (φ)
(azSQ/nm2)
azSQ — 0.101
FP0 PA/azSQ 0.05 0.051
FP1 PA/azSQ 0.09 0.033
FP2 PA/azSQ 0.12 0.039
FP3 PA/azSQ 0.17 0.039
FP4 PA/azSQ 0.28 0.034
FP5 PA/azSQ 0.49 0.024
FP6 PA/azSQ /azPEG 0.09 0.031
FP7 PA/azSQ /azPEG 0.49 0.012
2.3 Results & Discussion
A schematic of the particles studied in this effort is presented in Figure 2.1. The poly(proparg-
yl acrylate) (PA) colloids were prepared using a standard aqueous emulsion polymerization tech-
nique resulting in spheres with a diameter of 49.9 ± 0.58 nm (mean and standard deviation). To
functionalize the surface of the particles, a multiple step copper-catalyzed azide/alkyne cycloaddi-
tion (“click” transformation) was performed in water[86] to produce PA particles that had both
squaraine and polyethylene glycol (PEG) attached to their surface. Initially, an azide-modified
squaraine derivative (azSQ) was attached to the PA particles through a “click” transformation.
Squaraine dyes are typically classified as a NIR dye though technically their emission is in the far-
red regime[141, 142, 143, 144]. Due to their high fluorescent quantum yields compared to other NIR
organic fluorophores like indocyanine green[31, 145], squaraine dyes have found a broad range of
applications[141, 146, 147], with the biomedical community expressing an especially strong interest
in this class of dyes[142, 143, 144, 148, 149].
To attach the fluorophores to the particles, the azSQ was initially clicked onto the par-
ticles for 15 mins and then the reaction was stopped by the removal of unreacted azSQ, sodium
ascorbate, and Cu(II)SO4 through a repeated particle washing procedure consisting of centrifuga-
tion and redispersement in methanol. To reduce the grafting density of dye, the initial amount of
azide-modified dye used in the reaction was decreased. The cleaned PA/azSQ (FP5) particles were
subsequently utilized in a secondary click transformation with azide-modified polyethylene glycol
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chains with molecular weight of 5k (azPEG) that was allowed to run for 48 hours and then washed
to remove unreacted species; these particles are referred to as PA/azSQ/azPEG (FP7) particles. The
use of PEG to infer a hydrophilicity to the particles has been found to be important for directing
protein absorption on the particles and achieving long circulation times[77]. The characteristics of
the particles synthesized for this study are presented in Table 2.1.
2.3.1 Emission Spectrum
Figure 2.2a presents the molar extinction coefficient and photoluminescence of the free azide-
functionalized squaraine (azSQ) dispersed in methanol. In this solvent, azSQ has a peak absorption
maximum at 663 nm, while the corresponding emission peak is at 672 nm, for a relatively small
Stokes shift of 9 nm. The symmetry for the absorption and emission spectra is evident, though
the absorption exhibits a small peak at 626 nm. This lower energy absorption is often seen in
concentrated aqueous solutions of squaraine due to the formation of H-aggregates[149, 150]; the
appearance of this peak in the freshly prepared dilute methanol solution of azSQ is due to the
sulfonate group which causes higher self-affinity[151].
A structurally similar squaraine dye has been recently presented[152] that was characterized
by an absorption and emission peak maximum of 672 nm and 678 nm, respectively, when dispersed
in toluene. In this solvent, this dye gave a fluorescence quantum yield of 0.51. In comparison, the
relative fluorescence quantum yield for azSQ in toluene differed by 0.1% when measured in methanol
(φ = 0.101; cf. Table 2.1). Despite the minor solvent-dependent changes in the spectra between this
latter squaraine dye and azSQ, the fluorescence quantum yield of the azSQ is significantly lower at
0.101. The reduction in quantum yield was speculated to be due to the substitution of an azide to the
chromophore and its ability to better facilitate non-radiative deactivation to the ground state[151].
In comparison, Figure 2.2b presents the absorption and photoluminescence spectra of PA
particles after they have been surface modified with the attachment of azSQ chromophores and
azPEG chains (FP7) and dispersed in methanol. The absorption spectra of the FP7 particles indicate
an absorption peak maximum that is at a wavelength of ca. 672 nm, a 9 nm bathochromic shift from
the free dye. Utilizing the molar extinction coefficient in the dilute regime for the free azSQ particles
in methanol (cf. Figure 2.2a) allows for the estimation of the number of chromophores attached to
the particles. Following this approach, the FP7 particles had a grafting density of 0.49 azSQ/nm
2
when analyzed over the wavelength range of 615 nm to 685 nm. The grafting density of the azPEG
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Figure 2.2: (a) Molar extinction coefficient (green) and photoluminescence (red) of azide functionalized squaraine
derivative chromophore (azSQ; 6.98 µM in methanol); (b) Absorbance (green) and photoluminescence (red) of
PA/azSQ/azPEG (FP7) particles in methanol. Excitation energy at a wavelength of 630 nm.
to the particles was not assessed but the contact angle of the PA particles to water changed from θ >
70 ◦ to θ < 10 ◦ after the attachment of the azPEG indicating that their surface was hydrophilic.
2.3.2 Quantum Yield
It is well known that when fluorophores are dispersed in a solvent that a limiting concen-
tration can be found where the dye–dye separation becomes small and statistical closely spaced
pairs and larger aggregates are formed[153]. Once excited, these aggregates can find non-radiative
routes to lower their energy, thereby reducing the observed luminescence quantum yield. Once the
chromophores are attached to the surface of particles, the “local” concentration of the emitters
is elevated due to the two-dimensional nature of the attachment. This elevated concentration of
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emitters results in an enhanced propensity for aggregate formation and non-radiative routes for the
excited emitters to return to their ground state. Therefore, the counter intuitive speculation is that a
reduced number of chromophores grafted to a particle’s surface will result in a higher quantum yield.
Table 2.1 and Figure 2.3 presents the quantum yield for the “free” azide-functionalized squaraine
derivative dye and the modified particles with varying fluorophore grafting densities. In addition,
Table 2.1 presents a subset of the PA/azSQ particles clicked with an azide-modified PEG.

















Figure 2.3: Quantum yield of azide functionalized squaraine derivative chromophore (azSQ) with variation in
grafting density to PA particles (methanol). Excitation energy at a wavelength of 650 nm.
As indicated earlier, the free azSQ dye exhibited a quantum yield of φ = 0.101. Once the
chromophores are attached to a particle, the observed quantum yield was significantly diminished
relative to the free dye’s value (cf. Figure 2.3). The PA/azSQ particles (FP5; cf. Table 2.1) with a
dye grafting density of 0.49 groups/nm2 exhibits a 76 % drop in quantum yield relative to the free
dye, while the PA/azSQ particles (FP1; cf. Table 2.1) with a grafting density of 0.09 groups/nm
2
exhibits a 67 % drop in quantum yield. The particles may act as quenching centers of fluorescence for
chromophores that are adsorbed onto their surface since (1) the planar surface offers a constrained
2-dimensional region on which the chromophores can dimerize[154] and (2) a non-radiative energy
transfer can occur from the excited molecules to the particle[153].
As speculated earlier, the reduction of the number of fluorophores grafted onto the particle’s
surface results in an increase in quantum yield (cf. Table 2.1). For the PA/azSQ particles, a 37 %
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Figure 2.4: (a) Photoluminescence of FP7 particles dispersed in: PBS (—), PBS and 0.05mM BSA (green), PBS
and 0.05mM HSA (red). Particles were incubated with serum albumin for ca. 4 days to insure increase was invariant
with time, though 25% of the increase occurred within the first 30 minutes. (b) Photoluminescence spectra of FP5
particles in PBS with 15 mg BSA initially at 20 ◦C (◦), at 70 ◦C (•), after 70 ◦C anneal then cooled to 20 ◦C (4),
after 70 ◦C, cool to 20 ◦C, heated to 70 ◦C (5), and after 70 ◦C, cool to 20 ◦C, heated to 70 ◦C, then cooled to 20
◦C (—). Inset presents the intensity ratio at 682 nm (red) for the thermal cycles relative to the initial emission and
the intensity ratio (green) of the J-aggregates (745 nm) to the monomeric emission (682 nm). Excitation energy at a
wavelength of 630 nm.
reduction in grafting density, from 0.49 to 0.09 groups/nm2, results in a 38 % increase in quantum
yield. The azSQ dye can be roughly approximated as an ellipsoid with a long axis of 21 Å and
a cross section of 10 Å x 5 Å. At a grafting density of 0.49 groups/nm2, the inter-dye separation
distance on the surface of the particle would be statistically 16 Å. This distance is sufficiently close
that two dyes could approach one another to partially dimerize and reduce the quantum yield of
emission. In contrast, a grafting density of 0.09 groups/nm2 gives a separation distance of ca. 38 Å,
a distance sufficiently large enough to frustrate dye-dye aggregation.
It is well established that PEG polymers, when attached to the surface of particles, provide
steric stabilization and reduces protein absorption in biomedical applications[155]. Protein absorp-
tion promotes opsonization, which can lead to aggregation and clearance from the bloodstream.
The resultant rapid removal is due to phagocytosis by the mononuclear phagocyte system (MPS) in
the liver and splenic filtration[156]. Nonetheless, the addition of PEG chains to the surface of the
particles reduces the quantum yield of the particles. Table 2.1 presents the fluorescence quantum
yield of the particle with varying grafting densities and PEGylation. At higher grafting densities,
the quantum yield of the FP7 particles was half of the PEG-free FP5 particles, while at the lower
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grafting densities (FP1 & FP6), the PEGylation did not effect the yield significantly. This suggests
that the attachment of the PEG chains increases the non-radiative transfer of energy when excited,
and hence influences the emission characteristics of the attached squaraine.
2.3.3 Squaraine/Protein Complexation.
The utilization of an azSQ-modified particle for any in vivo or in vitro imaging application
will require the particles to be dispersed in an aqueous environment. The replacement of methanol
for a PBS solution in the FP7 particles resulted in a total quenching of fluorescence (cf. Figure 2.4a).
Due to the hydrophobic nature of the dye, the employment of PBS is speculated to force the bound
azSQ to sequester to the particle surface and dimerize[37, 153].
It has been established that the fluorescence quantum yield of squaraine dyes can change
when the dye is adsorbed onto macromolecules such as proteins and enzymes[113, 149], and this
response can be employed as a fluorescent diagnostic probe in medical and biological applications.
Previous studies have established that squaraine adsorption occurs on the ca. 10 nm sized human
albumin protein and that dye adsorption will dominate over dye dimerization when the dye number
density is less than a few times the protein number density[113]. In the current system, the FP7
particles in water were mixed with bovine serum albumin (BSA) at concentration of 0.05 mM. The
emission intensity in Figure 2.4a exhibited an immediate increase within the first 30 minutes that
accounted for ca. 25% of the total increase in intensity followed by a long-term gradual increase.
Even though the emission turn-on occurred in just a few minutes, the change in intensity was mon-
itored over a 4-day incubation period to insure it had plateaued. At BSA concentration of ca. 0.05
mM, the number of BSA molecules is approximately equal to 15.4 times the total number of azSQ
in the system. There was a 1991 % increase in output intensity at the peak wavelength of 687 nm,
while the total integrated intensity was ca. 10 times greater. As indicated in Figure 2.4a, the study
was also performed with human serum albumin (HSA) instead of BSA and the fluorescence enhance-
ment with the human variant was identical to the bovine version. A similar study was performed
with the enzymes, lysozyme and trypsin, and with the surfactant, sodium dodecyl sulfate (SDS).
The surfactant was successful in breaking up the aggregation of the fluorophores and activating
the fluorescence of the particles[88], while the lysozyme and trypsin were not (cf. Supplementary
Information (SI)). Serum albumin is a major protein constituent of blood plasma and this protein
facilitates the disposition and transport of a variety of exogenous and endogenous ligands to specific
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regions. The delivery of ligands originates from two (BSA) and one (HSA) structurally selective
binding site(s) where the binding affinity originates from a combination of hydrophobic, hydrogen
bonding, and electrostatic interactions. The observed increase in fluorescence intensity with BSA
and HSA binding likely results from the ability of the protein to “dissolve” hydrophobically ag-
gregated azSQ on the surface of the particles[113, 143]. In addition, tight binding to the protein
environment, possibly at the hydrophobic pockets, may increase the molecular rigidity of the dye,
which reduces the vibrational modes and further raises the fluorescence signal[116].



























Figure 2.5: Change in fluorescence intensity at wavelength of 671 nm with exposure to hydrogen peroxide of free
azSQ dye (•) and FP7 particles incubated with BSA (◦). Aqueous solution with excitation energy at a wavelength of
630 nm.
The most commonly used NIR probes, organic fluorescent dyes, are often chemically un-
stable and susceptible to bleaching by the attack of nucleophiles that are abundant in biological
environments[29]. An approach to overcome this deficiency is through steric protection of the fluo-
rophore by forming a rotaxane with the dye[141, 148, 157] or encapsulation inside a particle[127, 128,
129, 130, 131]. The former approach requires sophisticated chemistry to thread the dye through the
macrocyclic cavity, usually resulting in a low yield, while the latter approach negates the prospect
of forming beneficial guest/host assemblies with the fluorophore. The simpler and more versatile
approach is the physical entrapment of the hydrophobic fluorophore inside the hydrophobic pock-
ets of an aqueous dispersible protein or vesicle[144]. Figure 2.5 presents the normalized change in
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fluorescence intensity of the free azSQ dye and FP7 particles incubated with BSA, all dispersed in
water, with exposure to hydrogen peroxide, an effective nucleophile. The drop in observed fluores-
cence intensity of the free dye is due to the degradation of the fluorophore by the hydrogen peroxide,
while the fluorophores that are within the hydrophobic pocket of the BSA (or merely engulfed)
continue to fluoresce even at much higher concentrations of hydrogen peroxide. It appears that
the fluorophore/protein complex that activates the fluorophore’s emission is possibly preventing the
ingress of the hydrogen peroxide to the dye or acting as a scavenger for the peroxide[158, 159].
BSA has been indicated to initiate irreversible unfolding at temperatures greater than 60
- 70 ◦C[160]. Below this temperature, in the folded state, the protein exhibits global translational
and rotational diffusion, but when above this temperature, the protein undergoes structural changes
which are accompanied by changes in the protein dynamics[161, 162]. Figure 2.4b presents the
increase in fluorescence when the FP5 particles that are dispersed in PBS, have been incubated with
BSA and undergo thermal cycling at temperatures above the irreversible unfolding temperature of
BSA. At temperatures in the denaturation regime, the proteins initially unfold and extend, and if the
proximity to one another is sufficiently high, the unfolded protein chains can entangle and potentially
partially cross-link[161]. As indicated earlier, the incubation of the aqueous-phase particles with BSA
results in a dramatic turn-on in emission intensity of 1.2x105 counts/second at 682 nm (cf. Figure
2.4a). Raising the temperature to 70 ◦C results in a 35 % enhancement of the emission, though
once the particles are cooled to 20 ◦C, the emission increases by 105 % (at 682 nm). An addition
annealing cycle results in a total increase in emission intensity of 125 % (cf. Figure 2.4b inset). The
absolute increase in emission with annealing is dependent on both the ratio of azSQ to BSA as well
as their thermal history. Nonetheless, there is a significant change in the emission characteristics
with annealing.
In comparison to the “monomeric” absorbance, squaraine dyes that are dispersed in aqueous
solutions tend to form aggregates that exhibit an absorbance that has a bathochromic (J-aggregates)
or hypsochromic (H-aggregates) shift. These aggregates also affect the emission properties, with H-
aggregates usually being poor emitters and J-aggregates often giving efficient fluorescence[149]. The
inset in Figure 2.4b presents the intensity ratio of the J-aggregates (745 nm) to the monomeric
emission (682 nm) and suggests a conversion of the aggregates to the monomeric form with thermal
cycling; a conclusion that is corroborated with the absorption characteristics (cf. SI). Due to the steric
limitations of the azSQ being tethered to the surface of the particle, J-aggregates are characterized
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structurally as having only one end of the azSQ aligned with the end ring of the other azSQ. The
large fluorescence turn-on associated with the conversion of the surface-attached azSQ fluorophores
from “aggregate to monomeric species” may be attributed to the inclusion of the dye into the
hydrophobic pocket of BSA when in its native folded form. The fluorescent enhancement of the
particles when they are thermally cycled above the denaturing temperature of BSA suggests that
other factors than just a pocket-based complexation is operative in converting the dye molecules from
their non-emissive aggregate states to the fluorescent monomeric form. The unfolded state may offer
opportunities of the protein to bind to additional fluorophores on the surface of the particle, reducing
the non-radiative decay rate of the fluorescent molecules and raising the fluorescence signal[163, 164].
The PEGylated particles, FP6 & FP7, did not exhibit such a dramatic increase in photoluminescence
with annealing. The FP7 particles exhibited a modest 13 % increase in integrated intensity with
annealing and it is speculated that the PEG chains are effective in preventing the unfolded BSA
from finding, adhering to, and destroying fluorophore aggregates.
Figure 2.6: Variation of photoluminescence spectrum of FP5 particles in PBS incubated with BSA (sequence 0),
with four annealing cycles (sequence 1-5), with introduction & incubation of trypsin (sequence 6-10), reintroduc-
tion & incubation of BSA (sequence 11-13) and with four annealing cycles (sequence 14-17). Excitation energy
at a wavelength of 630 nm. An annealing cycle consists of raising the sample temperature to 65 ◦C for 20 min and
then returning the temperature to 20 ◦C.
A number of reports have demonstrated the “activation” of NIR particles through the em-
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bodiment of a guest/host complexation on the surface of the particles[31, 88]. Recently, particles
surface functionalized with azadipyrromethenes had their emission turned-on when mixed with either
an anionic or nonionic surfactant, as well as a phospholipid[88]. Our laboratory has recently demon-
strated the BSA activation of indocyanine green (ICG) functionalized particles[31]. These studies
both accomplished the activation of emission through the formation of a guest/host complex, yet
there has been no methodology to deactivate the emission. To this end, the use of a protein in our
studies allows for its digestion once on the particle and a route to deactivate the fluorescence. Figure
2.6 presents the fluorescence activation/deactivation of FP5. These particles were equilibrated with
0.025 mM BSA in a Tris-HCl buffer of pH 8, then annealed at 65 ◦C and cooled to 20 ◦C. The
annealing step was repeated four times. As demonstrated previously (cf. Figure 2.4b), the annealing
resulted in a significant enhancement in the emission intensity. Mixing the particles with trypsin
(0.143 mM), a standard enzyme used for the digestion of albumin, and incubating the mixture at
37 ◦C for 15 hours resulted in a 71 % drop in emission, while after 64 hours the decrease was 85 %
complete. With 184 hours of incubation there was an almost complete cessation of emission. The
majority of the emission turn-off was complete in a few minutes, the reaction was monitored over a
substantial incubation period (ca. 7.6 days) to insure a plateau was reached. Trypsin catalyses the
hydrolysis of peptide bonds so that albumin is broken into smaller peptides and its speculated that
the fragments from BSA are unable to effectively “coat” the azSQ and these chromophores again
coalesce and quench on the surface of the particles. Performing the same digestion study with parti-
cles that had not been annealed resulted in a similar response, though the fluorescence deactivation
was not as complete. It is speculated that the BSA is more structurally open after annealing and
trypsin is more effective in digesting the denatured protein[165, 166]. Once again adding an excess
of BSA to the FP5 particles after the trypsin digestion results in a return to the approximate initial
emission intensity after 48 hours of incubation, though the trypsin was not removed from the system
and would continue to digest the BSA, preventing a full return to the initial emission characteristics.
In addition, an UV/Vis absorption study confirmed that the particles could not recover all of their
initial emission intensity after an annealing & digestion study due to a slight degradation of the
fluorophores (cf. SI)[141]. The repeated turn-on and turn-off of the fluorescence is demonstrated
in Figure 2.6, which presents the change in the photoluminescence spectrum with annealing of the
FP5 particles with BSA to activate and enhance the emission, exposure to trypsin to deactivate the







Figure 2.7: Confocal images of FP7 particles (1 µM) incubated with UMSCC22A cells for 1, 8, and 17 hours. One
hour before imaging, cells were loaded with LysoTracker Green (LTG) to image lysosomes. LTG (green, 473 nm) is
left image, PA/azSQ/azPEG particles (red, FP7) is the center image, and the right image is their overlay.
resulted in a 48 % increase in the number of active emitters and an increase in the relative quantum
yield to 0.036 from 0.024, while the trypsin digestion turned-off 97 % of the emitters and dropped
the relative quantum yield to 7.2x10−4. Similarly, the PEGylated particles, FP5 & FP7, exhibited
an almost complete cessation of emission with tryptic digestion of the BSA. The FP7 particles ex-
hibited an eleven-fold increase integrated intensity with BSA activation, that was improved 13 %
with annealing. The introduction of trypsin returned the particles to a quenched state within just
a few hours of the enzyme addition.
2.3.4 In Vitro Co-localization.
In medical diagnostics, one of the problems limiting the use of many small molecule fluo-
rophores is the difficulty in preparing pharmaceutical formulations that are amenable to parenteral
administration[126].
The majority of organic chromophores that are of interest are not soluble in water and cannot
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Figure 2.8: Confocal images of FP7 particles (1 µM) incubated with A549 cancer cells depicting the activation of
fluorescence with incubation time (0.5 h - 1 h) and subsequent reduction in fluorescence with incubation time (2 h
- 24 h) as particles enter lysosomes. Media did not contain FBS and excitation laser power was constant between
images.
be simply injected. To remedy this, a number of different approaches, including encapsulation of
the fluorophore in colloidal carriers such as oil-dispersions, liposomes, and polymeric particles, have
been investigated[148, 157, 167, 168]. The encapsulation in an aqueous dispersible particle allows
for the straightforward insertion of the fluorophore into the patient but prevents the formation of
any advantageous guest/host complexes with the chromophore and a target protein.
The surface-attachment of the fluorophore onto the particle insures its accessibility to pro-
teins but may alter the ability of the particles to penetrate cells of interest. To that end, the cellular
uptake and intracellular trafficking of the FP7 particles (cf. Table 2.1) were studied by live cell con-
focal laser scanning microscopy. In addition, cell viability studies were carried out with the A549
and HepG2 cell lines and the FP7 particles were deemed not cytotoxic at the concentrations used in
this study (cf. SI).
The particles were incubated with UMSCC22A head and neck cancer cells and confocal
images of the cells were collected after 1, 8, and 17 h of incubation with particles (cf. Figure 2.7);
the particles’ fluorescence was activated by fetal bovine serum (FBS) in the culture medium. We
labeled the lysosomes with LysoTracker Green (LTG), which stains acidic compartments such as late
endosomes and lysosomes, to study the co-localization between the lysosomes and particles. The
fluorescence of the particles co-localized with the LTG (Figure 2.7), indicating that the particles
were taken up by the cells through endocytosis and accumulated into the lysosomes. The FP7
particles were also incubated with A549 cells which are a human alveolar adenocarcinoma cell line.
These cells synthesize lecithin with a high percentage of disaturated fatty acids and are believed to
be responsible for pulmonary surfactant synthesis[169]. Figure 2.8 presents a confocal image of the
FP7 emission channel overlayed on the transmitted image of the A549 cancer cells. The particles
were incubated with the cells without FBS and were initially nonfluorescent, but after 30 minutes of
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Figure 2.9: Manders’ co-localization coefficient M1 (green channel) and M2 (red channel) from Figure 2.7 of FP7
particles incubated with UMSCC22A cells.
incubation the particles were fluorescent as they collected onto the cell membranes (cf. Figure 2.8);
the fluorescence is clearly evident by 1 hour of incubation as the particle begin to be engulfed by
the cells. In this study, no FBS was utilized in the medium and the fluorescence was activated by
constituents of the cells. This fluorescence turn-on is speculated to be due to the phospholipids in
the cell membrane, specifically lecithin, and is mechanistically similar to the use of the surfactant
SDS to activate the fluorophores[88].
For the co-localization study with the UMSCC22A cancer cells, the Manders’ co-localization
coefficient M1 and M2[170] for the FP7 particles and LTG increased in a time-dependent manner
and after 17 hours, the co-localization coefficient has risen to ca. 0.75 (cf. Figure 2.9). The relative
equivalence of the coefficients (M1 or M2) at any sampled time suggests that the particle/LTG
emitter ratio is not changing significantly, though the slight increase (0.07) in M2 (red channel)
relative to M1 (green channel) at longer times could indicate a reduction in the number of emitting
FP7 particles. Since the lysosomes constitute the intracellular digestion compartment, the observed
co-localization between the lysosomes and the FP7 particles should result in the degradation of the
fluorescence activating FBS that is absorbed on the particles and result in a return of the particles
to a quenched state. Figure 2.8 presents confocal images of the FP7 emission channel overlayed on
the transmitted image of the A549 cells. As discussed earlier, since no FBS was added to the cell’s
38
media, the fluorescence activation of the particles was accomplished by the phospholipids in the
cell membrane, specifically lecithin production of the cells binding to the fluorophores and reducing
their aggregate-based quenching. At 2 hours of incubation (cf. Figure 2.8), the FP7 particles have
migrated into the lysosomes and there is a high density of FP7 emitters in the cells. Over the course
of an additional 22 hours of incubation (cf. Figure 2.8), the number of FP7 emitters appears to
be diminishing, consistent with the trypsin digestion study of Figure 2.6. In order to estimate the
number of emitters per cancer cell, images of the cells at 17 and 24 hours had a common threshold
applied to the red channel and the number of pixels above the threshold were counted. Following
this procedure, the cells incubated for 17 hours had 691 pixels per cell above the threshold, while
the cells incubated for 24 hours had only 167 pixels per cell, a 75 % reduction. All in vitro studies
with the particles indicate that the rapid emission turn-off is not due to merely dye degradation.
Similarly to the previously described tryptic digestion study, we speculate that the phospholipids
which are sequestered on the particles are being removed once the particles localize in the lysosomes
and the adherent can no longer prevent the chromophores from aggregating and quenching their
emission.
There are multiple mechanisms of endocytosis that can be utilized for penetration of nanopar-
ticles into cells. A pharmacologic approach was used to determine which mechanism of endocytosis
was involved in cellular uptake of the FP7 particles in UMSCC22A cells. A number of compounds,
when incubated with mammalian cells, disrupt specific routes of endocytosis. For example, cytocha-
lasin D inhibits macropinocytosis, chlorpromazine inhibits clathrin-mediated endocytosis by inhibit-
ing disassembly of clathrin-coated pits and inhibiting receptor recycling to the plasma membrane,
nocodazole inhibits clathrin- and caveolae-independent endocytosis by disrupting microtubules, and
filipin III inhibits caveolae-mediated endocytosis by sequestering cholesterol available for lipid rafts.
When cytochalasin D, chlorpromazine, and nocodazole were initially added to the UMSCC22A cells
30 min before the addition of the FP7 particles, no change in the final Pearsons’ co-localization
coefficient between LTG and the FP7 particles were seen. In contrast, filipin (FIL) had a significant
influence on the coefficient. Figure 2.10a presents confocal images of the cells incubated with the
FP7 particles without the inhibitor of the raft/caveolae endocytosis pathway and with the com-
pound (FIL). Confocal images revealed patches of nanoparticles bound to the plasma membrane in
filipin-treated cells (arrows), indicating that filipin prevented FP7 particles from entering cells. The
inclusion of the filipin decreased the Pearsons’ co-localization coefficient by ca. 50% (cf. Figure 2.10b).
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(a) (b)PA/azSQ/azPEG PA/azSQ/azPEG+FIL
Figure 2.10: (a) Confocal images of FP7 particles (1 µM) incubated with UMSCC22A cells for 2 hours (left image)
and with the addition of the raft/caveolae endocytosis pathway inhibitor filipin (FIL) (right image) and corresponding
(b) Pearsons’ co-localization coefficient between LTG and FP7 particles. An asterisk indicates statistical significance
from the control by ANOVA followed by Tukeys multiple comparisons test (p<0.01).
The results indicate that the nanoparticles are taken up by the cells through caveolae-mediated en-
docytosis for a final intracellular destination at the lysosomes. A number of studies have found that
nontargeted particles follow a caveolae-mediated endocytosis route from early endosomes to late
endosomes and lysosomes[171, 172, 173].
2.4 Experimental
2.4.1 Reagents and solvents
All the commercial reagents were purchased from TCI America and used without further
purification. All the solvents were dried according to standard methods. Deionized water was
obtained from a Thermo Scientific Barnstead NANOpure Water Purification System and exhibited
a resistivity of ca. 1018 ohm−1cm−1.
2.4.2 Chemical characterization methods
1H and 13C NMR spectra were recorded on JEOL ECX-300 spectrometers (300MHz for
proton and 76MHz for carbon). Chemical shifts for protons are reported in parts per million down-
field from tetramethylsilane and are referenced to residual protium in the NMR solvent (CDCl3: δ
7.26 ppm, DMSO-d6: δ 2.50 ppm). Chemical shifts for carbons are reported in parts per million
downfield from tetramethylsilane and are referenced to the carbon resonances of the solvent (CDCl3:
δ 77.16, DMSO-d6: δ 39.52 ppm). Coupling constants are reported in Hertz (Hz). LC/MS mass
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spectra were obtained using Finnigan LCQ spectrometer and HP 1100 (HPLC). The IR spectra were
recorded at room temperature in the wavenumber range of 400-4000 cm−1 and referenced against
air with a Nicolet 6700 FTIR instrument. A total of 32 scans were averaged for each sample at 2
cm−1 resolution.
2.4.3 Preparation of azide-modified squaraine derivative chromophore
(azSQ)
The reaction scheme for synthesis of azSQ is presented in Figure 2.11
3-(3-azidopropyl)-1,1,2-trimethyl-1H-benzo[e]indolium iodide (1) The solution con-
taining 2,3,3-trimethyl-4,5-benzo-3H-indole (1 g, 4.78 mmol) and 1-azido-3-Iodopropane (2 g, 9.56
mmol) in acetonitrile (50 ml) was refluxed for 72 hours. The solvent was evaporated under vacuum
and the residue was dissolved in dichloromethane (10 ml). This solution was added drop-wise to
diethyl ether solution (80 ml) to precipitate the product. This purification step with diethyl ether
solution was performed 3 times and the solid obtained was filtered and dried under vacuum (hygro-
scopic). Compound 1 was obtained as a dark-brown solid (1.61 g, yield 80 %). 1H NMR (CDCl3)
δ 1.87 (s, 6H), 2.37 (m, 2H, J=5.9 and 6.9), 3.25 (s, 3H), 3.76 (t, 2H, J=5.9), 5.00 (t, 2H, J=6.9),
7.70 (m, 3H, J=8.6 and 1.4), 7.96 (d, 1H, J=8.9), 8.10 (m, 2H, J=8.6 and 8.9).
4-(1,1,2-trimethyl-1H-benzo[e]indolium-3-yl)butane-1-sulfonate (2) The mixture
containing 2,3,3-trimethyl-4,5-benzo-3H-indole (0.6 g, 2.87 mmol) and 1,4-butanesultone (1.17 g,
8.59 mmol) was heated at 120 ◦C for 2 hours. After cooling, the crystallized product was washed
with acetone, filtered and dried to give the compound (2). White solid (0.92 g, yield 93 %). 1H
NMR (DMSO-d6) δ 1.75 (s, 6H), 1.78 (m, 2H, J=7.2), 2.03 (m, 2H J=7.6), 2.52 (t, 2H, J=7.2), 2.95
(s, 3H), 4.61 (t, 2H, J=7.6), 7.69-7.80 (m, 2H, J=8.3), 8.20 (d, 2H, J=8.9), 8.27 (d, 1H, J=8.9), 8.36
(d, 1H, J=8.3).
3,4-diethoxy-3-cyclobutene-1,2-dione (3) was prepared according to the method publis-
hed[147].
3-{[(2E)-3-(3-azidopropyl)-1,1-dimethyl-1H,2H,3H-benzo[e]indol-2-ylidene]met-
hyl}-4-hydroxycyclobut-3-ene-1,2-dione (4) Pyridine (2ml) was added to the solution contain-
ing compound (1) (0.3 g, 0.71 mmol) and 3,4-diethoxy-cyclobut-3-ene-1,2-dione (1 g, 5.9 mmol) in
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Figure 2.11: Reaction scheme for synthesis of azSQ.
ethanol (10 ml) and refluxed for 4 hours. After cooling, the green solution was evaporated and
the residue was dissolved in a mixture of methanol (20 ml) and water solution of NaOH (3 ml, 0.9
mol). This mixture was refluxed for 30 min. After cooling, the mixture was filtered and evaporated.
The residue was extracted with dichloromethane and washed with water 2 times. The organic layer
was separated, dried with Na2SO4 and filtered. The filtrate was evaporated and the residue was
dissolved in dichloromethane (2 ml) and added dropwise to diethyl ether solution (20 ml) to pre-
cipitate a green solid. This solid was separated by centrifugation and dried on air to give a mix of
compounds (4) and (5) with molar ratio 1:2. This mixture (225 mg) was used in next step without
further purification. 1H NMR (CDCl3) δ 1.93 (s, 6H), 2.14 (m, 2H), 3.40 (t, 2H, J=6.0), 3.98 (t,
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2H, J=6.0), 5.72 (s, 1H), 7.20 (d, 1H, J=8.5), 7.47 (m, 1H), 7.82 (m, 2H), 8.07 (d, 1H, J=8.5).
2-{[(1E)-3-{[(2Z)-3-(3-azidopropyl)-1,1-dimethyl-1H,2H,3H-benzo[e]indol-2-yli-
dene]methyl}-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]methyl}-1,1-dimethyl-3-(4-sulfo-
natobutyl)-1H-benzo[e]indol-3-ium (6) The mixture of compounds (4) and (5) (225 mg) (see
synthesis of compound (4)) and compound (2) (140 mg, 0.4 mmol) was dissolved in butanol (15 ml)
and benzene (15 ml). This solution was refluxed with Dean-Stark apparatus for 18 hours. After
cooling, the solvent was evaporated under vacuum and the residue was purified by flash column
chromatography (dichloromethane : methanol 9:1, silicagel). 120 mg of compound (7) (a deep blue
solid) was obtained. Rf=0.2, yield 24 % (recalculated to compound (1)). 1H NMR (DMSO-d6) δ
1.80 (m, 4H), 1.96 (s, 6H), 1.97 (s, 6H), 2.02 (m, 2H, J=6.6), 2.55 (t, 2H), 3.55 (t, 2H, J=6.6),
4.26 (b.t, 2H), 5.89 (s, 1H), 5.90 (s, 1H), 7.45 (m, 2H), 7.62 (m, 2H), 7.69 (d, 1H, J=9.0), 7.75 (d,
1H, J=9.0), 8.02 (m, 4H), 8.23 (d, 2H, J=8.4). 13C NMR (CDCl3) δ 22.45, 26.36, 26.60, 26.80,
29.81, 40.71, 43.77, 48.63, 51.22, 51.28, 86.12, 87.10, 109.88, 110.64, 122.45, 124.20, 124.36, 127.19,
127.34, 128.33, 128.61, 129.69, 129.97, 131.17, 131.44, 133.94, 134.59, 139.17, 139.55, 170.81, 172.53.
ESI-Mass (LC/MS) (m/z; rel. intensity ): 715.3 (M+; 100), 987.2 (8) 632.2 (8), 330.2 (17).
2.4.4 Preparation of azide-modified polyethylene glycol (azPEG).
The azPEG was prepared according to the method published[31].
Mono-methoxy-PEG5000-methansulfonate Methylsulfonyl chloride (0.92 g, 8 mmol)
in dichloromethane (5 mL) was added dropwise at room temperature to the stirring solution of
triethylamine (0.89 g, 8.8 mmol) and mono-methoxy-PEG5000 (20 g, 4 mmol) in dichloromethane
(70 mL). The solution was stirred at 20 ◦C for 4 hours, then washed with water and the organic
layer was dried with Na2SO4 with further filtration. The solvent was evaporated under vacuum to
give the product as a white solid. Yield: 20.3 g (97 %). 1H NMR (CDCl3) 3.07 (s, 3H), 3.36 (s,
3H), 3.48 (t, 2H), 3.53 (m, 2H), 3.62 (m, ca. 400H), 3.75 (m, 4H), 4.36 (m, 2H).
Mono-methoxy-PEG5000-azide The mixture of mono-methoxy-PEG5000-methansulfo-
nate (20.3 g, 4 mmol) and sodium azide (1.1 g, 17 mmol) in acetonitrile (80 mL) was refluxed and
stirred for 15 hours. After cooling, the mixture was filtered and the solvent was evaporated. The
residue was dissolved in dichloromethane and washed with water, organic layer was separated, dried
with Na2SO4 and filtered. The solvent was evaporated, the crystalline residue was washed with
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hexane, filtered and dried in air to give the product as a white solid. Yield: 19 g (94 %). 1H NMR
(CDCl3) 3.35 (s, 3H), 3.38 (t, 2H), 3.62 (m, ca. 400H), 3.85 (m, 2H). FTIR (cm
−1): 1095 (s, C-O-C);
1340, 1465 (CH2); 2100 (N3); 2880 (s, CH2).
2.4.5 Preparation of the particles
Propargyl acrylate (PA) particles were prepared according to a standard emulsion polymer-
ization method published[31].
For a typical surface modification of the particles, for example, the grafting of azSQ and
azide-modified PEG chains with molecular weight of 5000 (azPEG) onto the particles, 1 mL PA
particles and 3.94 mg azSQ were added to 2 mL of deionized water. Solutions of 0.07624 g copper(II)
sulfate (99.999 % Aldrich) in 10 mL deionized water and 0.3024 g sodium ascorbate (99 % Aldrich) in
10 mL deionized water were made. Initially, 0.5 mL of the CuSO4 solution was added to the PA/azSQ
solution, followed by 0.5 mL of the sodium ascorbate solution. The resulting mixture was maintained
at a temperature of ca. 28 ◦C for 15 minutes and then the reaction was stopped by the removal of
unreacted azSQ, sodium ascorbate, and Cu(II)SO4 through a repeated particle washing procedure
consisting of centrifugation and redispersement in methanol. The cleaned PA/azSQ (FP5) particles
in water were subsequently utilized in a secondary click transformation with 54.99 mg azPEG,
and previously presented CuSO4 and sodium ascorbate solutions. The reaction was allowed to run
for 48 hours and then washed to remove unreacted species as determined by photoluminescence
measurements; these particles are referred to as PA/azSQ/azPEG (FP7) particles.
2.4.6 Cell analysis
Human HepG2 and A549 cell lines were obtained from ATCC (Rockville, MD). Human UM-
SCC22A head and neck squamous carcinoma cell line was a gift from Dr. Besim Ogretmen (Medical
University of South Carolina). Hep G2 cells were cultured in phenol red-free Dulbeccos modified
Eagles media (DMEM) containing 5 % fetal bovine serum (FBS), 1 % Penicillin-Streptomycin, and
supplemented with glutamine (Invitrogen, Carlsbad, CA). A549 cells were cultured in F-12K media
(Kaighn’s Modification of Ham’s F-12 medium) containing 10 % fetal bovine serum (FBS) and 1
% Penicillin-Streptomycin. UMSCC22A cells were cultured in Dulbeccos modified Eagles media
(DMEM) supplemented with L-glutamine containing 10 % FBS and 1 % Penicillin-Streptomycin.
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Cells were cultured at 37 ◦C in a humidified atmosphere of 95 % air 5 % CO2.
2.4.7 Cytotoxicity assay
HepG2 cells & A549 (20,000 cells per well) were cultured on 96 well plates for 24 hours. Sub-
sequently, cells were, exposed to 2x109, 2x1011, and 2x1013 particles/mL. After 96 hours, cell death
was assessed with a MTS assay according to the manufacturer’s instructions (Promega, Madison,
WI). Briefly, medium was aspirated and a solution of 100 µL of DMEM containing 10 % FBS and 20
µL 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, salt
(MTS) and phenazine methosulfate (PMS) was added onto each well. After 60 minutes, wells were
scanned colorimetrically at 490 nm on a VersaMax spectrophotometer (Molecular Devices, Sunny-
vale, CA). The conversion of MTS into an aqueous soluble formazan product is achieved only by
dehydrogenase enzymes which are present in metabolically active cells; the absorbance at 490 nm
from the formazan product is directly proportional to the number of living cells in culture.
2.4.8 Confocal microscopy
UMSCC22A cells were cultured onto 35 mm glass-bottomed Petri dishes (MatTek Corpo-
ration, Ashland, MA) at 150,000 cells/dish and incubated for 24 hours. Subsequently, cells were
incubated with 1 µM PA/ azSQ/ azPEG (FP7) particles for different time periods of 1, 2, 4, 8, 17,
and 24 hours. At the end of the incubation, the medium was aspirated and the cells were incubated
with 500 nM LysoTracker Green (LTG) for 1 hour. Before imaging the concentration of the LTG
dye was lowered to 100 nM. Dishes were placed in an environmental chamber at 37 ◦C on the stage
of Olympus FV10i LIV laser scanning confocal microscope. The images of LTG (473 nm excitation
and 490-540 nm emission) and FP7 particles (635 nm excitation and 660 - 760 nm emission) were
collected using a 63 X N.A. 1.4 oil immersion planapochromat objective. ImageJ software was used
to post-process the images and calculate the co-localization coefficients.
2.4.9 Optical characterization methods
Absorption spectra were taken using a Perkin-Elmer Lambda 900 UV/VIS/NIR spectropho-
tometer. Photoluminescence (PL) spectra were collected using a Photon Technology International
QuantaMaster 60 NIR with PMT spectrofluorometer and a Thermo Oriel xenon arc lamp (Thermo
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Oriel 66902) mated with a Thermo Oriel Cornerstone 7400 1/8 m monochromator (Thermo Oriel
7400) and a Horiba Jobin-Yvon MicroHR spectrometer coupled to a Synapse CCD detector. Quan-
tum yields (φ) of the dyes and modified particles were determined relative to the reference dye
1,1’,3,3,3’,3’-hexamethylindotricarbocyanine iodide (HITCI) in methanol, which has a fluorescence
quantum yield of φref = 0.12[153, 174], employing established procedures[175]. It is to be noted
that the diameter of the particles used through out the paper was 49.9 nm except for quantum yield
measurement where a couple of particles of diameter 88.5 nm were used.
2.5 Conclusion
The 50 nm poly(propargyl acrylate) particles which were surface modified through the
copper-catalyzed azide/alkyne cycloaddition of an azide-terminated squaraine derivative, a near-
infrared emitter, and polyethylene glycol exhibited a protein triggered activation/deactivation of
the emission. When dispersed in PBS, the initially nonfluorescent particles exhibited an albumin-
based activation which resulted in an eleven-fold enhancement in integrated intensity. Deactivation
with the addition of trypsin to cleave the albumin resulted in a complete return to the initial
quenched state. Quenched NIR emitting particles which can have their emission activated by their
exposure to a specific protein, then deactivated by exposure to another protein, are a potentially
valuable nanodevice for the fight against cancer. A new generation of photonic imaging systems will
be created from adaptive & responsive contrast mechanisms using highly specific fluorescent agents,
such as activated fluorescent probes described in this effort, when these probes are leveraged with
the recent advances in illumination & detection schemes, tomographic principles, and mathematical
models that describe photon propagation in tissues[176].
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2.6.1 Results & Discussion
Figure 2.12: Fluorescence spectra of FP5 nanoparticles (6.53 µM) in water before (-) and 18 hours after addition
of 50 mg of SDS (◦). Excitation at 630 nm.
2.6.2 Experimental
Calculation of grafting densities The molar extinction coefficient of the free dye in the dilute
regime and wavelength range of 615 nm to 685 nm is used to estimate the number of fluorophores
attached to the particles. First, the molar extinction coefficient for the dye in the dilute regime
is measured. The concentration of the modified particles solution is estimated using Beers law (A
= εbc where A is absorbance, ε is molar extinction coefficient, in M−1cm−1, b is path length in
cm, and c is concentration in M). 500 µL of the modified particles solution is dried out to measure
the mass. The diameter of the unmodified particle is measured using the DLS (Dynamic Light
Scattering) and the surface area, mass and volume of a particle are calculated. Using the mass of a
particle and the mass of 500 µL of solution, the number of modified particles per mL is calculated
by assuming that the mass of the dye is negligible compared to the mass of the particle. Finally,
the concentration and number of particles is used to determine the grafting density and distance
between two chromophores.
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Figure 2.13: Fluorescence spectra of FP7 nanoparticles (4.97 µM) in water before (-) and 18 hours after addition
of 50 mg of SDS (◦). Excitation at 630 nm.
Figure 2.14: Changes in photoluminescence intensity of FP5 nanoparticles (0.03 mM) in phosphate buffered
solution (PBS) with the addition of the four different proteins (0.04 mM) [Bovine serum albumin (◦), human serum
albumin (•), lysozyme (4), and trypsin (N)]. The HSA and BSA curves typically merge after 4 days of incubation,
though the lysozyme and trypsin never significantly increase the particles emission. Excitation at 630 nm.
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Figure 2.15: Changes in absorbance spectra of FP5 nanoparticles in phosphate buffered solution (PBS) with 15
mg of BSA. [Initially at 20 oC (•), at 70 oC (◦), after 70 oC anneal then cooled to 20 oC (H), after 70 oC, cool to 20
oC, heated to 70 oC (4) and after 70 oC, cool to 20 oC, heated to 70 oC, then cooled to 20 oC ()]
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Figure 2.16: Changes in photoluminescence of FP7 nanoparticles in phosphate buffered solution (PBS) with 5 mg
of BSA. [Initially at 20 oC (•), after heat and cool cycle 1 (◦), after heat and cool cycle 2 ((H), after heat and cool
cycle 3 (4) and after heat and cool cycle 4 ()]. Excitation at 630 nm.
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Figure 2.17: Proliferation of HepG2 cells after 2 days of incubation with neat PA and PA/ azSQ (FP5) nanoparticles
at concentrations of ca. 2 x 1013, 2 x 1011 and 2 x 109 particles/ mL. Each condition was tested in six replicates. Cell
viability was determined via 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium inner salt (MTS) assay. 2 x 1013
particles/ mL is about 63 µM for PA/ azSQ (FP5).
Figure 2.18: Proliferation of HepG2 cells after 2 days of incubation with PA/ azSQ/ azPEG (FP7) nanoparticles
at concentrations of ca. 2 x 109, 2 x 1011 and 2 x 1013 particles/ mL. Each condition was tested in six replicates. Cell
viability was determined via 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium inner salt (MTS) assay. 2 x 1013
particles/ mL is about 37 µM for PA/ azSQ/ azPEG (FP7).
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Figure 2.19: Proliferation of A549 cells after 2 days of incubation with neat PA and PA/ azSQ (FP5) nanoparticles
at concentrations of ca. 2 x 109, 2 x 1011 and 2 x 1013 particles/ mL. Each condition was tested in six replicates. Cell
viability was determined via 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium inner salt (MTS) assay. 2 x 1013
particles/ mL is about 98 µM for PA/ azSQ (FP5).
Figure 2.20: Proliferation of A549 cells after 2 days of incubation with PA/ azSQ/ azPEG (FP7) nanoparticles at
concentrations of ca. 2 x 109, 2 x 1011 and 2 x 1013 particles/ mL. Each condition was tested in six replicates. Cell
viability was determined via 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium inner salt (MTS) assay. 2 x 1013
particles/ mL is about 75 µM for PA/ azSQ/ azPEG (FP7).
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Chapter 3
Surface modified colloids with
targeting molecules to disrupt
Survivin activity and enhance
apoptosis in cancer cells
3.1 Attributions
The synthesis of the unmodified and azide modified small molecules was conducted or aided
by Dr. Yuriy P. Bandera at Clemson University. The preparation of Survivin and gel affinity pull
down studies were carried out by Andrew A. Kelso, Dr. LeAnna L. Ledford and Dr. Michael
G. Sehorn at Clemson University. The cellular studies in glioblastoma cells were carried out with
the aid of Dr. Mrinmay Chakrabarti and Dr. Swapan K. Ray at University of South Carolina.
Cell growth and viability assessments in A549 cells were conducted with the aid of Ashlee Tietje
and Dr. Yanzhang Wei at Clemson University. The results in this chapter are in preparation for
publication as Jenkins et al., Sequestring Survivin to functionalized nanoparticles: A strategy to
enhance apoptosis in cancer cells, 2015.
53
3.2 Introduction
A prophetic indicator of cancerous cells is their circumvention of programmed cell death
(apoptosis). The maintenance of tumors has been speculated to be achieved through nodal proteins
that are involved in multiple signaling mechanisms[177]. One such protein Survivin (BIRC5), a
member of the inhibitors of apoptosis (IAP) family, is vital for cellular homeostasis, playing a role in
cell division and cell death[178], This protein is abundant in embryonic and fetal development[179],
but is below detection limits in most terminally differentiated adult tissues[180, 181, 182], though it
has been detected in primitive hematopoietic cells, T lymphocytes, polymorphonuclear neutrophils,
and vascular endothelial cells[183]. A number of studies have shown that Survivin is overexpressed
in human cancers and its appearance in a patient results in an increased risk factor for cancer
progression and a poor prognosis[180, 184, 185, 186, 187, 188]. Survivin appears to bestow on
tumor cells an enhanced adaptability, capacity to proliferate, and aversion to cell death[189, 190,
191]. Achieving apoptosis is integral to the cytotoxic activity of most chemotherapeutic drugs and
radiation therapies and their reduced potency stems from antiapoptotic proteins[192]. In an effort
to enhance the potency of cancer therapies, the targeting of antiapoptotic proteins expressed by
cancer cells has become an important approach to cancer treatment[193].
The focus on Survivin as a means to combat cancer through a mitigation of its antiapoptotic
functions has resulted in a number of inhibition or sequestration strategies, with only three inhibitors
reaching clinical trials by 2013[194]. These inhibition or sequestering strategies can be divided into
four broad categories: (1) molecular antagonists (antisense oligonucleotides, siRNA, and transfection
of a plasmid encoding the dominant-negative Survivin) based inhibition[195, 196, 197, 198, 199, 200,
201, 202]; (2) gene therapy with small molecules such as YM155 or FL118[203, 204, 205, 206]; (3)
immunotherapy, where the immune cells such as natural killer cells, dendritic cells, and cytotoxic
T lymphocytes, are isolated from the patient, activated in vitro and transfused back to the patient
to target cancer cells[194, 207, 208]; and (4) Survivin binding small molecules which attach to the
protein to disrupt its antiapoptotic function[209, 210]. The antisense or siRNA approaches may
result in undesirable broad phenotypic consequences, effecting normal cells and exhibit varying anti-
cancer potency in vitro, in vivo, and in humans[194, 198, 211]. There is also a lack of appreciation
in how these antisense oligonucleotides distribute to tissues and are taken up by cells in the human
body[212]. The dominant-negative Survivin method in treating cancers is still clinically impractical,
54
as the mutant protein is unstable in the blood stream[194]. Phase II clinical trials of YM155, a small
molecule Survivin gene suppressant, failed as adverse effects were reported and the objective tumor
response rate (ORR) of patients to the treatment was only 3 - 6 %[213, 214]. Immunotherapy is
a relatively new strategy compared to the other methods, and investigations are being carried out
to find the epitopes that generate the strongest immunodominant, immunoprevalent T-cell reaction
against Survivin[215]. Finally, the use of small molecule ligand that simply binds to the protein and
disrupts Survivin’s activity may present a more focused and less destructive therapeutic approach
if the binding can be designed to only occur in a tumor of interest[206, 216]. Unfortunately, the
widespread development of new binding ligands for Survivin is frustrated by the perceived lack
of structural pockets of the appropriate geometry and hydrophilicity on the protein that act as a
druggable site[209]. Survivin forms a bow-tie shaped symmetrical homodimer and contains a single
baculoviral IAP repeat (BIR) domain, which is common in the IAP family[217]. A newly discovered
small molecule binding site at the dimer interface on Survivin, which is distinct from the BIR site,
has been recently reported[209]. This second potential binding site appears to possess a higher
propensity for small-molecule binding than the BIR site, though the functional role of this site is
currently unknown. Nonetheless, it is speculated that the interface site may be involved in binding
to other proteins that regulate Survivin function of inhibiting apoptosis[209, 218]. Recently, high-
affinity small molecule ”Survivin ligands” have been proposed by Abbott Laboratories for binding to
the site[209] and, based on their structural variability, this site may be a biologically relevant protein
binding site that can be targeted with small molecule drugs. The small molecule ligand binds at
the dimer interface and frustrates the binding of other proteins to the site, leading to the activation
of apoptosis. A recent effort[218] has focused on a modified Abbott ligand[209] that was designed
to disrupt the Survivin-Ran protein complex, a complex identified to promote spindle formation in
tumor cells[219].
All the strategies mentioned previously exhibit varying degrees of success for disrupting
the function of Survivin, but all suffer from inherent problems such as systemic toxicity, reduced
bioavailability, and ineffective delivery[194]. These setbacks can be overcome by employing different
delivery platforms such as liposomes, dendrimers, and polymeric nanocarriers that can enhance a
drug’s protection, availability, and tissue distribution[194], resulting in an improved effectiveness[194,
220, 221, 222, 223, 224, 225]. To this end, a small molecule drug that binds to Survivin was modified
to allow its attachment to the surface of sub-100 nm polymer particles to assess its propensity to bind
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Figure 3.1: (a) Structures of Survivin ligands, Abbott8 and Abbott17 (targeting molecule TM) proposed by
Abbott Labs and an azide modified targeting molecule (azTM). (b) Schematic of 50 nm poly(propargyl acrylate)
(PA) particles surface modified with an azide-terminated Survivin ligand (azTM) through an aqueous-phase ”click”
transformation sequestering anti-apoptotic protein Survivin.
with Survivin and its effectiveness in inducing apoptosis relative to the “free” drug. Specifically,
the “Survivin ligand” developed by Abbott labs was selected for this comparison[209]. In this
current effort, the ligand was modified to include an azide group and attached to poly(propargyl
acrylate) nanoparticles through an azide/alkyne Huisgen cycloaddition using a copper catalyst.
These surface-modified particles were incubated with various cancer cell lines that are known to
overexpress Survivin. The extent of Survivin sequestration and resulting enhancement in apoptosis
was assessed.
3.3 Results & Discussion
Figure 3.1 presents the structures of the Survivin-binding ligands and the proposed route
for ”capturing” free Survivin with nanoparticles surface modified with ligands. As indicated earlier,
prior art has focused on several Survivin inhibition approaches, such as, antisense oligonucleotides
targeting mRNA, immunotherapeutic strategies, and small molecule binding to the BIR (Baculoviral
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IAP repeat) domain. A new binding site at the dimer interface of Survivin, distinct from the BIR
site, has been recently identified and appears to have an increased binding to small molecules and
maybe useful for targeting & inhibition. Recently, high-affinity small molecule ”Survivin ligands”
have been proposed for binding to the site by Abbott Labs with binding constants (KD) ranging
from 0.037 µM to 0.88 µM and were obtained by monitoring the chemical shift changes as a function
of ligand concentration[209]. According to their studies, a favorable binding of a small molecule to
the dimer interface is indicated by a small value binding dissociation constant, KD. A KD value
of sub-5 µM suggests a relative strong affinity. In their studies, it was speculated that the dimer
interface plays an important role in binding to other proteins which serve a role in apoptosis. This
was subsequently proven with a variant (LLP3) of an Abbott Labs compound which also binds
to the dimer interface of Survivin and was utilized to prevent Ran from binding to Survivin and
forming a Survivin-Ran protein complex. This disruption allowed the native apoptosis pathway to
continue[219].
Figure 3.1a presents the Abbott8 compound (with labeled rings) employed by Abbott to
establish the structure-activity relationship (SAR) of the Survivin ligand. In these original stud-
ies, ligands that bind to Survivin shared in a number of structural characteristics. Through high
temperature superconductor (HTS) NMR studies[209], it was determined that Ring-2 must be a
central pyridone, while Ring-3 must be a phenol, so that a hydrogen bonding network can form, via
the 2-hydroxypyridine central ring tautomer, forcing the two rings into a coplanar arrangement. In
addition, a cyano group must be on the center ring (Ring-2)[209, 226] for binding, though NMR struc-
tures provided no indication of a specific interaction with Survivin. Replacing this latter group with
carboxamide, methyl, halogen, or hydrogen all greatly diminished binding[209]. In addition, only
hydrophobic groups were preferred when substituted into Ring-1. On this latter ring, substitutions
on 2,4 and, particularly, 2,5 with chlorine and methyl groups at the 2 position, with chlorine, methyl,
and CF3 substitution at the 4 and 5 positions resulted in energetically acceptable structures[209].
In the current effort, azide terminated methoxyalkanes with (CH2)n of n=2 at position 4 of Ring-1
(Figure 3.1a; azTM) was employed to covalently attach the ligand to a poly(propargyl acrylate)
(PA) particle through a copper-catalyzed click transformation (cf. Figure 3.1b).
in vitro viability and apoptosis studies of Survivin ligands in glioblastomas. Currently,
there are not many in vitro cytotoxicity studies in the literature that demonstrate that the Abbott-
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Figure 3.2: Preliminary cell viability data in glioblastoma cells, U251MG and U118MG, using MTT assay. Un-
treated cells were used as the control (ctl). Cells were treated with the small molecule ligands at the indicated
concentrations for 24 hours. Cell viability is presented as a percentage of viable cells in the total population. Signifi-
cant difference from control value was indicated by *p<0.05. (a) TM and (b) azTM treatment of the glioblastomas.
derived Survivin ligands can disrupt Survivin activity and induce apoptosis[216, 218, 227, 228]. To
that end, the Survivin ligand originally proposed by Abbott Labs (6-(5-Chloro-2-hydroxyphenyl)-4-
[2-chloro-5-(trifluoromethyl)phenyl]-2-oxo-1H-pyridine-3-carbonitrile; TM) and its structural analog
modified with an azide linker (4-[m-(2-Azidoethoxy)
phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1H-pyridine-3-carbonitrile; azTM) (cf. Figure 3.1a) were
synthesized and tested to verify their potential for Survivin activity disruption in two human glioblas-
toma cell lines, specifically U251MG and U118MG, which exhibit Survivin overexpression[184].
Glioblastomas are the most common form of malignant primary brain tumors and they have a
propensity to encroach quickly into the surrounding tissues, frustrating surgical routes to their
removal[184, 191]. These tumors were chosen for study as they exhibit an increased resistance to
apoptosis and are relatively resistant to radiation and chemotherapy[184, 191].
Figure 3.2 presents the determination of cell viability of targeting molecules, TM or azTM,
using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. Cell viability
is presented as a percentage of viable cells in the total population and a significant difference from
the control value was indicated by a p-level with *p<0.05[184, 229]. The original Abbott-developed
drug TM exhibited a ca. 10% reduction in cell viability for both cell lines that was not statistically
significant, while the azide-modified version azTM resulted in a statistically significant reduction of
ca. 30 % in viability for both cell lines at a dosage of 2.5 µM. A cell death of over 30 % at a dosage of
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Figure 3.3: Increased apoptosis in glioblastoma cells, U251MG and U118MG, with azTM small molecule ligand
when compared to TM. Untreated cells were used as the control (ctl). Cells were treated with TM or azTM ligand at
indicated concentrations for 24 hours. (a) In situ Wright staining for detection of morphological features of apoptosis.
Bar diagram shows percent apoptosis based on Wright staining for (b) TM and (c) azTM treatments. Cell death is
presented as percentage of apoptosis in total population. Significant difference from control value was indicated by
*p < 0.05 or **p < 0.01.
2.5 µM indicates a high ratio in comparison to other Survivin activity disruption studies; a study on
the cytotoxicity in glioblastomas of a number of small molecules derived from 6-(o-Hydroxyphenyl)-
2-oxo-4-phenyl-1H-pyridine-3-carbonitrile (i.e. Abbott8)[209] was recently presented[218]. In this
study, the IC50 value for the lead compound (LLP3), a variant of Abbott8, was determined to be
31.2 µM, which is an order of magnitude greater than that of azTM for a similar efficacy. Assuming
that the enhancement is due to an increased Survivin binding to azTM, the structural difference
between TM and azTM is localized to Ring-1 (cf. Figure 3.1). The substitution of the trifluoromethyl
group and chlorine on Ring-1 with the azidoethoxy group is speculated to enhance the binding of
the drug to the dimer interface of Survivin[209]. The occupancy of the dimer interface has been
theorized to interfere with Survivin’s binding to other proteins which are required to activate its
IAP functions. Specifically, LLP-3 was designed from Abbott8, the targeting molecule used in
this project, by adding 2 phenyl rings to displace the Leu98 and Leu102 interactions in Survivin
dimerization and weaken the protein-protein interface and results in blocking the binding of Survivin
to Ran[218, 230]. GTP-binding nuclear protein Ran is a protein that is encoded by the RAN gene
in humans and is a regulator of bipolar mitotic spindle assembly.
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The observed efficacy of azTM in promoting cellular death in the U251MG and U118MG cell
lines could be through an enhanced apoptosis (desired programmed cell death) or simply toxicity of
the drug. In order to differentiate these routes to cell death, a standard in situ Wright staining study
was employed (cf. Figure 3.3a). Typical morphologic changes in cells undergoing apoptosis include
cell shrinkage, enhanced round shape, chromatin condensation, blebbing of cell membrane, and
enhanced refractivity of cells under phase-contrast imaging[231]. Utilizing these visual descriptors,
the cells treated with TM and azTM at a concentration of 0.1, 0.5, and 1.0 µM were compared to the
untreated control cells and observed the morphological features of apoptotic cells (cf. Figure 3.3).
Figure 3.3b presents the number of cells undergoing apoptosis relative to the control, and while both
drugs resulted in enhanced apoptosis in both cells lines, azTM resulted in a greater proportion of
cells exhibiting these feature at a set concentration relative to cells incubated with TM. The azTM
treatment with 1 µM induced more than 35 % apoptosis in both cell lines and corresponds to the
cell death observed in the viability study (cf. Figure 3.2). This data is presented in a bar graph
in Figure 3.3b. These results confirm that azTM induces apoptosis and disrupts Survivin activity
more effectively than the original TM small molecule ligand.
Surface-functionalized particles. The previous studies are promising and indicate that the
Abbott derived Survivin targeting ligands are a potential tool for Survivin activity disruption as
a small molecule. However, small molecules have a short in vivo circulation lifetime, which limits
the feasibility of Survivin ligands for use in therapies. To circumvent this issue, the small molecule
azTM can be attached to poly(propargyl acrylate) (PA) nanoparticles to increase circulation times
and at the same time allowing the ligands to form beneficial host/ guest assemblies. A schematic
of the particles studied in this effort is presented in Figure 3.1b. The PA colloids were prepared
using a standard aqueous emulsion polymerization technique resulting in spheres with a diameter
of 66.1 ± 0.26 nm. To functionalize the surface of the particles, a multiple step copper-catalyzed
azide/alkyne cycloaddition (”click” transformation) was performed in water to produce PA particles
that had Survivin ligand and polyethylene glycol (PEG) attached to their surface. To attach the
azide modified Survivin ligand to the particles, the azTM was initially clicked onto the particles
for 15 minutes and then the reaction was stopped by the removal of unreacted azTM, sodium
ascorbate, and Cu(II)SO4 through a repeated particle washing procedure consisting of centrifugation
and redispersement in tetrahydrofuran(THF) and methanol. The cleaned PA/ azTM particles were
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Figure 3.4: Purification of Survivin and affinity pull-down of Survivin by surface-functionalized particles. (a)
SDS-PAGE of purified recombinant Survivin (ca. 0.8 µg); (b) Poly(propargyl acrylate) (PA) particles were surface
modified with azTM ( cf. Figure 3.1) and azPEG. Control particles lacked the presence of ligand. Both sets of particles
were incubated with Survivin or BSA protein. The supernatant was removed and the particles were washed with
buffer. Proteins retained on the particles were eluted. The supernatant (S), wash (W) and elution (E) were separated
on a 15 % polyacrylamide gel and stained with Coomassie blue. (c) Percentage of bound proteins on functionalized
and control particles (data taken from SDS-PAGE in Part (b) as well as two other pull-down experiments).
subsequently utilized in a secondary click transformation with azide-modified polyethylene glycol
chains with molecular weight of 5k (azPEG) that was allowed to run for 24 hours and then washed
to remove unreacted species; these particles are referred to as PA/ azTM/ azPEG particles. We
have demonstrated previously that this method of cleaning was sufficient to remove all the copper
from the system and these cleaned particles are not toxic to cells[31, 71]. In addition cytotoxicity
tests were carried out using PA/ azPEG particles (data not shown) to verify that these particles are
not toxic. The use of PEG to infer a hydrophilicity to the particles has been found to be important
for directing protein absorption in the particles and achieving long circulation times[77].
Selective binding of functionalized particles. As stated earlier, prior art suggests that the
ligand directly binds at the dimer interface of Survivin. Computational modeling of the molecular
interactions along the dimerization interface[209, 230], affinity screening studies[209], cytotoxicity
studies[218, 227, 228] and fluorescence binding studies of several modified analogs of TM with the
wild-type protein and the mutant form of SurvivinF101A/L102A[218], have been explored to establish
the direct binding between the small molecule ”free” ligand and Survivin, but no studies have been
performed to establish the efficacy of the ligands when attached to the surface of nanoparticles. To
this end, affinity pull-down experiments were employed. A purification protocol that utilized both
affinity and conventional chromatography to purify Survivin to near homogeneity was developed
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(Figure 3.4a). About 0.4 mg of Survivin was obtained from 60 g of bacterial cell pellet. The
particles were surface modified with an azide-terminated (azTM) conjugate and poly(ethylene glycol)
(azPEG) chains of 5k molecular weight attached to their surface while control particles only had
the azPEG modification. After incubation of the particles with purified Survivin, the supernatant
was removed and the particles were washed with buffer. Any Survivin retained on the particles
was eluted and subjected to SDS-PAGE analysis. As indicated in Figure 3.4b, Survivin bound
the functionalized particles evidenced by its presence in the elution (cf. Figure 3.4b, lane 4). The
interaction with the azTM conjugate is specific since Survivin is only present in the supernatant
with the control azPEG particles (cf. Figure 3.4b, lane 10). As expected, bovine serum albumin
(BSA) failed to interact with either the azTM or the azPEG.
Figure 3.4c quantifies the results presented in Figure 3.4b, as well as two other pull-down
experiments. In this figure, the columns of + or - above the graph indicate what combination of
particle and protein was employed. For example, in lane 1, the amount of bound Survivin on the
functionalized particles was quantified while in lane 2, the amount of BSA on the functionalized
particles was assessed. Lane 3 & 4 are the control lanes and present the amount of bound protein
with Survivin & control particles (lane 3) and BSA & control particles (lane 4). These results suggest
that the binding specificity of the Survivin ligand is not altered when attached to particles and over
85 % of the Survivin bound to the functionalized particles.
Enhanced apoptosis with functionalized particles. It’s clear that the functionalized particles
are capable of selectively binding Survivin, but the question remains, will this binding of the protein
result in any enhancement of apoptosis of cancer cells. The precise mechanism by which Survivin
suppresses apoptosis is still in debate, but it is speculated that Survivin directly suppresses Caspase-
3, a protein which is believed to play a central role in the execution-phase of cell apoptosis[190].
To this end, Western blotting for Survivin and other proteins involved in Caspase-mediated apop-
tosis was employed to determine how effectively the modified particles restrain Survivin activity in
comparison to the ”free” drug. Both glioblastoma cell lines were treated with azTM or PA/ azTM
nanoparticles (1.0 µM ligand concentration) prior to extraction of protein samples. Protein samples
were separated by SDS-PAGE and Western blotting was performed using the primary IgG antibod-
ies against Survivin, Caspase-3, and β-Actin. The horseradish peroxidase conjugated anti-rabbit
IgG was used as secondary antibody. Western blots were incubated with ECL detection reagents,
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Figure 3.5: (a) Survivin conjugate azTM disrupted the activity of Survivin to promote Caspase mediated apoptosis.
Both glioblastoma cell lines were treated with Survivin conjugate azTM as a free small molecule or attached to the
surface of nanoparticles (1.0 µM ligand concentration) prior to extraction of protein samples. Protein samples were
resolved by 4 - 20 % SDS-PAGE and Western blotting was performed using the primary IgG antibodies against
Survivin, Caspase-3, and β-Actin. Quantification of expression of Survivin and Caspase-3 after treatment with free
ligand (azTM) and modified particles (PA/ azTM) in (b) U251MG or (c) U118MG cells. Significant difference from
control value was indicated by *p<0.1, **p<0.01 and #p<0.001.
exposed to X-OMAT AR films, and photographed (cf. Figure 3.5). The Western blot indicated that
both azTM and PA/ azTM nanoparticles increased the activation of Caspase-3, the final executioner
of apoptosis, in these glioblastoma cell lines. Importantly, PA/ azTM nanoparticles exhibited a pro-
nounced Survivin sequestration relative to the ”free” azTM for activation of Caspase-3 for apoptosis
in both glioblastoma cell lines. Figure 3.5 presents the quantification of the Western blot data. For
both the cell lines, the quantification demonstrated that the Caspase-3 expression was increased by
95 % and 140 % for azTM and PA/ azTM, respectively, when compared to the untreated control
cells. In addition, it was noticed that for the PA/ azTM treatment, the expression of Survivin was
decreased by 60 %. This decrease might not be an actual reduction in expression of Survivin as
it is speculated that the sequestered Survivin could have still been bound to the nanoparticles and
couldn’t be extracted completely for SDS-PAGE and Western blotting studies.
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Viability studies in other cell lines. To further support and validate the results obtained
in the glioblastoma cells, cell viability studies were carried out in the A549 line, cell line known
to overexpress Survivin[232]. Figure 3.6 presents the cell viability data with A549 cells using the
MTS assay. A549 cells are a human alveolar adenocarcinoma cell line which can synthesize lecithin
with a high percentage of disaturated fatty acids and are believed to be responsible for pulmonary
surfactant synthesis[169]. The cells were treated with azTM and PA/ azTM with two different
grafting densities (gd), 0.58 and 1.91 azTM/nm2, at varying concentrations for 48 hours. In A549
cells, the small molecule and modified particles exhibited the same behavior as exhibited in the
glioblastomas cells, though there was an observed dependence on cell reduction with the particle’s
azTM grafting density. In this A549 line, the “free” molecule exhibited an IC50 of 25 µM, while
particles with a grafting density of 0.58 gave an IC50 between 1 and 6.5 µM. Surprisingly, particles
with a higher grafting density of 1.91 gave an IC50 that was greater than 25 µM. Similarly, PA/
azTM particles with a low grafting density of 0.77 azTM/nm2 gave an IC50 between 6.5 and 25 µM
in MCF7 cells, a human breast adenocarcinoma cell line. Clearly, the dosage of the small molecule
azTM when attached to the particles is a combination of particles administered and the grafting
density of the ligand to the particle, so a range of particles with grafting densities were investigated.
Figure 3.7 presents the A549 cell viability with particles of varying grafting densities. As a reference
point, 1 µM concentration the free ligand (azTM) indicated cell death of ca. 15%, which is lower than
the 35 % obtained from glioblastomas (cf. Figure 3.6). For the ”free” molecule, this lower efficiency
in the A549 cell line could be due to the fact that the over-expression of Survivin in A549 might
be higher than in Glioblastomas; it is commonly observed that the efficiency of drugs or targeting
molecules varies with different cell lines due to the differing expression levels[232]. From Figure 3.7,
particles with the lowest grafting density (e.g., 0.58 azTM/nm2) exhibited the greatest impact in
cell viability with a 60 % reduction at an azTM concentration of 6.5 µM. Subsequent increases in
dosage with the 0.58 azTM/nm2 particles result in a reduction in efficacy that converge on the cell
viability exhibited with particles of higher grafting density. Particles with grafting densities between
0.90 and 1.91 azTM/nm2 exhibited similar efficacies with a IC50 which is greater than 25 µM.
It is speculated that the enhanced IC50 values for particles with higher grafting densities
was due to an inability of the protein to bind to the particles because of steric concerns. The surface
grafting density of 1.91 azTM groups/nm2 corresponds to a 91 % coverage (on a 67 nm diameter
particle) if the distance of an azTM at its widest point (ca. 7.8 Å) can be assumed to define the
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Figure 3.6: Cell viability of A549 cells treated with small molecule azTM and PA/ azTM particles with two
different grafting densities (gd), 0.58 and 1.91 azTM/nm2, at varying concentrations for 48 hours. Cell viability is
presented as percentage of viable cells compared to the control and the MTS assay was employed.
diameter of a cylinder enclosing the moiety and attached to the PA surface; each particle would then
have ca. 29.5k azTM moieties. Similarly, it was noticed that particles modified with both azTM
and long azPEG chain (5k) exhibited a decreased percentage of cell death (data not presented).
This decrease could be due to the fact that the long PEG chains physically hinder the binding of
the ligand with a Survivin protein or that a higher dosage is required because the transport of the
particles into the cells is reduced with the large hydration shell when the PEGs are attached to the
particles[233, 234, 235, 236].
Functionalized particles localized in cells. Survivin has been found to only operate within the
cell, and to verify that these particles are taken up by the cells and not just located on the surface
of cell, particles were modified with the Survivin ligand (azTM) and a near infrared fluorophore
squaraine (azSQ). A549 cells were treated with 15 µM PA/ azTM/ azSQ for 24 hours and washed
with PBS before imaging. The fluorescence from the squaraine dye was used to identify that the
particles were taken up by the cells (cf. Figure 3.8). In methanol, azSQ has a peak absorption
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Figure 3.7: Viability of A549 cells with PA/ azTM particles of varying ligand surface density. The cells were
treated with azTM and PA/ azTM of varying different grafting densities (gd) of 0.58, 0.90, 1.71, 1.77 and 1.91 azTM/
nm2 and at varying concentrations for 48 hours. Cell viability is presented as percentage of viable cells compared to
the control and the MTS assay was employed.
maximum at 663 nm, while the corresponding emission peak is at 672 nm, for a relatively small
Stokes shift of 9 nm. Previous efforts from this laboratory have indicated that PA/ azSQ particles
are activated by the phospholipids in cells and typically taken up through endocytosis and localize
in the late endosomes and lysosomes of UMSCC22A head and neck cancer cells[71]. Based on these
previous studies, we speculate that the PA/ azTM/ azSQ particles would also be taken up by the
A549 cells through endocytosis and localize in the endosomes and lysosomes of the cells after a 24
hour treatment. This is confirmed in Figure 3.8 where, due to the low quantum yield of the azSQ,
the brightness and contrast of the image obtained was increased to enhance the emission of the PA/
azTM/ azSQ particles. In addition, the imaging study was carried out with an azide terminated
Coumarin-6 (zC6). The azC6 is attached to the PA/ azTM particles through a secondary click
reaction and referred as PA/ azTM/ azC6. The A549 cells were treated with the PA/ azTM/ azC6
particles for 24 hours and then washed with PBS. This fluorophore has a higher quantum yield than
azSQ and is easier to visualize; the fluoroscope images of the localization of modified particles with
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Figure 3.8: Imaging of A549 cells treated with 15 µM PA/ azTM/ azSQ and PA/ azTM/ azC6 for 24 hours and
fluorescence images were taken under RFP and GFP filters, respectively. All scale bars represent 100 µm.
azC6 in the A549 cells can be clearly seen (cf. Figure 3.8). In THF, azC6 has a peak absorption
maximum at 437 nm, while the corresponding emission peak is at 485 nm, which gives a large Stokes
shift of 48 nm and also couples in well with the properties of the GFP filter of the fluoroscope.
In addition, an apoptotic/necrotic/healthy cells detection kit that contains three stains:
Hoechst 33342, Annexin V labeled fluorescein, and Ethidium homodimer III, was employed to es-
tablish the state of the A549 cells when incubated with PA/ azTM particles. Hoechst 33342 (λabs/
λem = 350/461 nm) is a membrane permeable dye, which stains the nuclei of the cells as it binds
specifically to the DNA[237]. Upon binding to the DNA, the Hoechst dye emits a blue fluorescence
that can be seen under a DAPI filter of the fluoroscope[238]. For healthy cells where the DNA is
intact, the emission is bright, while for apoptotic or necrotic cells the emission is dimmer if the treat-
ment damages the DNA of the cell[237, 239, 240]. Annexin V labeled fluorescein (FITC - Annexin
V) (λabs/ λem = 492/514 nm) is used to detect apoptotic cells. In apoptosis, the disassembly of
the cell takes place with changes in the phospholipid content of the outer leaflet of the cytoplasmic
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membrane and the Phosphatidylserine (PS) is translocated from the inner to the outer surface of
the cell for phagocytic cell recognition[241]. Annexin V (35 kD) is a phospholipid protein that binds
to the translocated PS with a high binding affinity and upon binding to the PS, the FITC-Annexin
V emits a bright green fluorescence that can be seen with a GFP filter of the fluoroscope[242, 243].
For the detection of necrotic cells, an Ethidium homodimer III (EthD-III) (λabs/ λem = 528/617
nm) stain is used. EthD-III is a highly positively charged nucleic acid probe, which is impermeant
to live or apoptotic cells, but stains necrotic cells intensively with red and can be seen under a RFP
filter of the fluoroscope[244, 245].
In the current study, A549 cells were treated for 24 hours with 25 µM of azTM, unmodified
PA particles, PA/ azTM particles of two different grafting densities of 0.63 and 1.77 azTM/ nm2,
and PA/ azTM/ azPEG particles. After the treatment, the cells were stained with the Hoechst
33342, FITC-Annexin V, and EthD-III stains as per the manufacturer’s instructions and imaged
with a standard fluoroscope and Figure 3.9 presents the images obtained. As expected, for the two
control treatments (cf. Figure 3.9 - panels 1 to 6), only the emission from Hoechst staining (blue) was
seen. This confirms that the cells are healthy and that the PA particles are not toxic. For the azTM
treated cells, the Hoechst staining (cf. Figure 3.9 - panel 7) indicated that the number of healthy
cells decreased by ca. 38 % which was coupled with a decrease in the intensity of the blue emission,
suggesting the possibility of DNA damage. In addition, the emission was not a normal bright round
spot but appeared to be shaped like clumped random strands. It was subsequently verified that this
blue emission from random strand like shapes was attributed to the emission of the azTM and not
the Hoechst dye. The azTM treated cells indicated ca. 43 % apoptotic cell death and the images
obtained (cf. Figure 3.9 - panels 7 to 9) suggested that the cells were in the late apoptotic stage, as
they were stained by all the three dyes (blue, green and red). When cells are stained with the triple
colors blue, green, and red, this indicates that those cells are dead cells progressing from apoptotic
cell population[246, 247]. For the treatment of PA/ azTM particles with a grafting density of 0.63
azTM/ nm2 (cf. Figure 3.9 - panels 10 to 12), ca. 66 % reduction in healthy cells was observed and
the late apoptotic cell population was ca. 18 %. In this treatment, the apoptotic cell death was lower
than expected, which could be due to a loss of dead cells during the wash with buffer prior to the
staining process. For treatments with particles of higher grafting density of azTM/nm2 (cf. Figure
3.9 - panels 13 and 16), the number of healthy cells was not reduced when compared to the controls
(cf. Figure 3.9 - panels 1 and 4), suggesting that the high azTM grafting density particles were not
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that effective. This result is in accordance with the earlier speculation that particles with higher
grafting densities of the ligands did not allow the proteins the spatial flexibility to bind (cf. Figure
3.7). In addition, there is a ca. 30 to 40 % decrease in the number of late apoptotic cells for treatment
with the PEGylated particles (cf. Figure 3.9 - panel 17) when compared to non-PEGylated particles
(cf. Figure 3.9 - panel 14), which also supports the previous speculation that protein transport to
the surface of the particles is reduced with a large PEG hydration shell.
3.4 Experimental
Reagents and solvents. All the commercial reagents were purchased from TCI America and
Alfa Aesar and used without further purification. All the solvents were dried according to standard
methods. Deionized water was obtained from a Thermo Scientific Barnstead NANOpure Water
Purification System and exhibited a resistivity of ca. 1018 ohm−1cm−1.
Chemical characterization methods. 1H and 13C NMR spectra were recorded on JEOL ECX-
300 spectrometers (300MHz for proton and 76MHz for carbon). Chemical shifts for protons are
reported in parts per million downfield from tetramethylsilane and are referenced to residual protium
in the NMR solvent (CDCl3: δ 7.26 ppm, DMSO-d6: δ 2.50 ppm). Chemical shifts for carbons are
reported in parts per million downfield from tetramethylsilane and are referenced to the carbon
resonances of the solvent (CDCl3: δ 77.16, DMSO-d6: δ 39.52 ppm). Coupling constants are
reported in Hertz (Hz). LC/MS mass spectra were obtained using Finnigan LCQ spectrometer and
HP 1100 (HPLC). The IR spectra were recorded at room temperature in the wavenumber range of
400-4000 cm−1 and referenced against air with a Nicolet 6700 FTIR instrument. A total of 32 scans
were averaged for each sample at 2 cm−1 resolution.
Preparation of Survivin ligands (TM and azTM) The Survivin ligand TM was prepared
based on the method published[209, 248, 249]. The reaction scheme for the synthesis of TM is
presented in Figure 3.10.
6-(5-chloro-2-hydroxyphenyl)-4-(2-chloro-5-(trifluoromethyl)phenyl)-2-oxo-1,2-
dihydropyridine-3- carbonitrile (1) 1-(5-Chloro-2-hydroxyphenyl) ethanone (0.1 g, 0.586 mmol),
2-chloro-5-(trifluor-
omethyl) benzaldehyde (0.122 g, 0.586 mmol), ethyl cyanoacetate (0.1 g, 0.88 mmol), and ammonium
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acetate (0.45 g, 5.86 mmol) were dissolved in ethanol (7 mL) and stirred under nitrogen atmosphere
in sealed flask at 110 oC for 3 hours. After cooling, the precipitated yellow solid was diluted with
diethyl ether (7ml), filtered, washed with diethyl ether and with water, and then dried to give the
product. Yield: 0.1 g (40 %). m.p. = 330 oC with destruction. 1H NMR (DMSO-d6) δ 6.69 (d, 1H,
J = 8.9 Hz), 6.83 (s, 1H), 7.15 (d.d, 1H, J = 8.9 Hz, J= 2.6 Hz), 7.82 (m, 1H), 7.86 (m, 1H), 7.88
(m, 2H); 8.02 (d, 1H, J= 2.6 Hz). 13C NMR (DMSO-d6) δ 95.78, 102.78, 117.52, 118.18, 120.00,
120.60, 121.86, 125.46, 127.10, 127.30 (m), 127.83, 128.26, 130.81, 131.63, 135.75, 137.77, 154.11,
155.33, 161.92, 163.50. ESI-Mass m/z (%): 426.7 (75), 423.27 ([M-H]−; 100).
The reaction scheme for the synthesis of azTM is presented in Figure 3.10.
4-(3-azidopropoxy)benzaldehyde (2) p-Hydroxybenzaldehyde (0.1 g, 0.82 mmol) and
1-azido-3-iodo propane (0.19 g, 0.9 mmol) were dissolved in acetone (15 mL). Potassium carbonate
(0.113 g, 0.82 mmol) was added to the solution and obtained mixture was stirred and refluxed for
5 hours. After cooling the mixture was quenched with water and extracted with dichloromethane.
Organic layer was separated, dried with Na2SO4 and filtered. The filtrate was evaporated to give a
clear oil. Yield: 0.13 g (77 %). 1H NMR (CDCl3) δ 2.09 (m, 2H, J = 6.3 Hz), 3.54 (t, 2H, J = 6.5
Hz), 4.14 (t, 2H, J = 6.0 Hz), 7.00 (d, 2H, J = 8.6 Hz), 7.80 (d, 2H, J = 8.6 Hz), 9.88 (s, 1H).
4-(4-(3-azidopropoxy)phenyl)-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydro-
pyridine-3-carbonitrile (3)1-(5-Chloro-2-hydroxyphenyl)ethanone (0.277 g, 1.62 mmol), 4-(3-
azidopropoxy) benzaldehyde (0.4 g, 1.95 mmol), ethyl cyanoacetate (0.238 g, 2.11 mmol) and am-
monium acetate (0.75 g, 9.72 mmol) were dissolved in ethanol (7 mL) and stirred under nitrogen
atmosphere in sealed flask at 110 oC for 16 hours. After cooling, the precipitated yellow solid was
filtered, washed with cold ethanol and with water, and then dried. Obtained yellow solid (0.265 g)
is the mix of two compounds with same molecular weight. The mix was separated by flash column
chromatography on silica, solvent ethyl acetate : hexane (1 : 1). RF =0.8. Yield: 0.105 g (15 %).
m.p. = 186 oC with decomposition. 1H NMR (DMSO-d6) δ 2.02 (m, 2H, J = 6.5 Hz), 3.54 (t, 2H,
J = 6.5 Hz), 4.13 (t, 2H, J = 6.0 Hz), 7.05 (d, 2H, J = 8.9 Hz), 7.36 (d, 1H, J = 8.9 Hz), 7.60 (d.d,
1H, J = 2.4 Hz, J = 8.9 Hz), 7.92 (s, 1H), 8.28 (d, 2H, J = 8.9 Hz), 8.65 (d, 1H, J = 2.4 Hz). 13C
NMR (DMSO-d6) δ 28.16, 47.73, 64.87, 95.28, 100.27, 114.37, 118.72, 119.0, 124.65, 129.05, 129.29,
130.05, 132.0, 143.41, 150.60, 160.18, 160.48, 160.65. ESI-Mass m/z (%): 423 (70) [M+H]+, 418
(100).
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Preparation of azide-modified polyethylene glycol (azPEG). The azPEG was prepared
according to the method published[31].
Mono-methoxy-PEG5000-methansulfonate Methylsulfonyl chloride (0.92 g, 8 mmol)
in dichloromethane (5 mL) was added dropwise at room temperature to the stirring solution of
triethylamine (0.89 g, 8.8 mmol) and mono-methoxy-PEG5000 (20 g, 4 mmol) in dichloromethane
(70 mL). The solution was stirred at 20 oC for 4 hours, then washed with water and the organic
layer was dried with Na2SO4 with further filtration. The solvent was evaporated under vacuum to
give the product as a white solid. Yield: 20.3 g (97 %). 1H NMR (CDCl3) δ 3.07 (s, 3H), 3.36 (s,
3H), 3.48 (t, 2H), 3.53 (m, 2H), 3.62 (m, ca. 400H), 3.75 (m, 4H), 4.36 (m, 2H).
Mono-methoxy-PEG5000-azide The mixture of mono-methoxy-PEG5000-methansulfo-
nate (20.3 g, 4 mmol) and sodium azide (1.1 g, 17 mmol) in acetonitrile (80 mL) was refluxed and
stirred for 15 hours. After cooling, the mixture was filtered and the solvent was evaporated. The
residue was dissolved in dichloromethane and washed with water, organic layer was separated, dried
with Na2SO4 and filtered. The solvent was evaporated, the crystalline residue was washed with
hexane, filtered and dried in air to give the product as a white solid. Yield: 19 g (94 %). 1H NMR
(CDCl3) δ 3.35 (s, 3H), 3.38 (t, 2H), 3.62 (m, ca. 400H), 3.85 (m, 2H). FTIR (cm
−1): 1095 (s,
C-O-C); 1340, 1465 (CH2); 2100 (N3); 2880 (s, CH2).
Preparation of the particles. Propargyl acrylate (PA) particles were prepared according to a
standard emulsion polymerization method published[31].
For a typical surface modification of the particles, for example, the grafting of azTM and
azide-modified PEG chains with molecular weight of 5000 (azPEG) onto the particles, 1 mL PA
particles and 5 mg azTM were added to 2 mL of deionized water. Solutions of 0.07624 g copper(II)
sulfate (99.999% Aldrich) in 10 mL deionized water and 0.3024 g sodium ascorbate (99% Aldrich)
in 10 mL deionized water were made. Initially, 0.5 mL of the CuSO4 solution was added to the
PA/ azTM solution, followed by 0.5 mL of the sodium ascorbate solution. The resulting mixture
was maintained at a temperature of ca. 28 oC for 15 minutes and then the reaction was stopped
by the removal of unreacted azTM, sodium ascorbate, and Cu(II)SO4 through a repeated particle
washing procedure consisting of centrifugation and redispersement in methanol. The cleaned PA/
azTM particles in water were subsequently utilized in a secondary click transformation with 54.99 mg
azPEG, and previously presented CuSO4 and sodium ascorbate solutions. The reaction was allowed
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to run for 24 hours and then washed to remove unreacted species as determined by absorbance
measurements; these particles are referred to as PA/ azTM/ azPEG particles.
Affinity pull-down assay. The particles (conjugated or control) were washed 3 times with Buffer
A (20 mM KH2PO4 pH 7.5, 10 % glycerol, 0.5 mM EDTA, 0.01 % Igepal, and 1 % Triton) before
the addition of Survivin-HIS(6) or BSA (6 µg each). The reactions were agitated at 4
oC for 30 min
in Buffer B containing 150 mM KCl (final volume of 30 µL). The supernatant was removed from
the beads followed by 3 washes of the beads with Buffer A containing 300 mM KCl. Equal volumes
of 2x SDS dye was added to the supernatant and wash fractions, while 30 µL of 2xSDS loading dye
was added to the bead fraction. The fractions were subjected to SDS-PAGE analysis on 15 % gels
followed by Coomassie Blue staining.
Cell analysis. Human A549, MCF7, and U118MG cell lines were obtained from ATCC (Rockville,
MD). Human glioblastoma U251MG cell line was obtained from National Cancer Institute (Frederick,
MD). A549 cells were cultured in F-12K media (Kaighn’s Modification of Ham’s F-12 medium)
containing 10 % fetal bovine serum (FBS) and 1 % antibiotic. MCF7 cells were cultured in phenol
red-free Dulbeccos modified Eagles media (DMEM) containing 10 % fetal bovine serum (FBS) and
1 % Penicillin-Streptomycin. U118MG cells were cultured in Dulbeccos modified Eagles media
(DMEM) containing 10 % fetal bovine serum (FBS) and antibiotics. U251MG cells were cultured
in Roswell Park Memorial Institute (RPMI) 1640 containing 10 % fetal bovine serum (FBS) and
antibiotics. Cells were cultured at 37 ◦C in a humidified atmosphere of 95 % air 5 % CO2.
Cytotoxicity assay. A549 cells (5,000 cells per well) were cultured on 96 well plates for 24 hours.
Subsequently, cells were, exposed to 15 and 20 µM of PA, 15 and 20 µM of PA/ azPEG, 1, 6.5, 25,
45, and 65 µM of azTM, 1, 6.5, 25, 45, and 65 µM of PA/ azTM and 1, 6.5, 25, 45, and 65 µM of PA/
azTM/ azPEG. After 48 hours, cell death was assessed with a MTS assay according to the manufac-
turer’s instructions (Promega, Madison, WI). Briefly, medium was aspirated and a solution of 100
µL of F-12K containing 10% FBS and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, salt (MTS) and phenazine methosulfate (PMS) was added onto each
well. After 150 minutes, wells were scanned colorimetrically at 490 nm on a spectrophotometer. The
conversion of MTS into an aqueous soluble formazan product is achieved only by dehydrogenase en-
zymes, which are present in metabolically active cells; the absorbance at 490 nm from the formazan
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product is directly proportional to the number of living cells in culture. MCF7 cells (20,000 cells per
well) were cultured on 96 well plates for 24 hours. Subsequently, cells were, exposed to 1, 6.5, 25,
45, and 65 µM of azTM, 1, 6.5, 25, 45, and 65 µM of PA/ azTM and 6.5, 25, 45, and 65 µM of PA/
azTM/ azPEG. After 72 hours, cell death was assessed with a MTS assay according to the manufac-
turer’s instructions (Promega, Madison, WI). Briefly, medium was aspirated and a solution of 100
µL of DMEM containing 10% FBS and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, salt (MTS) and phenazine methosulfate (PMS) was added onto
each well. After 180 minutes, wells were scanned colorimetrically at 490 nm on a spectrophotome-
ter. Human glioblastoma U118MG and U251MG cells were cultured on 96 well plates for 24 hours.
Subsequently, cells were, exposed to 0.05, 0.1, 0.25, 0.5, 1.0, and 2.5 µM of TM and 0.05, 0.1, 0.25,
0.5, 1.0, and 2.5 µM of azTM. The growth medium was supplemented with 2 % FBS and treated
with TM or azTM. After 24 hours, cell death was assessed with a MTT assay according to the
manufacturer’s instructions. Briefly, medium was aspirated and a solution of DMEM containing 10
% FBS and 0.2 mg/ mL MTT was added onto each well. After 180 minutes, DMSO (200 µL) was
added to each well to dissolve the formazan crystals and absorbance was measured at 570 nm with
background subtraction at 630 nm. Cell viability was presented as percentage of viable cells in total
population. Significant difference from control value was indicated by ∗p < 0.05.
In situ Wright staining for the detection of morphological features of apoptosis. The
U118MG and U251MG cells were grown in 6 - well plates and treated with TM (0.1, 0.5, or 1.0
µM) or azTM (0.1, 0.5, or 1.0 µM) for 24 hours. At the end of treatments, both adherent and
floating cells were centrifuged at a low rpm to sediment them. The cells were then washed twice
with PBS, pH 7.4, before being fixed and subjected to in situ Wright staining. The 6 - well plates
were then allowed to dry and cells (n = 300) were examined under the light microscope. The
morphology of the apoptotic cells as examined under light microscopy included such characteristic
features as chromatin condensation, cell-volume shrinkage, and membrane-bound apoptotic bodies.
Four randomly selected fields were counted for at least 300 cells. The percentage of apoptotic cells
was calculated from three separate experiments.
Western blotting using specific antibodies. Both glioblastoma cell lines (U118MG and
U251MG) were treated with azTM or PA/ azTM (1.0 µM Survivin ligand concentration) prior to
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extraction of protein samples. The protein samples (10 µg) were mixed with Laemmli composition
of buffer and boiled in water for 5 min. The boiled protein samples were loaded onto precast 4
- 20 % polyacrylamide gradient gels (Bio-Rad Laboratories, Hercules, CA) and electroblotted to
the polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA). The non-specific binding
sites in the membrane were blocked with 5 % non-fat dry milk for 1 hour at room temperature. The
membranes were then incubated overnight at 4 oC on a rocker with appropriate dilution of primary
IgG antibody followed by three times washing in washing buffer (20 mM TrisHCl, pH 7.6, 137 mM
NaCl, 0.1 % Tween 20). After washing, the membranes were incubated with the appropriate alkaline
horseradish peroxidase (HRP)-conjugated secondary IgG antibody for 1 hour followed by three times
washing in washing buffer. Specific protein bands were detected by incubation for 5 min at room
temperature with Immun-StarTM HRP Lumino/Enhancer (Bio-Rad Laboratories, Hercules, CA)
and exposing to BIOMAX XAR films (Kodak, Rochester, NY) for autoradiography. The antibody
against β-Actin (clone AC-15) was purchased from Sigma (St. Louis, MO), and antibodies against
Survivin and Caspase-3, were from Santa Cruz Biotechnology (Santa Cruz, CA). The alkaline HRP-
conjugated anti-rabbit and anti-mouse secondary IgG antibodies were purchased from Biomeda
(Foster City, CA) and anti-goat secondary IgG antibody was from Santa Cruz Biotechnology (Santa
Cruz, CA). The autoradiograms were scanned on an EPSON Scanner using Photoshop software
(Adobe Systems, Seattle, WA, USA) and optical density (OD) of each band was determined using
the NIH Image software. The OD of bands in the control treatment was designated as 100. All
experiments were performed in triplicates and results were analyzed for statistical significance.
Determination of apoptotic,necrotic and healthy cells A549 cells (5,000 cells per well) were
cultured on 96 well plates for 24 hours. Subsequently, cells were exposed to 25 µM of azTM, unmod-
ified PA particles, PA/ azTM particles of two different grafting densities of 0.63 and 1.77 azTM/
nm2, and PA/ azTM/ azPEG particles. After 24 hours of treatment, the apoptotic, necrotic and
healthy cells quantification kit purchased from Biotium, Inc. (Hayward, CA, USA) was used accord-
ing to the manufacturer’s instruction. The stained cells were observed under a Life Technologies
EVOS R© FL Cell Imaging System using filter sets of DAPI, GFP and RFP. Healthy cells were stained
with Hoechst 33342 and had only blue emission. Necrotic cells were stained with Hoechst 33342
and Ethidium homodimer III, and had both blue and red emissions. Apoptotic cells had blue, red
and green emissions as those cells were stained by all the three stains: Hoechst 33342, Ethidium
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homodimer III and fluorescein labeled Annexin-V. Cells stained by the triple colors indicate dead
cells progressing from apoptotic cell population[246, 247]. All the three types of cells were counted
and expressed as percentage of total cells.
3.5 Conclusion
Disrupting the activity of anti-apoptotic proteins that are over-expressed by cancer cells is
a potentially attractive route to combating this disease. Survivin belongs to the family of inhibitor
of apoptosis proteins (IAP) and is present in most cancers while being below detection limits in
most terminally differentiated adult tissues, making it an attractive protein to target for diagnostic
and, potentially, therapeutic roles. To this end, sub-100 nm poly(propargyl acrylate) particles were
surface modified through the copper-catalyzed azide/alkyne cycloaddition of an azide-terminated
Survivin ligand derivative (azTM) originally proposed by Abbott Labs and speculated to bind di-
rectly to Survivin (protein) at its dimer interface. Using affinity pull-down studies, it was determined
that the PA/azTM nanoparticles selectively bind Survivin. Incubating the modified particles with
glioblastomas and other Survivin over-expressing cell lines such as A549 and MCF7 resulted in
a higher percentage of cell death relative to cells incubated with the original Abbott-derived small
molecule. In situ Wright staining and selective dyes were used to confirm that the cell death observed
was through apoptosis. In addition, a Western blot assay indicated that there was an significant
increase in the expression of Caspase-3, the final executioner of apoptosis, during the treatment
with the PA/azTM particles. Overall, the results obtained validate the statement mentioned in the
introduction that the nanocarriers increase circulation lifetimes and enhance the effectiveness of the
drug/ligand for Survivin inhibition or sequestration. This nanocarrier technique can be expanded to
the other Survivin inhibition approaches, such as attaching a plasmid or siRNA, as well as a target-
ing group that will single-out specific tumors and avoid healthy cells. These particles offer a flexible
platform that can be easily surface modified to recursively attach a range of moieties such as near
infrared fluorophores, antibodies, and drugs to one particle, creating a multifunctional nanodevice
for use against cancer.
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Figure 3.9: Fluoroscope images of A549 cells after incubation with 25 µM of azTM, PA/ azTM particles with
two different grafting densities, PA/ azTM/ azPEG particles and PA particles. Cells were treated with an apop-
totic/necrotic/healthy cells detection kit to differentiate the status of the cells. All scale bars represent 200 µm.
77
Figure 3.10: Reaction scheme for synthesis of Survivin ligands, TM and azTM
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Chapter 4
A bioresponsive and versatile
particle-protein-dye system for
small molecule delivery and FRET
based imaging
4.1 Attributions
The synthesis of the azide and alkyne modified small molecules was conducted or aided
by Dr. Yuriy P. Bandera at Clemson University. Cell growth and viability assessments in A549
cells were conducted with the aid of Ashlee Tietje and Dr. Yanzhang Wei at Clemson University.
Photodynamic therapy study was carried out with the aid of Dr. Anna-Liisa Nieminen at Medical
University of South Carolina. a—e - UV-Vis-IR Spectral Software 1.2, FluorTools, was used to
decompose the overlapped spectra for ratiometric FRET calculations. The results in this chapter




In the recent years, there has been a significant growth and development of multifunc-
tional nanocarriers such as surface cross-linked micelles[15, 16], dendrimers[17], biodegradable poly-
meric nanoparticles[18, 19], magnetic and other metal particles[20, 21], and liposomes[20], for can-
cer theranostics. Among these technologies, platforms based on polymeric materials, especially
biodegradable nanoparticles, are of particular interest due to the flexibility offered by macromolec-
ular synthesis methods, high drug loading capacities, improved drug solubility and their ease of
multifunctionalization[22, 23, 24]. Combining imaging and therapeutic agents into a single formula-
tion enables direct visualization of the theranostic pharmacokinetics and provides important insight
into heterogeneities between tumors and patients, which will be helpful for the physician to decide
or change the dosage, drug choice and treatment method accordingly and results in an effective ’per-
sonalized medicine’ treatment of the disease[52]. In order for the ’personalized medicine’ treatment
to be successful, the single nanocarrier should demonstrate the following properties: (1) be biocom-
patible/ biodegradable; (2) prolonged circulation lifetimes; (3) ability to accumulate specifically in
the required zone of interest; (4) responsiveness to local stimuli, such as pH and/ or temperature
changes; (5) allow for an effective intracellular drug delivery; and (6) bear a contrast/ reporter
moiety for real-time observation[22, 78]. To prepare such a smart multifunctional nanocarrier, it is
necessary that the chemical moieties that are responsible for the properties should be attached on the
surface of the nanocarrier to prevent opsonization, facilitate for formation of beneficial host/guest
assemblies and specifically target the tumors[21, 78, 250].
A prevalent and quickly developing technique to prepare and surface functionalize the
nanoparticles is through ’click’ transformations because the reactions are reliable, experimentally
simple, facilitate bioconjugation and yield products of high orthogonality and functionalization[18,
87, 251]. Previously, we have reported a poly(propargyl acrylate) particle surface functionalized with
a near-infrared fluorophore for fluorescence imaging and photodynamic therapy applications[31, 71].
These particles exhibit a good tumor-to-background ratio and have a good circulation lifetimes but
attaching the fluorophore directly to the particle decreased the quantum efficiency of the system
by 60 to 70 %. In addition, the contrast agents are attached to the particles at all times, which
makes it less attractive for drug delivery applications. To this end we need to design an improved
system of surface modified particles, particularly, a system that attaches the drugs to the particle
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through a linker that responds specifically to release the drug. After a detailed literature search, it
was identified that BSA could be the potential linker for the improved system as it stable, inert to
many biochemical reactions and prevents non-specific adsorption of other proteins to surfaces[252].
Recently, the quantification and digestion of bovine serum albumin (BSA) covalently conju-
gated to gold nanoparticles was illustrated and in these particles, the protein was conjugated to the
surface of the particles using a standard NHS activation approach, where the primary amines of the
protein react with carboxyl containing substrates and form a covalent amide bond[252]. This conju-
gation with NHS substrates is a well established strategy and is widely used to construct fluorescent
oligonucleotides and proteins[253, 254]. Utilizing the NHS activation and click transformations, the
improved system of modified particles can be made. In this current effort, we present a particle-
protein-dye system (cf. Figure 4.1), where the particles are surface modified with the azide modified
BSA (azBSA) that is conjugated to fluorophores. These fluorophore functionalized particles exhibit
improved efficiencies in imaging and photodynamic therapy applications because they are activated
only after the digestion of the azBSA protein. This allows the particles to be in the ’off’ state till
they reach their end locations, which is the lysosome and endosome. In those regions of the cell,
the pH is ca. 4 - 5 and the digestive enzymes are located here, so the albumin linker is digested
and results in the release and turn ’on’ of the emission of the fluorophore. In this system as the
fluorophore will be released as a free molecule, there will not be a significant reduction in quantum
efficiency and photosensitizing activity. In addition, this system can also be prepared such that
a ligand or drug is attached instead of the fluorophore to use it for targeting and other delivery
applications and if desired the azBSA can be conjugated with a number of fluorophores, ligands,
antibodies and drugs at the same time by adjusting the ratios of those small molecules during click
transformations. These multiple functionalized particles represent a single ’nanodevice’ that can be
a very attractive platform for personalized medicine.
4.3 Results & Discussion
A schematic of the particle-based system studied in this effort is presented in Figure 4.1.
The poly(propargyl acrylate) (PA) colloids were prepared using a standard aqueous emulsion poly-
merization technique with sodium dodecyl sulfate as the surfactant, potassium persulfate as the
initiator, and divinyl benzene as a crosslinker, resulting in spheres with a diameter of ca. 88.5 nm.
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Figure 4.1: Schematic of the release of fluorophores from functionalized particles through trypsin digestion of the
albumin. Sub 100 nm poly(propargyl acrylate) (PA) particles were surface modified with an azide-modified bovine
serum albumin (azBSA) and alkyne terminated cyanine derivate fluorophore (YB317) through an aqueous-phase click
transformation.
To functionalize the particle surface with the protein bovine serum albumin (BSA), BSA has to be
modified to have terminal azide groups. Standard BSA was reacted with excess azide modified N -
hydroxysuccinimide ester (azNHS) to produce azide labeled BSA (azBSA) that has several free azide
terminated groups. A multiple step ”click” reaction was performed to conjugate alkyne terminated
cyanine derivative fluorophore (CYN) to azBSA and then functionalize the PA particles with the
azBSA-CYN conjugate.
4.3.1 Emission of free fluorophore and interaction with proteins
The structure of the free alkyne terminated cyanine 3 derivative (CYN) fluorophore is pre-
sented in Figure 4.2 and its absorbance and photoluminescence when dispersed in methanol is
presented in Figure 4.3. In this solvent, CYN has a peak absorption maximum at 546 nm and the
corresponding emission peak is at 569 nm, which gives a stokes shift of 23 nm. CYN exhibits a
reduced emission when dispersed in aqueous solutions due to quenching, (cf. Figure 4.4a) and for
biological applications, the fluorophore needs to be dispersed in aqueous solutions. The quenching
of the emission of fluorophores is a well-known phenomenon where the dye-dye separation becomes
small at a limiting concentration and the fluorophore forms aggregates. These aggregates, upon
excitation, transfer energy through a non-radiative pathway, which results in a decreased or zero
emission of the fluorophore[143, 255]. The emission of these large aggregates is typically activated
by albumins which solubilize the fluorophore by breaking up the aggregates and binding the fluo-
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Figure 4.2: Structures of (a) azide modified N-hydroxy succinimide derivative (azNHS), (b) alkyne modified
cyanine derivative fluorophore (CYN), (c) azide modified silicon phthalocyanine fluorophore with short PEG chains
(azSiPc1) and long PEG chains (azSiPc2), (d) alkyne modified silicon phthalocyanine fluorophore with short PEG
chains (SiPc1) and long PEG chains (SiPc2), (e) Abbott 17, (f) azide modified Survivin ligand (sl01), (g) alkyne
modified Survivin ligand (sl02), and (h) azide modified fluorescein derivative fluorophore (azFL).
rophore non-specifically[143, 255]. The activation of CYN in a Tris-HCL buffer of pH 8 is presented
in Figure 4.4a. Upon addition of 0.05 mM BSA to CYN, a dramatic increase in photoluminescence
was observed in 1 hour. There was a 4742 % increase in the integrated peak area of emission. The
activated emission can be deactivated using trypsin. It is well known that trypsin digests BSA
when incubated at high temperatures and at a pH of 7 - 8[166, 256]. When ca. 0.215 mM trypsin
was added to the BSA-CYN complex and incubated at 37 oC, BSA was broken down into smaller
peptides which can no longer bind to CYN. This leads the CYN to form aggregates and quench the
emission once again. At longer periods of incubation of the albumin activated CYN with trypsin,
the emission returned to the initial intensity as the BSA is completely digested. In addition to the
activation/ deactivation study of the CYN, it is necessary to study the changes in emission of CYN
with trypsin to eliminate the possibility of trypsin activating the emission of CYN. In this study, ca.
0.215 mM trypsin was added to CYN fluorophore and incubated at 37 oC. The emission of CYN
is monitored during incubation and after 2 hours of incubation, the photoluminescence intensity
increased by 95 % (cf. Figure 4.4b) which is much lower compared to the activation with albumin.
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Figure 4.3: Absorbance (green) and photoluminescence (pink) of alkyne functionalized cyanine derivative fluo-
rophore (CYN; 12.21 µM in methanol).
After incubation for longer periods of time, the emission returns to the initial intensity as trypsin
digests itself too. Therefore from the activation studies of CYN, it can be concluded that CYN is
selectively activated by BSA and activation by trypsin is negligible in comparison to the activation
by BSA.
4.3.2 Modification of BSA and attachment of the azBSA-CYN conjugate
to PA particles
To synthesize PA nanoparticles functionalized with azBSA-CYN conjugate, first BSA needs
to be modified to have free azide end groups. We follow a standard NHS coupling reaction that is
typically used to label oligonucleotides with azido group[253]. The BSA was reacted with excess
azide modified N - hydroxysuccinimide ester (azNHS) (cf. Figure 4.2) to produce azide labeled BSA
(azBSA). The product was dialyzed in a 12,000 - 14,000 MWCO dialysis bag for 2 days to remove
the excess starting material. To the cleaned azBSA, alkyne modified cyanine derivative fluorophore
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Figure 4.4: (a) Changes in photoluminescence intensity of (-) alkyne terminated cyanine fluorophore (CYN), with
addition of (◦) ca. 0.05 mM bovine serum albumin, followed by addition of ca. 0.215 mM trypsin, and incubated
for (•) 2 hours and (4) 7203 hours. (b) Changes in photoluminescence intensity of (-) alkyne terminated cyanine
fluorophore (CYN), with the addition of ca. 0.215 mM trypsin, and incubated for (•) 2 hours and (4) 7203 hours.
Figure 4.5: TEM micrographs of (a) unmodified PA particles, (b) and (c) particles surface modified with albumin/
cyanine 3 derivative fluorophore (PA-azBSA-CYN). All scale bars represent ca. 100 nm.
(CYN) (cf. Figure 4.2) was attached through a copper-catalyzed azide/ alkyne cycloaddition (’click’
transformation) that is performed in water[254]. The CYN was clicked onto the azBSA for 24
hours and then the reaction was stopped by the removal unreacted sodium ascorbate and Cu(II)SO4
through dialysis for 48 - 72 hours. The cleaned azBSA-CYN were subsequently utilized in a secondary
click transformation with poly (propargyl acrylate) nanoparticles (PA). This reaction was allowed
to run for 48 hours and then washed to remove unreacted species through dialyzing for 48 - 72 hours
and a repeated washing procedure consisting of centrifugation and redispersement in phosphate
buffered solution (PBS) that had 10 - 30 % THF. The last couple of washes were carried out using
just PBS and the cleaned particles were dispersed in fresh PBS. The absorbance of the supernate
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and thin layer chromatography (TLC) of the modified particles were used to confirm that all the
free unbound dye was removed. The final cleaned particles are referred as PA-azBSA-CYN. TEM
images were taken for particles before and after modification (cf. Figure 4.5). The initial unmodified
particles are very monodisperse and surface outline can be seen neatly. After the click reaction, the
PA-azBSA-CYN particles looked like they were clumped together and were held together with the
azBSA. The azBSA has multiple free azide groups before the secondary click reaction, so it is possible
to attach one azBSA to two or more particles. This results in a system where the particles are held
together with an adhesive-like substance, which is azBSA.
4.3.3 Release of the fluorophore upon tryptic digestion of the particles
functionalized with azBSA-CYN conjugate
Figure 4.6: (a) Increase in photoluminescence intensity of PA-azBSA-CYN nanoparticles with addition of trypsin
and incubation for 1 hour (◦) and 48 hours (•) at 37 oC when dispersed in PBS. The inset presents the change in
the integrated peak area of emission with the addition of trypsin. (b) Photoluminescence of the supernates of the
PA-azBSA-CYN nanoparticles stored at 4 oC (-), incubated at 37 oC (◦), and trypsin digested (•).
An important feature of the PA-azBSA-CYN nanoparticles is the release of the free fluo-
rophore upon tryptic digestion. Initially, the modified particles have a lower emission and are said
to be in an ’off’ state because the fluorophore transfers energy non-radiatively to the protein and
particles. In this scenario, the protein acts as a linker that attaches the fluorophore to the particle,
and it is expected that upon digestion of the protein, it gets broken down to smaller peptide chains
and results in the release of the fluorophore. As the fluorophore is free and no longer attached to
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Figure 4.7: nanoDSC runs of (a) BSA and (b) azBSA. Undigested proteins (pink) and trypsin digested proteins
(green)
the particles, the non-radiative transfer of energy is decreased, which leads to a significant increase
in the emission of the fluorophore, and this emission activation is called the ’on’ state of the system.
This system of particle-protein-dye has two main advantages. First, the particles are in the ’off’
state until they are taken up by the cells where eventually the protein gets digested to release the flu-
orophore and the emission is turned ’on’. This activation of the emission inside the cell will enhance
the tumor-to-background ratio. Second, the fluorophore is initially immobilized on the particles, so
it will accumulate inside the cells at a higher concentration due to the enhanced permeability and
retention (EPR) effect. These advantages make the particle-protein-dye system an attractive option
for fluorescence imaging applications.
To illustrate the emission ’turn on’ due to the release of the fluorophore from the modified
particles, clean PA-azBSA-CYN particles were incubated with 0.215 mM trypsin at 37 oC (cf.
Figure 4.6a). After an hour of incubation, an increase of ca. 2360 % in integrated intensity area
was observed, and that increase dropped slightly at longer incubation times. This response of the
modified particles implied that the majority of the fluorophore was released within the first hour
of incubation and at longer periods it is possible that the fluorophore is dropping out of solution
or the emission is quenching due to aggregation of the fluorophores[143, 255]. In addition, it can
be argued that the emission ’turn-on’ of the modified particles could be from the denaturing of the
BSA. It is speculated that during the initial unfolding stage, emission could be activated due to the
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increased non-specific interaction between the BSA and CYN[71]. To disprove this speculation and
confirm that the fluorophore was actually released, the PA-azBSA-CYN particles were centrifuged
at 15,000 rpm for 15 minutes to separate the particles from the free fluorophore. If the fluorophore
was released then it would remain in the supernate instead of still remaining attached to the crashed
particles, and measuring the emission of the supernate of the trypsin digested particles would reveal
if the fluorophore was released or not. Figure 4.6b presents the emission of the supernate when
excited at 550 nm. The undigested particles that were stored at 4 oC and the particles incubated at
37 oC without trypsin were used as controls in this supernate study. For both controls, the supernate
obtained after centrifugation had no emission and the supernate of the trypsin digested particles had
a strong emission (cf. Figure 4.6b). These measurements confirm the release of the fluorophore from
the modified particles, upon trypsin digestion. However, it is important to note that in some of the
batches of the PA-azBSA-CYN particles, the yields of the release of the fluorophore upon tryptic
digestion were low. This inconsistency in the release of the fluorophore was anticipated and can be
attributed to the modification of BSA and the digestion conditions[257]. In tryptic digestion, it is well
established that trypsin cleaves at the amino side of the cysteine residues. The primary amines of the
BSA are all modified for conjugation to azNHS to facilitate the attachment of the CYN fluorophore,
so there is a high possibility that most of the peptide bonds formed during the NHS coupling might
not be cleavable by the trypsin. Usually, the extent of digestion is usually defined by measuring
the amino acid sequence coverage (SQ %) but it can be a misleading parameter to use, as different
mass spectrometers and different search parameters in subsequent data analysis may reveal various
SQ % and is beyond the scope of this current project[258, 259]. Instead of measuring the SQ %, a
calorimetric study of thermal denaturation of the proteins was performed to understand the changes
in the protein during the tryptic digestion. The nanoDSC curves obtained (cf. Figure 4.7) showed
the essential differences between the undigested and digested proteins. Both the undigested proteins
exhibited a single endotherm peak in the nanoDSC curve. For the BSA curve, the single peak was
near 69 oC, which agreed well will the data obtained from literature[260]. On the other hand, the
azBSA curve showed the single peak near 66 oC, which indicated that there is slight modification in
the structure when compared to the native BSA but not a major conformation change. Regarding
the digested proteins, instead of the single isothermal peak, multiple smaller peaks were seen in the
nanoDSC curves. In those curves, the lower intensity of the peaks compared to undigested proteins
evidences that most of the protein was denatured during the digestion step and the multiple peaks
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obtained indicate that the changes observed could be from multiple structurally independent or
dependent parts. On comparison of the data from the two digested proteins, two main differences
were noticed: (1) the onset temperature for denaturing the digested BSA was ca. 44 oC, which is
much lower compared to the digested azBSA; and (2) in the case of digested azBSA there are two
transitions, one at ca. 62 oC and the other at ca. 68 oC, whereas, for the digested BSA, apart
from the two transitions at ca. 62 oC and ca. 68 oC, there were other additional transitions in
the ca. 44 oC to 60 oC temperature range. These differences in the calorimetric study confirm
that the azBSA is not being completely digested by trypsin. This drawback of partial digestion
of azBSA can be overcome by using other enzymes, such as pepsin, which have a higher digestion
efficiency of serums than trypsin[261]. We mentioned earlier that apart from the modification of
BSA, the digestion conditions could also lead to incomplete digestion of proteins. Usually to ensure
a complete digestion of the protein, it is denatured prior to the digestion step because digestive
enzymes, such as trypsin, cannot gain access to the cleavage sites if the protein is folded or in
the native ’globular’ form and upon denaturing the protein, the sites which were once inaccessible
become available for cleaving. In general, the protein can be denatured by a number of ways such
as: (1) high temperatures; (2) high/ low pH (depending on the protein and enzyme); (3) change
in ionic strength; and (4) addition of chaotropic agents and organic solvents[262]. In the above
study, the PA-azBSA-CYN particles were digested at 37 oC, which is lower than the irreversible
unfolding temperature of BSA (i.e. 60 - 70 oC)[71]. At 37 oC, there might be some unfolding which
is reversible so the trypsin can sometimes gain access to the cleavage sites and this leads to low
yields of the release of the CYN from the modified particles. This issue is fixable by denaturing the
modified particles by one of the four methods mentioned above, prior to the tryptic digestion step.
This sequential denaturation and digestion method will ensure a high release of the fluorophore,
provided the right digestive enzyme is used.
4.3.4 in vitro photodynamic therapy studies of the particles-protein-dye
system
The earlier section illustrated the use of the particle-protein-dye system for fluorescence
imaging. Apart from imaging, this system can be beneficial for therapeutical applications. It is
known that most of the small molecule fluorophores are used for photodynamic therapy (PDT) and
89
Figure 4.8: (a) The cells were treated with 200 nM of azSiPc1 or Pc4 for 18 hours. (b) The cells were treated
with varying concentrations of PA-azBSA-SiPc2 for 18 hours. Cell viability is presented as percentage of viable cells
in total population.
among them, porphyrins such as phthalocyanine fluorophores that emit in the near-infrared region,
are the more popular and widely used photosensitizing agents in PDT[40, 263]. In PDT, upon excita-
tion the photosensitizer undergoes inter-system crossing to longer-lived triplet states and this excited
triplet energy is transferred to ground-state triplet of the oxygen in tissue and the highly cytotoxic
reactive singlet oxygen (1O2) is formed. This toxic singlet oxygen can directly kill tumor cells by the
induction of necrosis and/or apoptosis, can cause destruction of tumor vasculature and produces an
acute inflammatory response that attracts leukocytes such as dendritic cells and neutrophils[264].
Previous efforts to localize the PDT by attaching the photosensitizer to polymeric nanoparticles were
moderately successful as the immobilization of fluorophore on the particle decreased the amount of
singlet oxygen yield formed as more of the energy was transferred non-radiatively to the particles
compared to free molecules[31]. To this end, the particle-protein-dye system can be a good solution
to the issue as the initial immobilization of the protein-dye conjugate on the particles allows for
the higher accumulation[265], and upon digestion of the protein the fluorophore is released. The
released fluorophore is free and no longer attached to the particles so energy is not lost through
other non-radiative transfers and high yields of singlet oxygen species can be obtained.
For the demonstration of the application of modified particles in PDT, silicon phthalocyanine
is chosen as the fluorophore as they have high quantum yields and excellent photostability. The
structures of the azide and alkyne terminated silicon phthalocyanines that were used to functionalize
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the particles are presented in Figure 4.2. Two different sets of silicon phthalocyanines were tested.
The first set of fluorophores include SiPc1 and azSiPC1, which have short poly(ethylene glycol)
(PEG)chains, and the second set include SiPc2 and azSiPc2, which have longer PEG chains. PEG
increases the solubility of the hydrophobic fluorophores in aqueous solutions and the two sets were
tested to check if the solubility has any effect on the PDT results. In the first round of PDT studies,
the photosensitizing abilities of azSiPc1 and azSiPc2 were tested and compared to the efficiency of
Pc4, a standard silicon phthalocyanine used in PDT[266, 267]. In this PDT experiment, UMSCC22A
cells were cultured for 24 hours and then incubated with varying concentrations of 25 - 400 nM of
fluorophore for 18 hours in culture medium. After 18 hours, the cells were irradiated with 670 nm
light and cell death was assessed with propidium iodide exclusion over time. Of the two fluorophores
tested, azSiPc1 gave results that had a similar response as the Pc4. The results from the 200 nM
treatment azSiPc1 is presented in Figure 4.8a and 100 % cell death was observed after 11 hours
from the irradiation, which is slightly longer compared to Pc4. Nonetheless, azSiPc1 is considered
effective as complete cell death was achieved with a reasonable concentration where the fluorophore
by itself was not toxic[266]. For the PDT study with azSiPc2 (data not shown) only 10 % cell
death was observed. From these results, it is speculated that solubility does not affect the PDT
capability of the fluorophore and for hydrophobic dyes the solutions for treatment can be made
from concentrated DMSO stocks and then diluting in aqueous solutions, such that the DMSO is less
than 1 %. In addition, as the azSiPc1 was more effective than azSiPc2, it can be speculated that
the long PEG chains might be responsible for the decreased PDT activity in azSiPC2, as energy
can be lost non-radiatively due to the long PEG groups. It is possible that the modification of the
silicon phthalocyanine at the porphyrin ring will not change the singlet oxygen yields significantly
but any modification at the axial position of the silicon will drastically change the yields because it
is well established in literature that the central metal moiety is the vital determining group of the
amount of singlet oxygen generation in phthalocyanines[268]. Moving onto the modified particles,
the second round of PDT studies was carried out with particles directly functionalized with just the
azide modified phthalocyanines (i.e. azSiPc1 and azSiPc2). The azSiPc1 or azSiPc2 groups were
attached to the surface of the PA particles through a click reaction, and these particles are referred
as PA-azSiPc1 or PA-azSiPc2. Both of these particles, failed to show any cell death and the number
of cells after the treatment were equal to the untreated control cells when monitored over a period
of 18 hours from the light irradiation step. This study confirms that when particles are directly
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Figure 4.9: Cell viability data using the MTS assay with A549 cells The cells were treated with sl01 and PA-
azBSA-sl02 at varying concentrations for 48 hours. Cell viability is presented as percentage of viable cells in total
population.
surface modified with fluorophores the energy is lost, perhaps non-radiatively, and causes the singlet
oxygen yields to diminish. This failure of PDT with modified particles, leads to a necessity to
identify alternate systems which can increase accumulation and in vivo circulation lifetimes without
decreasing the singlet oxygen yields. As mention earlier, the particle-protein-dye system could be
a solution to this issue so the last round of PDT studies was carried out with particles modified
with azBSA-SiPc2 conjugate. The preliminary results obtained (cf. Figure 4.8b) for treatment with
PA-azBSA-SiPC2 are promising as 12 % cell death was obtained for 1600 nM treatment.
4.3.5 in vitro studies of the particles-protein-ligand system
Apart from the delivery and therapy applications of the particle-protein-dye system, this
multifunctional system can be used for active targeting applications by replacing the dye in the
PA-azBSA-CYN with a ligand, that binds to a specific protein, to enhance targeting capabilities
of the ligand. For this enhanced targeting demonstration, the protein chosen is ’Survivin’, which
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Figure 4.10: in vitro fluorescence imaging in A549 cells (after 11 hours of treatment with modified particles)
is a member of the inhibitor of apoptosis (IAP) proteins and regulates cell division and death[178,
230]. In addition, Survivin is abundantly expressed during fetal development in humans, but rarely
present in adult tissues, which makes it an attractive target for tumor theranostics in the medical
community[180, 181, 182, 183]. The ligand used in this project is sl02 (cf. Figure 4.2), which is an
alkyne modified version of the original Abbott17 compound. In 2007, Abbott labs discovered a new
direct binding site at the dimer interface of the Survivin and a ligand called Abbott17, which binds
specifically to the dimer site using affinity-based screening methods[209]. In this current effort, the
Abbott17 is modified to include an alkyne moiety (cf. Figure 4.2) to facilitate the conjugation to
azBSA and this small molecule ligand is referred as sl02. The PA-azBSA-sl02 is prepared using the
same method as the PA-azBSA-CYN particles. The next step is to determine the binding efficiency
of the modified particles to Survivin and verify the enhancement in binding. The binding affinity
between the protein and ligand is usually expressed by the binding dissociation constant, KD, but in
the case of the Survivin and Abbott17 binding, the binding efficiency is directly correlated to toxicity
so toxicity studies can be used to understand the binding efficiencies between them. According to
literature, the ligand binds to the dimer interface of the Survivin and blocks other proteins, such
as Ran, which regulate the activity of Survivin. As these other apoptosis inhibitor proteins can
no longer bind at the dimer interface, the Survivin can no longer inhibit apoptosis and cell death
is observed[180, 218]. Therefore, it can be concluded that higher binding of the ligand, blocks the
inhibitors binding at that site and leads to activation of apoptosis, which results in cell death, so
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cell toxicity is a direct indicator of the binding of the ligand to the protein, and toxicity studies can
be used to prove the enhanced targeting of the Survivin by PA-azBSA-sl02 particles. Preliminary
toxicity studies were carried out in A549 cells, which are known to overexpress Survivin. The A549
cells were treated with varying concentrations of sl01, an azide modified version of the Abbott17
compound (cf. Figure 4.2), and PA-azBSA-sl02. After 48 hours, the cell viability was determined
using MTS assay. From the cell viability data (cf. Figure 4.9), it is evident that the particles have
a higher cell death, which indicates a higher binding affinity of the system compared to the free
small molecule. This increase in cell death is as expected because immobilizing the ligand on the
particle increases the accumulation of the ligand inside the cells due to enhanced permeability and
retention effect and the higher accumulation leads to an increased blocking of the inhibitors that
bind at the dimer interface, which results in enhanced cell death. However, one can argue that the
higher accumulation is not possible as the modified particles are larger (i.e. diameter greater than
1000 nm) as the particles are held together by the protein and most of the cell death seen could be
from the fact that these particles are suffocating the cell at the cell surface. To disprove that, in
vitro fluorescence imaging study of A549 was carried out to verify the location of the PA-azBSA-sl02
particles. The sl02 has an emission maximum at ca. 424 nm, and can be seen under a DAPI filter
on a fluoroscope. For the fluorescence imaging study the A549 cells were treated with 20 µM of
PA-azBSA-sl02 particles and the cells were viewed under a fluoroscope with DAPI filer. After 11
hours of treatment, it can be seen that the emission is coming from the inside of the cells, which
verifies the argument that the cells take up the modified particles without any issue (cf. Figure 4.10).
In addition, we know from the PA-azBSA-CYN system that the modified particles by themselves
do not have a strong emission and only upon denaturing or digestion of the azBSA the emission
is activated. From the Figure 4.10, it can be said that these particles are being activated in vitro
either due to the denaturing or cleavage of the peptide bonds when the particles are inside the cell.
4.3.6 Fluorescence resonance energy transfer (FRET) response of the
particles-protein-dye system
The bioresponsive aspect of this particle-protein-dye system makes these modified particles
attractive for fluorescence resonance energy transfer (FRET) based imaging applications. FRET is a
non-radiative transfer of energy from an excited donor molecule to a suitable ground state acceptor
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Figure 4.11: Schematic of the FRET response of functionalized particles through trypsin digestion of the albumin.
Sub 100 nm poly(propargyl acrylate) (PA) particles were surface modified with (1) an azide modified fluorescein
fluorophore and (2) an azide-modified bovine serum albumin (azBSA) that is conjugated to alkyne terminated cyanine
derivate fluorophore (YB317), through multiple aqueous-phase click transformations.
molecule in close proximity. This results in emission from the acceptor molecule, when excited at
the wavelength for donor emission. The non-radiative transfer of energy is highly dependent on:
(1) the distance between the two molecules and is typically effective up to ca. 10 nm; and (2) the
spectral overlap of donor’s emission and acceptor’s absorption. In this current effort, a suitable
donor fluorophore is attached to the PA-azBSA-CYN particles and the azBSA on the particles can
be digested, folded or unfolded to increase/ decrease the distance between the two fluorophores
which results in changes in the FRET response of the particles (cf. Figure 4.11).
The first step in this effort is to identify a fluorophore that forms a good FRET pair with the
CYN, which is a cyanine 3 derivative fluorophore. After a literature search, fluorescein is chosen as
the donor molecule, as fluorescein (donor) and cyanine 3 (acceptor) fluorophores form a good FRET
pair that is well documented and established[269]. The chosen fluorescein fluorophore is modified
to include an azide moiety (cf. Figure 4.2), which will facilitate the fluorophore to be attached to
the surface of the particles via a ’click’ reaction. As mentioned earlier, the FRET response depends
on the spectral overlap between the donor’s emission and acceptor’s absorption, so typically this
spectral overlap is used as the parameter to confirm that the chosen donor-acceptor molecules form
a good FRET pair. The emission of azFL has a good overlap with the absorbance of the CYN
fluorophore (acceptor)(cf. Figure 4.12), which verifies that the modifications of the standard fluo-
rophores did not alter the FRET response of the pair. After the selection and characterization of the
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Figure 4.12: Absorbance and photoluminescence spectra of azFL (donor, UV - light green and PL - dark red) and
CYN (acceptor, UV - dark green and PL - pink).
donor molecule, the PA particles are surface modified to attach azide modified fluorescein derivative
fluorophore (azFL) via ’click’ reaction and cleaned to remove unreacted species. Simultaneously,
alkyne modified cyanine 3 derivative fluorophore (CYN) was clicked to azBSA and cleaned. Then,
these two were parts were ’clicked’ together to obtain particles surface modified with azFL and
azBSA-CYN conjugate and these particles are referred as PA-azFL-azBSA-CYN.
The changes in the FRET response can be detected using several different methods such
as donor or acceptor photobleaching, ratio imaging, sensitized emission and fluorescent lifetime
measurements. For this current effort, the interest is mainly in recording the relative changes in
FRET efficiency when the azBSA is altered to change the distance between the fluorophores. To this
end, a simple ratiometric FRET that provides qualitative changes in FRET efficiency is sufficient.
In the ratiometric FRET method the ’relative’ FRET efficiency, Erel, is given by equation (4.1),
where IA and ID are the emission intensities of the acceptor and donor molecules, respectively.
The emission of the donor and acceptor molecules of the PA-azFL-azBSA-CYN particles overlap
slightly, so the spectra is decomposed into the isolated donor and acceptor emission components
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Figure 4.13: Changes in photoluminescence of PA-azFL-azBSA-CYN particles with addition of trypsin and incu-
bation at 37 oC. Emission of the particles was measured (-) initially, after incubation for (◦) 60 mins and (•) 2400
mins. The particles were dispersed in PBS and excited at 440 nm (donor).
before calculating the Erel value. The Erel of the cleaned particles was determined to be ca. 0.27,
which indicates a low FRET response. The changes in this value of Erel will give an estimate if the





In the previous section, it was established that trypsin digests the azBSA to release the free
fluorophore that was attached to the surface of the particles. Upon release, it is expected that the
free CYN can be in close proximity to the azFL attached to the surface of the particles and results
in an increase of FRET as the distance between the two fluorophores would be lower compared to
the initial particles. To verify this assumption, ca. 0.286 mM of trypsin was added to the PA-
azFL-azBSA-CYN particles and incubated at 37 oC. After 60 and 2400 minutes of incubation, the
particles were excited at 440 nm (the excitation wavelength of the donor molecule) and the emission
was measured (cf. Figure 4.13). From the Figure 4.13, it can be seen that the emission of CYN
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Figure 4.14: Changes in photoluminescence of PA-azFL-azBSA-CYN particles with addition of DTT and incubation
at 37 oC. Emission of the particles was measured (-) initially, after incubation for (◦) 30 mins, (•) 90 mins and (4)
210 mins. The particles were dispersed in PBS and excited at 440 nm (donor).
increased as expected and the Erel increased from ca. 0.27 to 0.39 after the 60 minutes incubation.
This ca. 46 % increase in ratiometric FRET might not seem significant but it should be noted that
this increase being discussed is the ratiometric FRET and not the actual FRET. The conversion to
FRET from ratiometric FRET depends on (1) the contribution of direct excitation of the acceptor
and (2) the ratio of quantum yields of the donor and acceptor. The quantum yield of fluorescein
is higher than that of cyanine 3 and when this difference in quantum yields is accounted for in the
conversion to FRET from ratiometric FRET, the increase in FRET will be significant[270, 271, 272].
In the current study, it was noticed that after the initial increase in ratiometric FRET,
it dropped to 0.33 at longer incubation times. The drop at longer times is unexpected and could
be either due to the fact that at longer durations the fluorophore might be falling out of solution
or FRET quenching is occurring. Another interesting change that was noticed during the tryptic
digestion of PA-azFL-azBSA-CYN particles is that along with the increase in FRET, the emission of
azFL (donor) also increased significantly. This increase in azFL emission indicates that the emission
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Figure 4.15: Changes in photoluminescence of PA-azFL-azBSA-CYN particles with addition of l-glutathione and
incubation at 4 oC. Emission of the particles was measured (-) initially, after incubation for (◦) 40 mins and (•) 1230
mins. The particles were dispersed in PBS and excited at 440 nm (donor).
of azFL was quenched initially by the azBSA-CYN conjugate. This quenching of the azFL emission is
not surprising as it was demonstrated previously in literature, where attachment of azPEG molecules
on the surface of the particles decreased the emission of the modified particles[71]. Further, it is
stated that the emission is dependent upon the grafting density of the fluorophore and at low grafting
densities, a higher emission is obtained[71]. Based on that, it can be concluded that initially the
azFL on the particles transfer energy non-radiatively to the azBSA-CYN conjugate and the emission
is quenched. Upon trypsin digestion the azBSA is broken down into smaller peptides and no longer
available for the azFL to transfer energy non-radiatively which results in the increase in emission
of azFL. In addition, this explains the drop in ratiometric FRET at longer periods of incubation
time. Initially, it was speculated that the drop could be due to the fluorophore falling out of solution
or FRET quenching, but that might not be the case as we know that there are two phenomena
happening during tryptic digestion. First is the FRET between the two fluorophore and second is
the turn on of the quenched emission of azFL by the azBSA conjugate. This implies that the initial
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increase in ratiometric FRET is mainly due to increase in FRET but at longer times it is possible
that the dominant change in ratiometric FRET is due to an increase in emission of azFL and the
FRET might be the same or unchanged. In addition, in this system the azFL is in grafted in excess
of CYN and upon digestion it is possible that not all of the azFL is in close proximity of the CYN,
so the energy of those fluorophores is not transferred to CYN and emits radiatively upon excitation.
Our current effort is to demonstrate the changes in FRET with modifying or unfolding the
azBSA and we have established that with trypsin digestion, a ca. 46 % increase in ratiometric FRET
can be obtained for the fluorophore pair of azFL and CYN. The next step is to monitor the changes in
FRET of these modified particles with the addition of strong reducing agents such as dithiothreitol
(DTT) and l-glutathione. Both of these compounds are routinely and frequently used to reduce
the disulfide bonds of proteins and prevent unwanted or wrong disulfide bonding between the thiol
groups of proteins[273, 274, 275]. First, the changes with respect to addition of DTT are studied.
DTT reduces a typical disulfide bond by two sequential thiol-disulfide exchange reactions and the
reduction usually does not stop at the mixed-disulfide species because the second reaction, which
forms the 6-membered ring containing the disulfide bridge, is more energetically favored[273, 276].
The reducing power of DTT is limited to pH values above 7, since only the negatively charged thiolate
form -S is reactive (the protonated thiol form -SH is not)[276, 277]. In addition, DTT cannot reduce
buried (solvent-inaccessible) disulfide bonds, so sometimes the reduction of disulfide bonds has to
be carried out under denaturing conditions, such as high temperatures or in the presence of strong
denaturants like urea or sodium dodecylsulfate[278]. In this project, the modified particles are
mixed with ca. 43 mM DTT and incubated at 37 oC. After 30, 90 and 210 minutes of incubation,
the particles were excited at 440 nm (the excitation wavelength of the donor molecule) and the
emission was measured (cf. Figure 4.14). The calculated Erel dropped significantly to 0.05. Unlike
in the case of trypsin, where both an increase in ratiometric FRET and azFL emission increased,
here the ratiometric FRET decreased and the azFL emission increased. This leads to the speculation
that the change in actual FRET is not known as the ratiometric FRET is mainly dominated by the
increase in azFL emission. Moreover, the temperatures used for the incubation were not high nor
were there other denaturants used so it is possible that only some of the disulfide bonds of azBSA
are reduced and the protein is partially unfolded[279, 280]. Consequently, the azBSA is no longer
quenching azFL emission and as the protein is only partially unfolded the distance between the two
fluorophores could either be the same or increased. It is well known that FRET is dependent on the
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proximity of the two molecules so if the distance is the same or increased then FRET either does
not change or decreases, respectively. It is also possible that the DTT might be oxidized as it is old
so it might not be reducing the disulfide bonds effectively. Secondly, coming to changes with the
addition of l-glutathione, a better FRET response was obtained (cf. Figure 4.15). L-glutathione
also reduces the disulfide bonds but is stronger reducing agent than DTT. It is possible that the
l-glutathione reduced the azBSA effectively, so the azBSA unfolded and collapsed on the surface of
the particle where more of the azFL come in close proximity to the CYN, which subsequently results
in an increase in ratiometric FRET. When ca. 21.7 mM of L-glutathione was added to the modified
particles and incubated at 4 oC for 40 minutes, the ratiometric FRET increased from 0.23 to 0.62 (cf.
Figure 4.15). The FRET response was measured again at longer incubation time of 1230 minutes
and only a slight drop in the ratio was observed. Overall, from the entire FRET responses studied it
can be concluded that the highest increase in FRET response of the PA-azFL-azBSA-CYN particles
was achieved when the azBSA was reduced using L-glutathione and ca. 156 - 171 % increase in
ratiometric FRET can be obtained.
4.4 Experimental
4.4.1 Reagents and solvents
All the commercial reagents were used without further purification. All the solvents were
dried according to standard methods. Deionized water was obtained from a Nanopure System and
exhibited a resistivity of ca. 1018 ohm−1cm−1.
4.4.2 Characterization
1H and 13C NMR spectra were recorded on JEOL ECX-300 spectrometers (300MHz for pro-
ton and 76MHz for carbon). Chemical shifts for protons are reported in parts per million downfield
from tetramethylsilane and are referenced to residual protium in the NMR solvent (CDCl3: δ 7.26
ppm, DMSO-d6: δ 2.50 ppm). Chemical shifts for carbons are reported in parts per million down-
field from tetramethylsilane and are referenced to the carbon resonances of the solvent (CDCl3: δ
77.16, DMSO-d6: δ 39.52 ppm). Electron impact (EI) (70 eV) ionization mass spectra were obtained
using Shimadzu GC-17A mass spectrometer. LC/MS mass spectra were obtained using Finnigan
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LCQ spectrometer and HP 1100 (HPLC). Thermal denaturation data of the proteins was obtained
using TA instruments Nano DSC.
Figure 4.16: Reaction scheme for synthesis of azNHS.
The azNHS was prepared based on the method published[281]. The reaction scheme for the
synthesis of azNHS is presented in Figure 4.16.
2,5-dioxopyrrolidin-1-yl 3-azidopropanoate (1) 2-azidopropyonic acid (1.8 g, 15.64
mmol) and N-hydroxysuccynimide (1.98 g, 17.2 mmol) were dissolved in THF (30 ml). Obtained
solution was cooled with ice and N,N’-dicyclohexylcarbodiimide (3.54 g, 17.2 mmol) was added.
Mixture was stirred at cooling for 0.5 hour, then at room temperature for 6h and filtered. Insoluble
solid was washed with dichloromethane. Filtrates were combined and evaporated, the residue was
dissolved in dichloromethane (15 ml), cooled in freezer and filtered to remove precipitates. The
filtrate was evaporated. Product was used in the next reactions without additional purification.
Yield 3.3 g (99 %), clear oil. 1H NMR (CDCl3) δ 2.86 (s, 4H), 2.89 (t, 2H, J = 6.5 Hz), 3.69 (t, 2H,
J = 6.5 Hz).
The reaction scheme for the synthesis of CYN is presented in Figure 4.17.
5-Iodopent-1-yne (2) 5-Iodopent-1-yne was synthesized according to the literature[282].
1,2,3,3-tetramethyl-3H-indolium iodide (3) 1,2,3,3-tetramethyl-3H-indolium iodide
was synthesized according to the literature[283]. 2,3,3-trimethyl-3H-indole (0.5 g, 3.14 mmol) and
iodo-
methane (1.34 g, 9.42 mmol) were dissolved in acetonitrile (5 ml) and refluxed for 5 hours. After
cooling, the precipitated solid was filtered and washed with acetone then dried to give white crys-
talline product. Yield 0.94 g (99 %), mp = 259 oC (lit). 1H NMR (DMSO-d6) δ 1.53 (s, 6H), 2.76
(s, 3H), 3.97 (s, 3H), 7.60 - 7.64 (m, 2H), 7.81 - 7.84 (m, 1H), 7.90 - 7.93 (m, 1H).
2,3,3-trimethyl-1-pent-4-ynyl-3H-indolium iodide (4) The solution of 2,3,3-trimethyl-
3H-indole (0.83 g, 5.21 mmol) and 5-iodo-pent-1-yne (1.5 g, 7.82 mmol) in acetonitrile (10 ml) was
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Figure 4.17: Reaction scheme for synthesis of CYN.
refluxed for 24 hours. After cooling, the solvent was evaporated and the brown residue quenched
with acetone to crystallize a product. Obtained solid was filtered, washed with acetone and dried.
Yield 1.05 g (57 %), mp = 190 - 191 oC. 1H NMR (DMSO-d6) δ 1.54 (s, 6H), 2.06 (m, 2H, J = 7.4
Hz), 2.42 (m, 2H, J = 7.4 Hz, J = 2.6 Hz), 2.84 (s, 3H), 2.96 (t, 1H, J = 2.6 Hz), 4.92 (t, 2H, J =
7.4 Hz), 7.63 (m, 2H), 7.85 (m, 1H), 7.96 (m, 1H).
2-[2-(acetyl-phenyl-amino)-vinyl]-1,3,3-trimethyl-3H-indolium iodide (5) 1,2,3,3-
tetramethyl-3H-indolium iodide (3) (0.65 g, 2.16 mmol) and N,N’-diphenyl-formamidine (0.51 g,
2.60 mmol) were mixed with acetic acid (8 ml) and acetic anhydride (4 ml). Obtained mixture was
refluxed and stirred for 1 hour. After cooling, the solvent was evaporated, the residue was dissolved in
dichloromethane (2 ml) and added to diethyl ether solution. Precipitated dark solid was separated
by centrifugation. This crude product was dissolved in dichloromethane and washed with water.
Organic layer was separated and evaporated, obtained residue was dissolved in dichloromethane and
precipitated with diethyl ether once again. The dark-brown solid was filtered and dried. Yield 0.87
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g (90 %), solid, mp = 228 oC. 1H NMR (CDCl3) δ 1.83 (s, 6H), 2.11 (s, 3H), 3.85 (s, 3H), 5.59 (d,
1H, J = 14.3 Hz), 7.46 - 7.50 (m, 4H, J = 5.2 Hz, J = 1.4 Hz), 7.53 - 7.55 (m, 2H, J = 5.2 Hz, J =
1.4 Hz), 7.63 - 7.73 (m, 3H, J = 7.4 Hz, J = 1.4 Hz), 9.17 (d, 1H, J = 14.3 Hz).
2-[3-(3,3-dimethyl-1-pent-4-ynyl-1,3-dihydro-indol-2-ylidene)-propenyl]-1,3,3-tr-
imethyl-3H-indolium iodide (6) Compounds (4) and (5) were dissolved in pyridine (6 ml) and
stirred at 45 oC for 3 hours. After cooling, the solution was added dropwise to diethyl ether solution
to precipitate a dark-brown crude product which was separated by centrifugation. Organic solution
was decanted and obtained residue was dissolved in dichloromethane, washed with water. Organic
layer was separated and concentrated. Product was precipitated from diethyl ether solution two
more times, filtered, dried. Yield 0.12 g (50 %), brown solid, mp = 211 - 213 oC with destruction.
1H NMR (CDCl3) δ 1.70 (s, 12H), 2.08 (t, 1H, J = 2.5 Hz), 2.11 (m, 2H, J = 6.6 Hz, 7.7 Hz), 2.62
(m, 2H, J = 6.6 Hz, J = 2.5 Hz), 3.80 (s, 3H), 4.40 (t, 2H, J = 7.7 Hz), 7.11 - 7.54 (m, 10H), 8.43 (t,
1H, J = 13.5 Hz); 13C NMR (CDCl3) δ 16.51, 26.22, 28.20, 28.29, 32.94, 43.67, 48.90, 69.81, 83.65,
104.96, 105.44, 110.92, 111.04, 122.13, 122.19, 125.36, 125.42, 128.98, 129.04, 140.60, 142.27, 142.79,
150.95; ESI-Mass (m/z): calculated for C29H33N2 [M-I]
+ 409.26, found 409.27.
The Survivin ligands (sl01 and sl02) were synthesized according to the literature[209, 248,
249]. The reaction scheme for the synthesis of sl02 is presented in Figure 4.18.
4-(prop-2-yn-1-yloxy)benzaldehyde (7) p-hydroxybenzaldehyde (0.3 g, 2.45 mmol) and
propargyl bromide (0.38 g, 3.19 mmol) were dissolved in acetone (20 ml), then potassium carbonate
(0.34 g, 2.46 mmol) was added. Obtained mixture was stirred under reflux for 12 hours. After cool-
ing, the mixture was quenched with cold water, extracted with dichloromethane. Organic solution
was washed with water, separated, dried with Na2SO4, filtered, evaporated under reduced pressure.
Yield 0.32 g (82 %). Clear crystals, mp = 73 - 74 oC. 1H NMR (CDCl3) δ 2.57 (t, 1H, J = 2.4 Hz),
2.77 (d, 2H, J = 2.4 Hz), 7.08 (d, 2H, J = 8.9 Hz), 7.85 (d, 2H, J = 8.9 Hz), 9.89 (s, 1H).
6-(5-chloro-2-hydroxyphenyl)-2-oxo-4-(4-(prop-2-yn-1-yloxy)phenyl)-1,2-dihyd-
ropyridine-3-carbonitrile (8) 1-(5-chloro-2-hydroxyphenyl)ethanone (0.266 g, 1.56 mmol) and
4-(prop-2-yn-1-yloxy)benzaldehyde (7) (0.3 g, 1.87 mmol) were dissolved in dry ethanol (7 ml).
Ethyl cyanoacetate (0.23 g, 2.03 mmol) and ammonium acetate (0.72 g, 9.36 mmol) were added into
the solution. Mixture was stirred in sealed pressure vessel at 110 oC for 2 hours. After cooling,
precipitated solid was filtered and washed with cold ethanol then with water, dried, purified by flash
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column chromatography on silica. Solvent ethyl acetate, Rf = 0.9. Yield 0.09 g (15 %), mp = 229
oC. 1H NMR (DMSO-d6) δ 3.64 (t, 1H, J = 2.2 Hz), 4.92 (d, 2H, J = 2.2 Hz), 7.13 (d, 2H, J = 8.9
Hz), 7.42 (d, 1H, J = 8.9 Hz), 7.66 (d.d, 1H, J = 8.6 Hz, J = 2.4 Hz), 7.91 (br.s, 1H), 8.01 (s, 1H),
8.33 (d, 2H, J = 8.6 Hz), 8.71 (d, 1H, J = 2.4 Hz); 13C NMR (DMSO-d6) δ 55.59, 78.58, 79.05,
95.40, 100.41, 114.78, 118.72, 119.03, 124.68, 129.05, 129.18, 130.37, 130.64, 132.03, 143.48, 150.62,
158.30, 159.18, 160.18, 160.59, 160.64; ESI-Mass (m/z): calculated for C21H13ClN2O3 [M+H]
+
377.07, found 377.07.
The reaction scheme for the synthesis of azFL is presented in Figure 4.19.
2-(3-(3-azidopropoxy)-6-hydroxy-9H-xanthen-9-yl)benzoic acid (9) and 3-azido-
propyl 2-(3,6-dihydroxy-9H-xanthen-9-yl)benzoate (10) Fluorescein (0.8 g, 2.4 mmol), 1-
azido-3-iodopropane (0.51 g, 2.4 mmol) and potassium carbonate (0.33 g, 2.4 mmol) were mixed
with dry DMF (15 ml) and stirred at 80 oC for 14 hours. After cooling, the mixture was quenched
with water. Precipitated orange solid was filtered, washed with water and dried to give 0.926 g of
mix of isomers 1 and 2 with a ratio 2:1. 1H NMR (DMSO-d6) (mix of two compounds) δ 1.53 (m,
2H), 2.02 (m, 1H), 3.09 (t, 2H), 3.52 (t, 2H), 3.99 (t, 2H), 4.22 (t, 1H), 6.27 (d, 0.5H), 6.42 (d.d,
0.5H), 6.61 (m, 3.5H), 6.81-6.95 (m, 3H), 7.27 (m, 1H), 7.50 (m, 1H), 7.70-7.90 (m, 3H), 8.00 (m,
0.5H), 8.22 (m, 1H).
4.4.3 Optical characterization methods
Absorption spectra were taken using a Perkin-Elmer Lambda 900 UV/VIS/NIR spectropho-
tometer. Photoluminescence (PL) spectra were collected using a Thermo Oriel xenon arc lamp
(Thermo Oriel 66902) mated with a Thermo Oriel Cornerstone 7400 1/8m monochromator (Thermo
Oriel 7400) and a Horiba Jobin-Yvon MicroHR spectrometer coupled to a Synapse CCD detector.
4.4.4 Materials
4.4.5 Preparation of the particles
Propargyl acrylate (PA) particles were prepared according to published method.
Cell analysis. Human A549 cell lines was obtained from ATCC (Rockville, MD) and were cultured
in F-12K media (Kaighn’s Modification of Ham’s F-12 medium) containing 10 % fetal bovine serum
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(FBS) and 1 % Penicillin-Streptomycin. Human UMSCC22A head and neck squamous carcinoma
cell line was a gift from Dr. Besim Ogretmen (Medical University of South Carolina) and were
cultured in Dulbeccos modified Eagles media (DMEM) supplemented with L-glutamine containing
10 % FBS and 1 % Penicillin-Streptomycin. Cells were cultured at 37 oC in a humidified atmosphere
of 95 % air 5 % CO2.
Photodynamic therapy. Cell cultures were incubated with 50 - 400 nm of the sample for 18
hours before exposure to 200 - 400 mJ/cm2 red light (670 nm) from an Intense-HPD 7404 diode
laser (North Brunswick, NJ). After exposure to red light, cells were incubated for various periods
of time prior to analysis. Cell death was assessed by propidium iodide (PI) fluorometry using a
multi-well fluorescence plate reader, as previously described[284]. Before exposure to light, cells
were changed to fresh medium supplemented with PI (30 m) and Insulin-Transferrin-Selenium-X
(ITX) reagent [insulin (10 g/ml), transferrin (5.5 g/ml), selenium (6.7 ng/ml), ethanolamine (0.2
mg/ml)] (Gibco) but omitting FBS. PI fluorescence was measured at frequent intervals using 530 nm
excitation (25 nm band pass) and 620 nm emission (40 nm band pass) filters. Between measurements,
microliter plates were placed in a 37 oC incubator. At the end of the experiment, digitonin (200 m)
was added to each well to permeabilize all cells and label all nuclei with PI. Cell viability determined
by PI fluorometry is essentially the same as cell viability determined by trypan blue exclusion[284].
Fluorescence imaging. A549 cells (60,000 cells per well) were cultured on 12 well plates for
24 hours. Subsequently, cells were, exposed to 20 µM of PA-azBSA-sl02. The emission from the
treated particles was monitored with a DAPI filter on the Life Technologies EVOS R© FL Cell Imaging
System.
Cytotoxicity assay. A549 cells (5,000 cells per well) were cultured on 96 well plates for 24 hours.
Subsequently, cells were, exposed to 20 µM of PA, 1, 2.5, 5, 10, 15 and 20 µM of sl01, and 1, 2.5,
5, 10, 15 and 20 µM of PA-azBSA-sl02. After 48 hours, cell death was assessed with a MTS assay
according to the manufacturer’s instructions (Promega, Madison, WI). Briefly, medium was aspirated
and a solution of 100 µL of F-12K containing 10% FBS and µL 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, salt (MTS) and phenazine methosulfate
(PMS) was added onto each well. After 150 minutes, wells were scanned colorimetrically at 490
nm on a spectrophotometer. The conversion of MTS into an aqueous soluble formazan product
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is achieved only by dehydrogenase enzymes, which are present in metabolically active cells; the
absorbance at 490 nm from the formazan product is directly proportional to the number of living
cells in culture. Cell viability was presented as percentage of viable cells in total population.
4.5 Conclusion
The sub 100 nm poly(propargyl acrylate) particles were surface modified with an azide
modified bovine serum albumin that is covalently conjugated to alkyne terminated fluorophore,
through a multi-step copper-catalyzed azide/ alkyne cycloaddition. Initially, these particles have
a quenched emission, and upon trypsin digestion they exhibited an activation of emission due to
the cleavage of the protein and release of the fluorophore. This release strategy gave promising
results when the silicon phthalocyanine fluorophore is used in photodynamic therapy studies. The
particles can also be used for fluorescence imaging studies and when modified with a FRET pair
of fluorophores, the FRET efficiency can be tuned by unfolding the protein. The particles are
modified with drugs or antibodies instead of the fluorophores, and are more effective than the
free small molecule in drug delivery and targeting applications. In addition, the fluorophore and
drugs modifications can be combined and attached to the same particle for direct visualization of
the treatment, which will enable the physician to decide and modify the treatment of the tumors
easily. To conclude, the particles modified with environmentally sensitive molecules using the bovine
serum albumin as the linker exhibited promising results for theranostic applications of tumors and
if optimized better this strategy will become a new and valuable platform for personalized medicine.
This versatile nanodevice is not just limited to the fight against cancer but has a huge potential to be
expanded to treatment of several other diseases and vaccinations, due to the ease of the modification
of the particles with several moieties.
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Figure 4.18: Reaction scheme for synthesis of sl02.
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The main objective of this project is to develop a polymer based near infrared
(NIR) particle that can serve as both, diagnostic and therapeutic agents, for fighting
cancer. Specifically these particles will be designed to have high-contrast, high signal
to noise ratios, long in vivo circulation lifetimes, and facilitate easy attachment of
functional and target components. To this end, a flexible platform of sub-100 nm poly(propargyl
acrylate) (PA) particles was synthesized. These PA particles can be surface-functionalized with
fluorophores or targeting molecules or drugs through a copper(I) catalyzed azide-alkyne Huisgen
1,3-Dipolar cycloaddition, and used for cancer theranostics. The results obtained are summarized
below and indicate the efficiency of the PA nanoparticles in various applications:
(1) Switching fluorescence of surface modified colloids with near-infrared emitters via protein
interaction for contrast-enhanced imaging (cf. Chapter 2); conclusions drawn from this work include:
• PA particles were surface functionalized with an azide terminated squaraine derivative fluo-
rophore (azSQ) and azide terminated poly(ethylene glycol) (azPEG) chains.
• Attachment of azPEG on the nanoparticle increased the nonradiative transfer of the emitters
during the return to ground state.
• Lower grafting densities of azSQ on nanoparticles resulted in higher quantum efficiencies, due
to lower rates of aggregation.
110
• The placement of azSQ onto the surface of the particles allowed for the fluorophores to complex
with proteins that resulted in the enhancement of the dye emission.
• The quantum efficiency of the nanoparticles can be boosted by a simple annealing experiment.
• Tryptic digestion was used to deactivate the nanoparticles, and can be reactivated when de-
sired.
• In human UMSCC22A head and neck squamous carcinoma cells, the non-toxic, functionalized
particles are taken up by endosomes/lysosomes, and 80 % of these nanoparticles co-localized
with the lysosome after 17 hours of incubation.
• The activation/ deactivation of the emission of the functionalized particles was demonstrated
in human A549 alveolar adenocarcinoma cells.
(2) Surface modified colloids with targeting molecules to disrupt Survivin activity and en-
hance apoptosis in cancer cells (cf. Chapter 3); conclusions drawn from this work include:
• PA particles were surface functionalized with an azide-terminated Survivin ligand derivative
(azTM).
• azTM is a small molecule that specifically targets and binds directly to Survivin (protein)
at the dimer interface of the protein, which disrupts the activity of anti-apoptotic proteins
that are over-expressed by cancer cells and is a potentially attractive route to combating this
disease.
• Using affinity pull studies, it was determined that the binding specificity of the Survivin ligand
is not compromised when attached to particles and over 85 % of the Survivin bound to the
functionalized particles.
• In vitro cytotoxicity studies with functionalized particles that were carried out in glioblastoma,
A549 and MCF7 cells indicated a higher percentage of cell death relative to cells incubated
with the original Abbott-derived small molecule.
• In situ Wright staining studies indicated that the cell death observed in glioblastomas was
through apoptosis and an apoptotic/necrotic/healthy cells detection kit was used to confirm
the apoptotic cell death in A549 cells.
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• Western blotting studies for the proteins indicated that the functionalized particles facilitated
for an enhanced increase in Caspase-3, a protein which is believed to play a central role in the
execution-phase of cell apoptosis.
(3) A bioresponsive and versatile particle-protein-dye system for small molecule delivery and
FRET based imaging (cf. Chapter 4); conclusions drawn from this work include:
• PA particles were surface functionalized with an azide modified bovine serum albumin (BSA)
that was covalently conjugated to alkyne terminated cyanine derivative fluorophore (CYN).
• The quenched emission of these functionalized particles was activated upon trypsin digestion
because the fluorophores went from being in a aggregated state, which caused the quenching
of emission, to free fluorophore in solution.
• The particles surface was modified with an azide terminated fluorescein fluorophore (azFL),
which is a fluorescence resonance energy transfer (FRET) pair to CYN, for FRET based
imaging. The FRET efficiency was tuned by altering the protein unfolding, which was through
heating and addition of denaturants such as L-glutathione.
• In vitro cytotoxicity studies for PA particles modified with BSA conjugated to azTM were
carried out in A549 cells to illustrate that they were more effective than the free small molecule,
and fluorescence imaging in A549 cells showed that these particles were taken up by the cells
even though the size of these were > 100 nm.
• Although the PDT study with the PA particles modified with BSA conjugated to SiPc (an
alkyne terminated silicon phthalocyanine derivative fluorophore) is promising, more thorough
studies with the functionalized particles are necessary and those studies are currently being
pursued by other members of the Foulger group.
5.2 Recommendations for future research
The results discussed in this dissertation establish that the polymeric nanoparticles are a
promising platform for cancer theranostics and lead to numerous possibilities for future work. Firstly,
the particle-protein-dye system can be explored in detail for photodynamic therapy. For this study,
a short alkyne PEG terminated silicon phthalocyanine can be attached to proteins and subsequently
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clicked to PA particles. Cytotoxicity and colocalization studies in tumor cells with these modified
particles can be carried out to better understand the uptake mechanism of the particles and improve
photodynamic therapy studies. Secondly, the targeting strategy can be expanded to target the
epidermal growth factor receptors (EGFR) located on cell surface and overexpressed by tumors.
Small molecules such as gefitinib can be modified to include an azide group and then attached to
particles via a ’click’ reaction. Gefitinib is a small molecule drug that specifically binds to EGFR
at the adenosine triphosphate (ATP)-binding site of the enzyme, which interrupts the signaling and
activates apoptosis. Thirdly, the particulate platform can be used to improve EGFR tyrosine kinase
inhibitors (TKIs) treatment for non-small cell lung cancer (NSCLC). Recently, it has been discovered
that the overall response rate to EGFR TKIs is limited because the treatment with the TKIs such as
erlotinib and gefitinib result in an overexpression of the Survivin, which in turn protects the cells from
TKI treatment induced apoptosis. To this end, the particle platform can be beneficial for sequential
application of drugs/ small molecules to enhance cell death by rewiring apoptotic signaling networks.
In this scenario, a TKI such as gefitinib can be directly attached to the particle and the Survivin
ligand is attached to the particles via the albumin linker. Upon treatment with the particles, initially
the particles bind to EGFR and lead to the activation of the apoptosis pathway. The Survivin ligand
is attached to the protein so it is released eventually after the digestion of protein and restrains the
overexpressed Survivin activity. Fourthly, the drug release strategy can be improved to a specific
response stimuli particles. For this scenario instead of using albumin, the linker can be switched
to a desired amino acid sequence, where one end is attached to the small molecule and the other
to the particle. This allows for tuning the release of the small molecule occurs during a specific
desired digestion environment. Fifthly, the particles can be modified to attach DNA/ RNA strands
and used as a transfection method or in DNA/ RNA based therapeutic applications. Lastly, the
particle platform can be expanded to other applications apart from cancer theranostics. Sub-100 nm
colloidal particles with an intrinsic radioluminescent component (core) can be synthesized and the
exterior of the particle (shell) can be functionalized with multiple environmentally-sensitive moieties
that have the potential to combine opsin activation and imaging with a single type of ”nanodevice”.
The particles can be additionally surface-modified with targeting ligands that have an affinity for
a protein domain engineered within the target opsin. Once tethered to the opsin, routine medical
levels of radiation (or lower) will be used to activate the radioluminescent component of the particles.
This light is then free to gate open the channel component of the opsin protein. The activation will
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be through a judiciously chosen donor-acceptor pairing to achieve Forster resonance energy transfer
(FRET), reducing or eliminating all local temperature increases normally experienced when the
region around the opsin is flooded by light. In this way, RLP technology is superior to current
methods because (1) it obviates the need for implanting devices into the brain tissue that can cause
damage and lose effectiveness over time, (2) it can be modulated to much lower power densities to
achieve opsin activation (reducing damage to tissue), and (3) the uniformity of light delivery will
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